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Abstract 
Mesoderm induction early response 1 (mierl) is a gene encoding MIERla, a 
corepressor of ERa (Mercer et al., unpublished data). As breast tumours become 
invasive, the subcellular localization of MIER I a changes from the nucleus to the 
cytoplasm, thereby potentially abrogating or changing its function, an action of which 
may have a role in breast cancer progression (McCarthy et al., 2008). This study 
analyzed the regulation of mierl in breast cancer cells by investigating the previously 
uncharacterized MLP-P1 promoter. The subsequent role ofthis promoter in the 
subcellular localization of MlER 1 a was then studied in order to further elucidate 
possible mechanisms underlying MlERla's documented change in subcellular 
localization. Transient transfection of a MLP-P I promoter deletion series driving a 
luciferase reporter gene in multiple cell lines was used to characterize the minimum 
promoter and revealed that MLP-Pl is the predominately active mierl promoter. The 
degree to which its activity was increased over the second mierl promoter, MAEP-P2, 
was largest in ER+ breast cancer cell lines. 
Transcriptional activation at MLP-P I can lead to the incorporation of an 
alternate exon that generates transcripts harbouring an extra 74bp insert containing 
either a putative nuclear export sequence (NES) or transmembrane domain. 
Immunocytochemical analysis showed that MIERI a isoforms resulting from 
transcripts harbouring this insert (denoted MIERl 3A alpha) localized to the 
cytoplasm, while MIERla isoforms lacking this extra amino acid sequence (denoted 
MIERl alpha) localized to the nucleus in ER+ MCF7 breast cancer cells. Leptomycin 
B (LMB), an inhibitor of the nuclear export system, decreased MIER I 3A alpha 
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cytoplasmic localization while simultaneously increasing its nuclear localization, 
thereby demonstrating that exon 3A encodes a functional NES. Interestingly, both 
MIERla isoforms were equally localized throughout the entire cell in ER- cell lines, a 
phenomenon which was not affected by LMB treatment. Thus, preferential activation 
ofMLP-Pl in ER+ rather than in ER- breast cancer cells may now be considered a 
prime candidate mechanism driving the subcellular localization change ofMIERla 
from the nucleus to the cytoplasm. 
iii 
Acknowledgements 
"Science is not belief, but the will to find out". - Anonymous 
"Somewhere, something incredible is waiting to be known" - Dr. Carl Sagan 
(American Astronomer, Writer, & Scientist, 1934-1996) 
"The most beautiful thing we can experience is the mysterious. It is the source of all 
true art and science". - Albert Einstein 
I would like to take this opportunity to extend my utmost appreciation and 
gratitude to my supervisor Dr. Laura Gillespie for everything she has done for me 
over the duration of my master' s degree. From her unwavering and unyielding support 
and encouragement, to her expert guidance and teaching, to the act of just always 
being there whenever I needed assistance; I cannot thank her enough. I' d also like to 
thank Dr. Gary Paterno for also helping me to further understand the theories and 
principles behind certain areas of my project, as well as its methodology. Moreover, 
I'd like to extend my gratitude to my supervisory committee members Dr. Ken Kao 
and Dr. Robert Gendron for helping me to really focus on the essential questions and 
direction of my work and for their council throughout the duration of my project. 
Furthermore I'd also like to thank Corinne Mercer and Heather Fifield who both really 
helped me with many aspects of my research from technical troubleshooting to the 
mastering of various protocols and techniques. As well, I' d also like to send out a 
huge thanks the rest ofthe Terry Fox Crew (Amanda, Youlian, Zhjian, Phil, Mark, 
Andrew, and Keelia) for always being there and extending a hand whenever I needed 
it. And finally I would like to thank my family and all my friends whose unfaltering 
iv 
confidence and belief in me never let my determination or persistence fade. Thanks 
again so much, to all of you, for helping to make this project and thesis a reality. 
v 
Table of Contents 
Abstract................................................................................................................ ii 
Acknowledgements.............................................................................................. iv 
Table of Contents................................................................................................. vi 
List of Figures....................................................................................................... xiii 
List of Tables ................................•........................................................................ xvi 
List of Abbreviations ...................•........................................................................ xviii 
Chapter 1: Introduction ....................................................................................... 1 
1.1 The Nature of Cancer & Its Development ........................................ 1 
1.1.1 The Complexity of Cancer ................................................... . 
1.1.2 Cancer Today ........................................................................ 2 
1.1.3 Cancer at the Cellular & Molecular Level... ......................... 3 
1.2 Gene Expression ................................................................................. 8 
1.2.1 Transcription............................. ............................................. 10 
1.2.1.1 Promoter Regions................................................... 11 
1.2.2 RNA Splicing................... ......... ............................................ 13 
1.3 Regulation of Gene Expression ......................................................... 14 
1.3.1 Regulation ofTranscription .......................... ......................... 14 
1.3.1. 1 Promoter Regions & Regulation ofTranscription .. 16 
1.3.1.2 Alternate Promoter Usage.................. .................... 16 
vi 
-------------
1.4 The Consequences of the Dysregulation of Gene Expression: 
A Focus on Carcinogenesis..................................................................... 21 
1.4.1 Abnormal Gene Expression & Cancer Development... ........ 21 
1.4.2 Abnormal Promoter Usage & Cancer Development... .......... 21 
1.4.3 Aberrant Transcription Factor & Coregulator Signalling 
in Cancer Development............................................ .................... .. 22 
1.5 Mesoderm Induction Early Response 1 (mierl) ............................... 26 
1.5.1 mierl Gene, Transcripts, & Protein lsoform Structure .......... 27 
1.5 .2 mier I promoters ...................................................................... 32 
1.5.2.1 MAEP-P2 ................................................................. 32 
1.5.2.2 MLP-Pl ............... ................................................. .... 39 
1.5.3 MIER1 Function ..................................................................... 42 
1.5.3.1 MIERI as a Transcriptional Activator .................... 42 
1.5.3.2 MIERI as a Transcriptional Repressor .................... 44 
1.5.3.2.1 Transcription Factor Tethering via 
the SANT Domain ................................................... 44 
1.5.3.2.2 Recruitment ofHDACI via the 
ELM2 Domain...................... .................................. 46 
1.5.3.2.3 Estrogen Receptor (ER) Corepressor 
function of MTER 1 a and implications for 
the LXXLL and the SANT Domain ........................ 47 
1.5.3.2.4 Negative Regulation ofthe Histone 
Acetyl transferase (HAT) activity of CREB 
binding protein via MIER 1 P's ELM2 Domain ........ 49 
1.5.4 MIER 1 Expression & Subcellular Localization ..................... 50 
1.5.5 Breast Cancer & MIERI ........................................................ 51 
1.5.6 Regulation of mierl ............................................................... 53 
vii 
1.6 The Aims and Principle Objectives of this Study............................ 54 
Chapter 2: Materials & Methods ......................................................................... 57 
2.1 Cell Culture .......................................................................................... 57 
2.1.1 Cell lines & Cell Maintenance ................................................ 57 
2.2 Vectors & Constructs .......................................................................... 61 
2.2.1 Experimental Control Plasmid Constructs ............................. 61 
2.2.2 pCS3+MTmierla. & pCS3+MTmierla exon3A .................... 62 
2.2.3 mierl Luciferase Reporter Gene Deletion 
Constructs .................... .... . . . . . ..... . ..... .. .... .. ....................... 62 
2.2.3.1 MLP-Pl Luciferase Reporter Gene 
Deletion Constructs .............................................................. 66 
2.2.3.2 MAEP-P2 Luciferase Reporter Gene 
Deletion Constructs .............................................................. 69 
2.3 Plasmid Construct Preparation, Purification, Quantification, 
& Storage .................................................................................................... 72 
2.4 Reporter Gene Deletion Construct Design, Cloning, 
& Construction ........................................................................................... 73 
2.4.1 in silico Promoter Analysis & Primer Design ......................... 75 
2.4.2 Polymerase Chain Reaction .................................................... 78 
2.4.3 TOPO Cloning ofmierl MLP-Pl Promoter Specific 
Insertion Sequences into the pCR2.1 Vector ................................... 81 
2.4.4 Colony Screening, Mini-Preparation & Purification, 
DNA Quantification, and Sequencing ofMLP-Pl (-91) 
pCR2.1 and MLP-Pl (-44) pCR2.1 ................................................. 82 
2.4.5 Restriction Digest, Gel excision, Ligation, and 
Directional Cloning ofMLP-Pl (-91) pCR2.1 & MLP-Pl 
(-44) pCR2.1 inserts into the pGL3 empty vector ........................... 86 
2.4.6 Colony Screening, Mini-Preparation & Purification, 
DNA Quantification, and Sequencing ofMLP-Pl (-91) 
pGL3 and MLP-P1(-44) pGL3 ................. .. ...... .............................. 88 
viii 
2.5 Transient Transfection ....................................................................... 88 
2.5.1 HEK 293, MDA MB 231, T47D, and Hs578T Cell 
Transfection ..................................................................................... 89 
2.5.2 MCF7 Cell Transient Transfection ......................................... 92 
2.6 Cell Lysis & Protein Extraction ......................................................... 93 
2. 7 Reporter Assays ................................................................................... 94 
2.7.1 Beta-Galactosidase (p-gal) Assay ................................. 94 
2. 7.2 Luciferase Assay ..................................................... 97 
2.7.3 Bio-Rad Protein Assay ............................................................ 98 
2.8 Immunocytochemistry & Transient Transfection ............................ 98 
2.8.1 Leptomycin B Treatment... ..................................................... I 06 
2.9 Statistical & in silico Analyses ............................................................ 106 
Chapter 3: Results............................................................................................... 108 
3.1 Characterization ofMLP-P1 Promoter Activity in Breast 
Cancer Cells ............................................................................................... 108 
3.1.1 The Minimal Promoter ofMLP-Pl in MCF7 Breast 
Cancer Cells ..................................................................................... I 13 
3.1.2 Maximal Promoter Activity at MLP-P1 in MCF7 
Breast Cancer Cells .......................................................................... 113 
3.2 Comparison of MLP-P1 Promoter Activity Patterns Across 
Multiple Breast Cancer Cell Lines varying in ER Status and the 
Non-Cancerous Cell Line HEK 293 ......................................................... 116 
3.2.1 MLP-Pl Promoter Activity Patterns in HEK 293 Cells ....... 116 
3.2.2 MLP-Pl Promoter Activity Patterns in Multiple Breast 
Cancer Cell Lines varying in ER Status...................................... 120 
3.2.3 MLP-Pl Promoter Activity in HEK 293 Cells compared 
to Multiple Breast Cancer Cell Lines varying in ER Status ........... 124 
ix 
3.3 In Silico Analysis of the MLP-P1 Promoter Proximal Region ........ 127 
3.3.1 Putative MLP-P1 Transcription Factor Binding Sites 
(TFBSs) ............................................................................... ............. 127 
3.3.2 Analysis of the Percent Homology of the MLP-Pl 
Promoter Proximal Sequence Conservation Across Various 
Species ............................................................................................ 133 
3.4 Comparison of MLP-Pl vs MAEP-P2 Promoter Activity 
in Breast Cancer Cells............................................................................. 137 
3.4.1 MAEP-P2 Promoter Activity Pattern in Breast 
Cancer Cells ............................. ........................................................ 138 
3.4.2 MLP-Pl vs MAEP-P2 Promoter Activity in Breast 
Cancer Cells ..................................................................................... 145 
3.5 Effect oflncorporation ofExon 3A on MIERla Subcellular 
Localization ............................................................................................... 149 
3.5.1 Subcellular Localization of mierl Isoforms derived 
from Transcripts either containing or lacking the 74bp 
Insert encoded by Exon 3A in MCF7 Breast Carcinoma Cells ....... 149 
3.5.2 Subcellular Localization of mierl Isoforms derived 
from Transcripts either containing or lacking the 74bp 
Insert encoded by Exon 3A following Leptomycin B 
Treatment in MCF7 Cells ................................................................ 154 
3.5.3 Subcellular Localization of mierl Isoforms derived 
from Transcripts either containing or lacking the 74bp 
Insert encoded by Exon 3A following Leptomycin B 
Treatment in HEK 293 Cells and MDA MB 231 Cells ................... 157 
Chapter 4: Discussion ............................................................................................ 161 
4.1 mierl's MLP-P1 Promoter Region and Promoter 
Activity in Breast Cancer Cells ................................................................. 163 
4.1.1 The Minimal Promoter of MLP-P1 ......................................... 163 
4.1.2 Maximum Activity Promoter Region ofMLP-P1 .................. 165 
X 
4.2 Effect of ER Status on MLP-P1 Promoter Activity in 
Breast Cancer Cells .................................................................................... 167 
4.3 MLP-P1 Promoter activity in breast cancer cells vs. the 
non-cancerous HEK 293 cellline .............................................................. 173 
4.4 Putative Transcription Factors involved in the Regulation 
of mier 1 at the MLP-P1 Promoter ........................................................... 177 
4.5 MLP-P1 Promoter Proximal Sequence Conservation Across 
Various Species .......................................................................................... 188 
4.6 MLP-P1 vs. MAEP-P2 Promoter Activity ......................................... 189 
4. 7 Implications for Preferential Transcriptional Activation 
at MLP-P1 and the Effect ofMLP-P1 Specific Exon 3A Inclusion 
on the Subcellular Localization ofMIER1a .......................•................... 193 
4.8 Final Summary of Conclusions & Implications ................................ 202 
References ............................................................................................................... 206 
Appendices .............................................................................................................. 226 
Appendix 1: mierl MLP-Pl Promoter Region showing location 
of 5' starting points for insertion sequences that were cloned into 
MLP-Pl Luciferase Reporter Gene Deletion Constructs ................ .... ....... 226 
Appendix 2: mierl MLP-PI Region Intron Sequence .... .... ................... 228 
Appendix 3: mierl MAEP-P2 Promoter Region & Location of 
Primers used to engineer Luciferase Reporter Gene Deletion 
Constructs ............... ..................................................................................... 230 
Appendix 4: Preliminary Results ofthe Characterization of the 
MLP-PI Promoter Proximal Region . . .... . ... . ............................................. 232 
Appendix 5: MAEP-P2 Activity in HEK 293 Cells Recapitulates 
Previously Established Results Characterizing MAE P-P2 Promoter 
Activity in Alternate Cell Lines .... ................................................... ........... 235 
Appendix 6: Comparison of the MAEP-P2 Promoter Activity 
Across Multiple Breast Cancer Cell Lines varying in ER Status 
and the HEK 293 Non-Cancerous Cell Line including the 
MAEP-P2 (+28) pGL3 Construct Results ................................................... 236 
-- - - ------
xi 
Appendix 7: Human MLP-Pl Promoter Sequence Aligned to 
Various Species ............................................................................................ 237 
xii 
List of Figures 
Figure 1.1: The six hallmarks of cancer ............................................................. 5 
Figure 1.2: The hallmarks of cancer development, including the 
stress phenotypes of cancer ...................................... .. ......... ............ 6 
Figure 1.3: The Central Dogma of molecular biology ...................... ................. 9 
Figure 1.4: Alternate RNA splicing and promoter usage .................................. 19 
Figure 1.5: mier1 Gene Structure ...................................................................... 28 
Figure 1.6: mier1 Transcript & Protein Isoform Combinations . .... ............. 31 
Figure I. 7: MAEP-P2 promoter structure........................................................ 34 
Figure 1.8: Characterization of MAEP-P2 promoter activity....... ................... 36 
Figure 1.9: MAEP-P2 promoter CpG island sequence & putative 
transcription factor binding sites .................................. .................. 38 
Figure 1.10: MLP-Pl promoter structure........................................................... 40 
Figure 1.11: MLP-Pl proximal promoter sequence ............................................ 41 
Figure 1.12: Structure of mier 1 protein isoforms including protein 
functional domains .......................................................................... 43 
Figure 2.1: Schematic of mier 1 MLP-P I promoter region with 
reference to the sequences incorporated into the 
MLP-Pl luciferase reporter gene deletion constructs ................ 67 
Figure 2.2: DNA sequence ofMLP-PI promoter proximal region ................... 68 
Figure 2.3: Schematic ofmier1 MAEP-P2 promoter region with 
reference to the sequences incorporated into the 
MAEP-P2 luciferase reporter gene deletion constructs ............... ... 70 
Figure 2.4: DNA sequence ofMAEP-P2 promoter proximal region ................ 71 
Figure 2.5: Flow-chart for reporter gene deletion construct 
design, cloning, & construction ...................... ................................ 74 
xiii 
Figure 3.1: Schematic of luciferase reporter gene deletion 
constructs used for the characterization of the 
minimum and maximum promoter activity regions 
ofMLP-P1 in MCF7 breast cancer cells.............................. ....... 112 
Figure 3.2: Characterization ofthe MLP-Pl promoter region of 
mier1 in MCF7 cells. ........ . .... ................... ....................... 115 
Figure 3.3: Characterization of the MLP-P1 proximal promoter 
region of mier 1 in HEK 293 cells .................................................... 119 
Figure 3.4: MLP-Pl promoter activity across multiple breast 
cancer cell lines varying in ER status............................................. 122 
Figure 3.5: MLP-Pl promoter activity in MDA MB 231 cells ................ ........ . 123 
Figure 3.6: Comparison of the MLP-P1 promoter activity across 
multiple breast cancer cell lines varying in ER status 
and the non-cancerous HEK 293 cell line..................................... 126 
Figure 3.7: The sequence ofthe 94bp stretch ofnucleotides residing 
between the 5' starting positions of the MLP-P1 promoter 
region inserts cloned into MLP-P 1 ( -185) pG L3 and 
MLP-Pl (-91) pGL3 ............. ........ .................................... .............. 128 
Figure 3.8: Putative human transcription factor binding sites in the 
mier1 MLP-Pl promoter proximal region..... .... ....... ..................... 132 
Figure 3.9: Graphical depiction of sequence homology of mier1 ' s 
MLP-P1 promoter region across six different species 
compared to the human sequence........................... ....................... 136 
Figure 3.10: Schematic of luciferase reporter gene deletion 
constructs used for the initial characterization 
of MAEP-P2 promoter activity in MCF7 cells.... ......................... 140 
Figure 3.11: Characterization of the MAEP-P2 promoter region 
of mier 1 in MCF7 breast cancer cell line....................................... 141 
Figure 3.12: Analysis of the MAEP-P2 promoter activity across 
multiple breast cancer cell lines varying in ER status 
and the HEK 293 non-cancerous cell line... ................................ 144 
Figure 3.13: Comparison of MLP-P I vs MAEP-P2 promoter activity 
across multiple breast cancer cell lines varying in ER status 
and the non-cancerous HEK 293 cell line ...................................... 147 
xiv 
Figure 3.14: MLP-PI ( -185) pGL3 vs. MAEP-P2 pGL3 luciferase 
activity comparison across various breast cancer cell 
lines and HEK 293 cells ..................... ............................ ........... ... ... 148 
Figure 3.15: Subcellular localization data of mier I isoforms derived 
from transcripts either containing or lacking the 74bp 
insert encoded by exon 3A in MCF7 breast carcinoma cells ........... I 51 
Figure 3.16: Subcellular localization pictures of mieri isoforms 
containing or lacking the 74bp insert encoded by exon 
3A in MCF7 breast carcinoma cells ............................. ................. ... I 53 
Figure 3.17: Effect ofLeptomycin B treatment on mieri isoform 
subcellular localization in MCF7 cells ........................... .. ................ 156 
Figure 3.18: Effect of Leptomycin B treatment on mier I isoform 
subcellular localization in HEK 293 cells and 
MDA MB 231 cells.... ....................... ................. .......... ................... 160 
Figure A 1: Preliminary results of the characterization of mieri 
MLP-Pl promoter proximal region in HEK 293 
cells . . . .... . ......... .. ... . ... . ...... .. ... ... ..................................... ..... 233 
Figure A2: Characterization of the MAEP-P2 proximal promoter 
region of mieri in HEK 293 cells .......... ........................................ 235 
XV 
List of Tables 
Table 1.1: Hallmark ascriptions of oncogenic transcription 
factors ...................................................................................... ........ 24 
Table 2.1: Cell lines ......................................................................................... 57 
Table 2.2: Cell line optimal confluency & subcultivation ratios ..................... 60 
Table 2.3: Experimental control plasmids ........................... ...... ...................... 61 
Table 2.4: Primers used for cloning & engineering ofMLP-P1 
reporter gene deletion constructs........ ........................................... 64 
Table 2.5: Primers used for cloning & engineering ofMAEP-P2 
reporter gene deletion constructs ..................................................... 65 
Table 2.6: Primers designed for the construction ofMLP-P1 
(-91) pGL3 and MLP-P1 (-44) pGL3 luciferase 
reporter gene deletion constructs .......................... ........................... 77 
Table 2.7: Platinum® Taq DNA Polymerase High Fidelity master 
mix reagents ................................................................................... .. 79 
Table 2.8: Thermocycler parameters for PCR using Platinum® Taq 
DNA Polymerase High Fidelity ....................................................... 80 
Table 2.9: Taq DNA Polymerase master mix reagents for colony 
screening ................................................................................... ....... 84 
Table 2.10: Thermocycler parameters for PCR colony screening 
using Taq DNA Polymerase ............................................. ............... 85 
Table 2.11: Cell line seeding densities for 6-well plates .................................... 90 
Table 2.12: Temperatures & sample aliquot amounts for P-Gal assay ............... 96 
Table 2.13: Cell line seeding densities for 8-well chamber slides ..... ... ... ... ... 105 
Table 3.1: Putative human transcription factor binding sites 
in the MLP-P1 promoter proximal region residing 
between -185 and -91bp from the MLP-P1 putative TSS ... ............ 129 
Table 3.2: Putative human transcription factor binding sites 
in the MLP-Pl proximal promoter region residing 
between -91 to -44bp from the MLP-Pl Putative TSS ................... 130 
xvi 
Table 3.3: Percent conservation ofMLP-Pl maximal and minimal 
promoter regions across six species compared to 
human sequences... ...................................................... ............. ..... 134 
xvii 
List of Abbreviations 
a alpha 
p beta 
P-gal beta-galactosidase 
P-M-ETOH beta-mercaptoethanol 
aa amino acid 
amp ampicillin 
ATCC American Type Culture Collection 
BLAST Basic Local Alignment Search Tool 
bp base pair 
BRCAI breast cancer 1, early onset 
BSA bovine serum albumin 
CAGE genome cap analysis of gene expression 
CAT chloramphenicol acetyltransferase 
CBP CREB binding protein 
eDNA complementary DNA 
C/EBPP CCAA T/ enhancer binding protein beta 
ChiP chromatin immunoprecipitation 
CMV cytomegalovirus 
co-IP co-immunoprecipitation 
co REST REST co-repressor 
CREB cAMP response element binding protein 
DAB 3, 3'- diaminobenzidine 
DCIS ductal carcinoma in situ 
DMEM Dulbecco' s Modified Eagle Medium 
DNA deoxyribonucleic acid 
EDTA ethylenediamine tetraacetic acid 
E. coli Escherichia coli 
ELM2 EGL-27 and MTAI homology 2 
ER estrogen receptor 
FAS fatty acid synthase 
FBS fetal bovine serum 
FCS fetal calf serum 
GST glutathione s-transferase 
H3K-9 histone H3 lysine 9 
HAT histone acetyltransferase 
HDAC histone deacetylase 
HDACI histone deacetylase I 
HEK human embryonic kidney 
ICC immunocytochemistry 
IDC invasive ductal carcinoma 
ILC invasive lobular carcinoma 
IP immunoprecipitation 
KLF kruppel-like factors 
kb kilobase pair 
xviii 
LB 
LMB 
MAPK 
mierl 
MIERI 
mRNA 
MTAI 
Na-pyruvate 
NCBI 
NCoR 
NES 
NLS 
PAS 
PBS 
PCR 
Pen/Strep 
Pl3K 
PIC 
PKl 
pre-mRNA 
PRF 
pRSV-P-gal 
PTEN 
Q-Bit 
qPCR 
RACE 
RB 
REST 
REV-T 
RLU 
RNA 
RSV 
RTK 
RT-PCR 
SAM-HRP 
SANT 
SFM 
siRNA 
SMRT 
Spl 
Src-3 
TBP 
Tet 
TFBS 
TFFI 
TFilD 
TSS 
Iuria broth 
leptomycin B 
mitogen activated protein kinase 
mesoderm induction early response 1 (DNA/RNA) 
mesoderm induction early response l (protein) 
messenger ribonucleic acid 
metastasis associated antigen l 
sodium pyruvate 
National Center for Biotechnology Information 
nuclear receptor corepressor 
nuclear export sequence 
nuclear localisation signal 
polyadenylation site 
phosphate-buffered saline 
polymerase chain reaction 
penicillin/ streptomycin 
phosphatidylinositol-3-kinase 
pre-initiation complex 
protein kinase A inhibitor 
pre-messenger ribonucleic acid 
phenol red free 
plasmid rous sarcoma virus beta galactosidase 
phosphatase and tensin homolog 
Quant-iT™ dsDNA BR Assay Kit 
quantitative PCR 
Rapid Amplification of eDNA Ends 
retinoblastoma 
REI silencing transcription factor 
reticuloendotheliosis retrovirus 
relative luciferase units 
ribonucleic acid 
rous sarcoma virus 
receptor tyrosine kinase 
reverse transcription PCR 
sheep-anti mouse horseradish peroxidase 
~W13, ADA2, N-CoR, and IFIIffi 
serum free media 
small interference RNA 
Silencing Mediator for Retinoid and Thyroid Hormone 
Receptors 
specificity protein 1 
steroid receptor co-activator 3 
TATA binding protein 
tetracycline 
transcription factor binding site 
trefoil factor I 
transcription factor liD 
transcription start site 
xix 
tk 
USF 
UTR 
uv 
xmierl 
XMIERI 
thymidine kinase 
upstream stimulatory factor 
untranslated region 
ultraviolet 
Xenopus mesoderm induction early response I (DNA/RNA) 
Xenopus mesoderm induction early response I (Protein) 
XX 
Chapter 1- Introduction 
1.1 The Nature of Cancer & Its Development 
1.1.1 The Complexity of Cancer 
The dawn of the new millennium has brought with it an explosion of scientific 
discovery. This rapid progress has not only been observed in the field of medicine, with 
its innovative therapeutic breakthroughs, but also with regards to the understanding of the 
molecular, cellular, and physiological intricacies of the human body as a whole. From the 
sequencing of the entire human genome and advancements in stem cell and 
developmental research, to the technological feats of improved bioinformatics and in 
silica analysis algorithms, it is clear that our knowledge is undoubtedly expanding. As 
these scientific hallmarks are reached, the nature of our biological framework becomes 
more characterized; however, we are further faced with the undeniable truth of the 
complexity of our existence. A complexity that extends, as it is now, beyond our 
complete comprehension, as we are just starting to uncover the plethora of signalling 
networks and interconnecting factors, both at the molecular & environmental level, that 
are involved in ensuring the functional homeostasis of our bodies. 
Currently, there exists no other disease that clearly exemplifies this complexity as 
cancer. Even though the past two decades have witnessed tremendous advances in our 
understanding of the pathogenesis of this disease, scientists are still continually unfolding 
new intricacies to the pro-cancer contributing factors, triggers, and the interplay between 
the neoplastic milieu and its surrounding environment (Luo et a!. , 2009). Each cancer is a 
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complex network of dynamically evolving spatial-temporal molecular interactions (Mees 
eta!. , 2009). Therefore, not only are there a multitude of factors and acquired properties 
that converge to generate the manifested phenotypes of cancer cells, but each type of 
cancer and even similar cancer-type cases from patient to patient can vary in patterns of 
origin, and can contain distinct key elements driving their progression. For example, 
many recent large-scale sequencing studies of multiple cancers have demonstrated that 
the collection of somatic mutations present in various cancer types differ, with each 
respective tumour harbouring a complex combination oflow-frequency mutations 
thought to drive the cancer phenotype (Cancer Genome Atlas Research Network, 2008; 
Ding et al., 2008; Jones et al., 2008; Parsons et al., 2008; Sjoblom et al., 2006; Wood et 
a/., 2007). 
1.1.2 Cancer Today 
An estimated 171,000 new cases of cancer and 75,300 deaths from cancer will 
have occured in Canada in 2009, which represents approximately 470 Canadians 
diagnosed each day last year with some form of cancer (Canadian Cancer Statistics, 
2009). Three types of cancer account for the majority of new cases in each sex: prostate, 
lung, and colorectal in males, and breast, lung, and colorectal in females. Based on 
current incidence rates, 40% of Canadian women and 45% of men will develop cancer 
during their lifetimes and 1 out of every 4 Canadians will die from it (Canadian Cancer 
Statistics, 2009). 
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To retaliate against such grim statistics, and the accruing resistance and 
shortcomings to current cancer therapies, research efforts are actively searching for 
innovative means to comprehend the molecular mechanisms of this disease and transfer 
this knowledge into novel therapies (Baudot et al., 2009). More particularly, in order to 
address the heterogeneous nature and infrastructure of cancer between patients, research 
and clinical practice have been progressively skewing towards the concept of a more 
individual and personalized approach to therapy (Overdevest et al. , 2009). Personalized 
medicine focuses on and takes into account the individual's own genetic composition for 
the prevention, detection, prognosis and treatment of disease (Overdevest et al., 2009; 
Phan et al., 2009; Jain et al., 2002). The eventual use of the personalized medicine 
approach will offer many benefits that hope to overcome the weaknesses and deficiencies 
facing current therapy (Refer to review Overdevest et al., 2009; Ginsburg et al. , 2001). 
Today, as our ability to reach personalized medicine and cancer management comes 
closer and closer, so continues the fundamental importance of the continual investigation 
into cancer progression and its manifestations at the basic molecular level (Phan et al. , 
2009; Allison et al. , 2008). 
1.1.3 Cancer at the Cellular & Molecular Level 
Cancer is a disease involving dynamic alterations in the genome whereby distinct 
properties are acquired through a multistep, mutagenic process that allow cells to escape 
essential cellular regulatory and control checkpoints (Hanahan & Weinberg, 2000; Luo et 
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a/. , 2009). The result of this subsequent liberation is a selfish, autonomously proliferating 
immortal cell that is completely noncompliant to the normal constraints governing cell 
growth & metabolism (Abelev & Eraiser, 2008). In 2000, Hanahan & Weinberg 
established a list of the six hallmarks of cancer that explain how normal human cells can 
transform into malignant cancers (Hanahan & Weinberg, 2000). Figure 1.1 depicts this 
list, which Hanahan & Weinberg, 2000 claim outline the essential cellular physiological 
alterations shared among all tumours that promote survival and proliferation. Recently, 
two additional groups have added further hallmarks representing the stress phenotypes of 
cancer (Fig 1.2) (Luo eta/. , 2009; Kroemer & Pouyssegur, 2008). Together with the 
originally proposed hallmarks, these alterations collectively describe how cells can enter 
into the essential steps of the tumourigeneic process, such as: gaining nutrients and 
oxygen, evading immune detection, attracting new blood vessels, and gaining support 
from surrounding stromal cells (Baudot eta/., 2009; Hanahan & Weinberg, 2000; Luo et 
a/. , 2009). 
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Figure 1.1: The six hallmarks of cancer 
This figure, from Hanahan & Weinberg, 20001 represents the six hallmarks of cancer : I. Self-sufficiency in 
growth signals, 2. lnsensitivity to anti-growth signals, 3. Evading apoptosis, 4. Sustained angiogenesis, 5. 
Limitless replicative potential, 6. Tissue invasion & metastasis. 
1 License agreement between JC and Elsevier provided by Copyright Clearance Center. License Number: 
2391090086079. License date: March 16, 20 I 0 
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Figure 1.2: The hallmarks of cancer development, including the stress phenotypes of 
cancer 
This figure, from Luo et af, 20092, depicts the aforementioned hallmarks of cancer development along with 
the additional stress phenotypes of cancer, which are: 1. Evading immune surveillance, 2. Metabolic stress, 
3. Proteotoxic stress, 4. Mitotic stress, 5. Oxidative stress. Luo eta!, 2009 assert that the functional 
interplay among these hallmarks promote the tumorigenic state and lead to the development of the 
originally proposed hallmarks, as illustrated by the demarked arrows. For example, the increased utilization 
of glycolysis that is often observed in tumor cells allows these cells to adapt to hypoxia and acidii)' the 
surrounding microenvironment, which further enables the evasion of the immune SLtrveillance. Increased 
hypoxia furthermore supports sustained angiogenesis. Another interplay specifically depicted by this figure 
illustrates that increased mitotic stress can cause aneuploidy which can subsequently promote proteotoxic 
stress. Furthermore, elevated levels of reactive oxygen species results in increased levels of DNA damage, 
thereby further propagating the effects of tumor development (Luo eta!, 2009). 
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The progression of the aforementioned hallmarks in cancer is either directly or 
indirectly due to an accumulation of changes in the genome at the molecular level of a 
prospective cancer cell's deoxyribonucleic acid (DNA) sequence (Hanahan & Weinberg, 
2000). These mutations and/ or structural changes are highly variable and can range from 
single point mutations in the DNA sequence, deletions and/ or insertions of specific 
nucleotides, to complex chromosomal rearrangements, translocations, fusions, and 
extensive changes in chromosome number (Luo et al. , 2009; Mees et a/. ,2009) 
Carcinogenesis is initiated when such genomic modifications result in either a) improper 
activation and/ or repression orb) abnormal gain-of and/ or loss-of function of key genes 
involved in safeguarding and controlling important cellular processes (such as: cell 
growth and proliferation, cell survival, migration, apoptosis, polarity, differentiation 
during embryogenesis, and cellular homeostasis) (Luo et al., 2009; Hahn & Weinberg, 
2002, Mees et al., 2009). 
Common target genes especially implicated in this genetic dysregulation are 
oncogenes and tumour suppressor genes (Hanahan & Weinberg, 2000). Oncogenes, such 
as phosphatidylinositol-3-kinase (PI3K), Ras, and MYC, are genes that encode proteins 
that specifically control cell proliferation and differentiation (Croce, 2008). For example, 
the c-MYC oncoprotein, which is normally involved in stimulating cell growth, is 
overexpressed in many tumours and contributes to the tumour' s growth potential (Croce, 
2008). Conversely, tumour suppressor proteins, such as p53 and phosphatase and tensin 
homolog (PTEN), originate from genes that act to provide cellular restraints to prevent 
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abnormal growth and survival, as well as genomic instability. Loss or transcriptional 
repression of these genes results in the loss of growth control (Sherr, 2004). 
As evident from information presented in this section, a principle outcome of 
genetic alteration is aberrant gene expression (Dupasquier & Quittau-Prevostel, 2009). 
Cells are a function of their gene expression, and consequently protein production, even 
the production of abnormally functioning proteins, is dictated by the regulation of this 
process. Therefore, understanding the molecular mechanisms at this level of the cellular 
regulatory network serves as a focal point for the characterization of the original factors 
initiating or inducing the development of diseases resulting from a lack of regulatory 
control, such as cancer. 
1.2 Gene Expression 
Gene expression is the process by which the inherent genotype specified by the 
DNA sequence or genetic code of a cell is used as an instructional template for the 
production of proteins (reviewed in Orphanides & Reinberg, 2002). Explicitly described 
by the central dogma of molecular biology, the first step of gene expression is the 
production of pre- messenger ribonucleic acid (pre-mRNA) by a process called 
transcription (Crick, 1970). In eukaryotic cells, the resulting pre-mRNA molecule is then 
further processed into a mature messenger ribonucleic acid (mRNA) molecule through a 
series of splicing reactions and the addition of both a 5' cap and 3' polyadenylation tail. 
Mature mRNA molecules are then translated by the ribosomal complex into protein 
(reviewed in Sonenberg & Hinnebusch, 2009). 
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Figure 1.3: The Central Dogma of molecular biology 
This figure, adapted from Crick, 1970, illustrates the central dogma of molecular biology which describes 
the residue by residue transfer of sequential sequence information whereby DNA can be copied to DNA 
through a process known as DNA replication or it can be copied into mRNA during transcription. Proteins 
can be then subsequently synthesized using the information in mRNA as a template during translation 
(Crick, 1970). 
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Organisms are essentially a function of their protein makeup, or phenotype. As 
gene expression is the manner by which proteins are generated, this phenomenon is of 
fundamental importance to the differentiation and development of all living things. The 
distinct and specific timing of gene expression initiation and the extent to which a 
particular gene is being expressed dictates how cells can differentially develop into 
separate cellular lineages, even though every cell in a living organism harbours the exact 
same genomic sequence (Emerson, 2002). 
There are essentially three principal stages involved in the process of gene 
expression (Orphanides & Reinberg, 2002). These stages, some of which are briefly 
addressed in the following sections, are as follows: 
1. Transcription 
2. Post transcriptional processing 
3. Translation 
1.2.1 Transcription 
Transcription, or mRNA synthesis, is the generation of a complementary 
ribonucleic acid (RNA) molecule using the DNA sequence ofthe gene of interest as an 
instructional code or template (Deutschman, 2005). There are various steps in this 
particular process. The first is the transcription initiation stage which initially involves the 
binding of trans-acting factors, such as sequence specific and/ or basal transcription 
factors (TFs) to the promoter region (Boeger et al. , 2005; Deutschman, 2005). Factor 
binding then enables the recruitment and complex coordination of the necessary 
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transcription machinery molecules making up the pre-initiation complex (PIC) to the 
transcription start site (TSS) (Butler & Kadonaga, 2007; Davuluri eta/., 2008; Heintzman 
& Ren, 2007; Maston eta/. , 2006; Morse, 2008). In most cases, it is this event that 
constitutes the rate-limiting step in transcription (Maston eta/. , 2006). This is then 
followed by the elongation step by RNA polymerase II, which continues until a 
termination signal is encountered and both the RNA polymerase and the newly 
synthesized pre-mRNA are released (Deutschman, 2005; Morse, 2008). 
1.2.1.1 Promoter Regions 
Promoter regions are sequences of DNA that lie immediately upstream of the 
TSS, which is defined as the 5' end of the mRNA of a given gene and is the site within a 
gene where transcription begins (Landry eta/., 2003; Werner, 2003). These promoter 
regions are key elements involved in transcription as they are specifically recognized by 
the transcription initiation machinery. The binding of this machinery to the promoter 
recruits the RNA polymerase II complex to the site of transcription initiation, thereby 
facilitating elongation and rnRNA synthesis (Carninci eta/., 2006; Heintzman & Ren, 
2007). Typically, the term 'promoter' refers to the 'core promoter' and its adjacent 
sequences. The core promoter immediately surrounds the TSS and comprises 70-80 base 
pairs (bp) that contain sequence elements sufficient for recognition by the basal 
transcription machinery (Heintzman & Ren, 2007; Smale & Kadonaga, 2002). The 
' proximal promoter' includes the region extending upstream of the core promoter 
(generally approximately 250 bp from the TSS) (Smale & Kadonaga, 2002). In mammals, 
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promoter regions are generally classified under one of two categories, either a conserved 
TATA box- enriched promoter, or a CpG rich promoter (Caminci et al., 2006). 
The TAT A box is a regulatory cis-element with a consensus sequence of 
TATA_NT_A_NT_ and is typically located about 25-31 bp upstream ofthe TSS (Cao 
eta!., 2008). This regulatory cis-element tethers the PIC to DNA, thereby eliciting 
transcription initiation via its interaction with the transcription factor liD (TFIID) 
component, the TATA binding protein (TBP) (Hume, 2008). TATA box-enriched 
promoters, which can also be referred to as "sharp" promoters, initiate at a well-defined 
site and have very precise positional preference to the TSS. They are associated with 
tissue-specific gene expression and are highly conserved across species (Hume, 2008). 
These promoters, though, comprise only a small fraction (10- 20%) of overall promoters. 
It is also important to note that a promoter may be classified as this type even if they do 
not contain a consensus TA TA box (Hume, 2008). 
Conversely, the other type of promoter, CpG rich promoters, constitutes the 
majority of eukaryotic promoters and is associated with ubiquitously expressed genes 
(Huang eta!. , 2009). These promoters, which are also described as "broad" promoters, 
are more flexible with regards to initiation sites and do not harbour a single defined 
transcription start site (Caminci eta!. , 2006; Levine & Tjian, 2003). Instead, the initiation 
of transcription at these promoters takes place throughout a cluster of nucleotide positions 
spread over an area of 50- 100 bp (Carninci et al. 2005; Carninci et al. , 2006; Frith et al. , 
2008). Frith et al., 2008 attest that these specific promoters can therefore be accurately 
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described as a distribution of initiation site events on a stretch of nucleotides (Frith et al. , 
2008). 
1.2.2 RNA Splicing 
Various stages are involved in post-transcriptional processing; RNA splicing 
being one of the principle steps. RNA splicing involves the concomitant joining of exons 
(regions ofmRNA transcript that encode the amino acid (aa) sequence ofthe protein) 
through the removal of non-coding sections, or introns, in the pre-mRNA (Matlin et al. , 
2005). This process is controlled and orchestrated by the splicesome, which is a 
macromolecular ribonucleoprotein complex that assembles on pre-mRNA (reviewed in 
Black, 2003). Consensus sequences at the end of introns, called splice sites, guide the 
assembly of the splicesome and subsequent intron removal. 
Ninety-eight percent of the human genome consists of intronic sequence and thus 
the removal of introns constitutes a central mode of genetic regulation. The timing and 
manner to which RNA splicing is employed affects gene expression, as alternate pre-
mRNA splicing allows individual genes to express multiple mRNAs. This phenomenon 
serves as a key mechanism enabling differential protein production, as the generation of 
multiple protein isoforms with diverse functions can result from a single gene (Black, 
2003; Matlin et al. , 2005; Venables, 2009). Production of variable mRNAs through 
alternate pre- mRNA splicing arises due to the incorporation of differing exons in mature 
mRNA transcripts and/ or the retention and/ or facultative usage of varying introns 
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(Venables, 2009). Consequently, such alternate inclusion of exons and introns can result 
in the incorporation of additional amino acids or can even shift the open reading frame at 
the level of translation thereby specifying diverse amino acid sequences in the resulting 
protein isoforms (reviewed in Black, 2003 and Venables, 2009; refer to section 1.3 .1.2 for 
further discussion of alternate RNA splicing and promoter usage). 
1.3 Regulation of Gene Expression 
The complexity of gene expression regulation is reflected by the multitude of 
intersecting elements, factors, and signal transduction pathways that have been 
demonstrated to influence an organism's phenotype (Emerson, 2002; Panning & Taatjes, 
2008). For the purposes of this thesis and study, the main focus will be transcriptional 
regulation. 
1.3.1 Regulation of Transcription 
Cellular transcriptomes, the set of all RNA molecules produced in a particular cell 
type at a specific time, are essentially dictated by the interactions of cis-acting regulatory 
elements (sequences inherent in the genomic sequence, generally located within promoter 
regions) with trans-acting factors (Hu et al., 2008). Of the most relevant trans-acting 
factors are transcription factors (TFs). TFs are generally categorized into two distinct 
groups: 1) the basal TFs, which are ubiquitous and recruit the RNA polymerase II multi-
protein complex to the minimal or core promoter, and 2) gene-specific TFs that activate 
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or repress basal transcription by binding to regulatory DNA sequences (Morse, 2007; 
Villard, 2004). Each eukaryotic genome encodes between several hundred and several 
thousand TFs that work to either positively or negatively affect the rate of transcription 
(as activators and repressors, respectively) (0 Barrera & Ren, 2006; Villard, 2004). 
As the regulatory network expands beyond the transcription factor-DNA 
interactions to include molecules involved in the regulation ofTFs specifically, the nexus 
of possible interconnections and interactions between many additional regulatory 
signalling molecules becomes even more extensive (Levine & Tjian, 2003). 
Consequently, transcription is also further controlled by: coregulators, cofactors, 
enhancers and silencers present in the promoter regions (Szutorisz eta/. , 2005), 
chromatin condensation (Fry & Peterson, 2002), DNA methylation and acetylation via 
histone modifiers (Morse, 2007), RNA polymerase complexes, and even multiple 
promoter usage (Kleinjan & Lettice, 2008; 0 Barrera & Ren, 2006). 
Coregulators, which pertain more specifically to aspects involved in this current 
study, are master regulator molecules that contol transcription by tethering to or 
interacting with TFs, by modulating cytoplasmic signalling cascades, and by mediating 
posttranslational modifications ofhistones at promoter regions (Kininis & Kraus, 2008; 
Lonard & O'Malley, 2007; McKenna & O'Malley, 2002; O' Malley, 2008). Coactivators 
augment transcription by remodelling and altering chromatin conformation, nucleosome 
structure, and position, by modifying core histone proteins, as well as by bridging 
receptor complexes to the basal transcriptional machinery (Hall & McDonnell, 2004; 
Heintzman & Ren, 2007; Naar eta/. , 2001; Smith & O'Malley, 2004). Conversely, 
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corepressors repress transcription through recruitment of histone deacetylases (HDAC), 
competition for coactivator binding, and recruitment of additional corepressors (Smith & 
O'Malley, 2004). 
1.3.1.1 Promoter Regions & the Regulation of Transcription 
Promoters intrinsically contain specific sequences of DNA that act as transcription 
factor-specific regulatory motifs, and are referred to as transcription factor binding sites 
(TFBS) (Cao et al. , 2008). These cis-elements facilitate the interaction and tethering of 
the promoter region DNA with TFs and other known enzymes involved in RNA 
polymerase recruitment. The pertinent interplay between these cis-regulatory elements 
and trans-acting TFs in specific cellular environments serves to coordinate transcription 
in time and space, as the promoter being recognized by the TFs and the time point of 
recognition are what essentially drive the initiation of transcription (Kadonaga, 2004; 
Landry et al., 2003; Lemon & Tjian, 2000; Levine & Tjian, 2003; Maston, et al., 2006; 
Mees et al. , 2009; Sakakibara et al., 2007; Werner, 2003). Promoters furthermore 
incorporate environmental influences in the regulation of transcription as the condition of 
the cell will dictate the type of TFs that are available to recognize and bind to promoter 
region specific cis-elements. 
1.3.1.2 Alternate Promoter Usage 
Early theories regarding the regulation of transcription have been challenged and 
made more complex following the discovery that a single gene can be under the 
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regulation of multiple separate promoters. The alternate promoter regions of a gene have 
their own specific TSSs upstream of distinct alternatively encoded exons (Landry et al., 
2003). These additional promoters can contain unique cis-elements and therefore can each 
be specifically activated or repressed by distinct TFs, adding to the multifarious 
intricacies of transcript production, as well as to the spatial and temporal diversity in the 
expression patterns for a single gene (Davuluri et al., 2006). 
It was previously suggested that 18-20% of protein encoding genes use alternate 
promoters (Carninci et al., 2006; Landry et al., 2003). However, Carninci et al. , 2006, 
using a whole genome cap analysis of gene expression (CAGE) approach with sequence 
tags corresponding to several hundred thousand TSSs in the mouse and human genome, 
showed that differentially regulated alternative TSSs are a much more common feature 
than previously thought, with 58% of protein coding genes using two or more alternate 
promoters (Carninci et al, 2006). Since this study, other whole genome studies have 
continued to illustrate the prevalence of gene expression regulation through alternate 
promoter usage, showing that more than 60% of protein coding genes are transcribed 
from multiple promoters and that these alternate promoters can span up to thousands of 
kilobase pairs (Baek eta!., 2007; Davuluri eta!., 2006; Kimura eta!. , 2006). 
The nature of the promoter structure and the cellular environment dictate the 
usage of one promoter over the other (Zhang eta!., 2004). Cellular environmental 
influences, which vary from cell to cell and tissue to tissue, can include multiple TFs 
from distinct signalling pathways, regional epigenetic events (such as DNA methylation, 
histone modification, and chromatin remodelling), and even the participation of cis-
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regulatory elements upstream of the promoter region (Davuluri eta!. , 2006; Huang eta!. , 
2009). For example, the human reduced foliate carrier gene is expressed at different 
levels throughout the· body due to differential regulation of its two promoters (for further 
examples of genes affected by alternate promoter usage refer to: Andres eta!. , 2007; 
Dehma & Bonham, 2004; Hebden eta!. , 2000; Koenigsberger eta!. , 2000; Legette eta!., 
2003; Mane eta!. , 2005; Whetstine eta!. , 2002). 
There exist numerous consequences to alternate and/ or multiple promoter usage. 
One consequence, which has recently attracted considerable attention, is the role of 
alternate promoter usage in the regulation of developmental stage- specific and/ or tissue-
specific expression. Many research groups have found that developmental stage-specific 
or tissue-specific expression of many genes, including receptor genes, are regulated by 
alternative promoters (Bharti et a/., 2008; Kakizawa eta!. , 2007; Puomila eta!. , 2007; 
Sehgal eta!. , 2008; Turner eta!. , 2006; Zhang eta!. , 2004). Additionally, alternate 
promoter usage results in the generation of new ex on combinations when transcribing 
from a single gene (Davuluri eta!. 2006; Xin eta!., 2008). The differing rnRNA 
transcripts arise from the incorporation of new exons associated with each respective 
promoter (refer to Figure 1.4). This incorporation leads to the production of variant 5' 
ends that then serve as templates for the generation of distinct N-terminal end domains in 
the subsequently translated proteins. The nature of the new alternatively incorporated 
exons to the 5' transcript ends will dictate whether the transcripts variants a) encode 
identical proteins with similar function or b) encode different, novel protein isoforms with 
diverse and even possibly antagonistic functional activities (Davuluri eta!. , 2006). 
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Figure 1.4: Alternate RNA splicing and promoter usage 
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This figure illustrates the process of how one gene can encode varying protein isoforms through both 
alternate RNA splicing and alternate promoter usage. The hypothetical gene depicted here has two 
promoters (A & B) with distinct transcription start sites. The exons are marked and represented by altering 
colors. As demonstrated by the possible mature mRNA transcripts, both differential RNA splicing and 
transcriptional initation at distinct promoters influences the diversity of transcript production, which can 
ultimately lead to the generation of distinct protein isoforms following translation. 
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The production of distinct protein isoforms that exhibit varying activity and/ or 
functions is mainly due to the fact that many alternate promoters are usually separated by 
one or more exons encoding important functional domains (Davuluri et al., 2006). Protein 
interaction motifs and subcellular localization signals located at theN- terminus, such as 
secretory signal peptides and mitochondrial targeting signals, are just some examples of 
the possible functional domains that could potentially be encoded by variant transcripts. 
Furthermore, distinct protein isoforms can be generated following either a variation in 
splicing, or a switch in the open reading frame caused by the inclusion of alternate exons 
at the 5' transcript end (Landry et al. , 2003). 
It is also worth noting that mammalian genes commonly employ multiple 
promoters to regulate translation as well (Landry et al., 2003). One of the most influential 
processes controlling translation efficiency is the modulation ofmRNA stability, a 
cellular process that is highly affected by the 5' untranslated regions (UTRs) of the 
mRNA (Smith, 2008). Consequently, as alternate promoter usage can dictate the 
composition of the 5' transcript ends, it highly affects the structure of 5'UTRs. It has been 
estimated that 10- 18% of genes express alternative 5' UTRs by using multiple promoters 
(Trinklein et al. , 2003; Zhang et al., 2004). Alternate promoter usage thus also produces 
variant UTRs along with variant transcripts. Moreover, the generation of variant 5' UTRs 
mediates tissue- and/ or cell-specific expression, as well as temporal-and/or 
developmental-specific expression, because different UTRs can contain distinct 
regulatory motifs that specifically control translation efficiency. Several past reports have 
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described genes that have alternate UTRs under a cell-type or tissue-specific manner 
(Hughes, 2006; Hughes & Brady, 2005; Zhang el al., 2004). 
1.4 Consequences of the Dysregulation of Gene Expression: A Focus on 
Carcinogenesis 
1.4.1 Abnormal Gene Expression & Cancer Development 
Dysregulation of transcription, and subsequent dysregulated gene expression, 
contributes to both cancer initiation and persistence (Mees et al. , 2009; Villard, 2004). 
Furthermore, signals involved in promoting cancer are principally controlled by the 
amplified expression of oncogenes and/ or the loss of tumour suppressor expression 
(Croce, 2008; Mees et al. 2009). All principle stages of gene expression have been 
implicated in carcinogenesis when improperly activated (Smith, 2008; Stoneley, 2003; 
Venables, 2009). For the purposes of this current thesis and study though, the following 
sections will focus on how alternate promoter usage and both aberrant TF and coregulator 
signalling contribute to the oncogenic state. 
1.4.2 Abnormal Promoter Usage & Cancer Development 
Comparable to most key regulatory processes in the cell, the dysregulation of 
alternate promoter usage has been implicated in the development of various diseases 
(Davuluri et al., 2006; Hughes, 2006; Nakanishi et al., 2006; Pedersen et al. , 2006). 
Recently, more and more evidence is surfacing that supports a pivotal link between 
aberrant alternate promoter usage and cancer, as several oncogenes and tumour 
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suppressor genes contain multiple promoters that become dysregulated throughout 
tumourigenesis. In some of these cases, an abnormal preference in promoter usage has 
even triggered the initial formation of neoplasia (Davuluri et a!. , 2006). 
One specific example that demonstrates how aberrant alternate promoter usage 
can result in cancer development is that of the CYP 19 gene, which itself is under the 
regulation of eight separate promoters (Agarwal et a/., 1996; Chen eta!, 2009). 
CYP19 encodes the cytochrome P450 enzyme aromatase, which is required for the 
biosynthesis of estrogen (reviewed in Chen eta!, 2009). Disproportionately high 
expression of this gene has been documented to play an important role in the 
development and progression of breast cancer (Agarwal eta!., 1996; Bulun et a!., 
2009, Chen eta!, 2009). Studies performed by Agarwal et al., 1996 revealed that 
alternative promoter usage is a major mechanism that mediates abnormal increased 
aromatase expression in breast cancer, as breast cancer patients more abundantly 
expressed transcripts deriving from a promoter that, under normal conditions, is 
quiescent (Agarwal et al., 1996; Bulun et al. , 2009). Furthermore, 20% of known 
aromatase expression in breast cancer has been found to originate from the aberrant 
activation of an additional distally located promoter ofCYP19, the 1.7 promoter 
(Bulun et al., 2009; Chen et al., 2009). 
1.4.3 Aberrant Transcription Factor & Coregulator Signalling in Cancer 
Development 
As TFs essentially dictate when a particular gene will be expressed, it is no 
surprise that TF dysregulation, either the over-activation or repression oftheir 
signalling, has been implicated in carcinogenesis (Darnell, 2002; Mees eta/. , 2009). 
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As illustrated in Table 1. I, Mees eta/., 2009 outlined various transcription factors in 
accordance to their influence on the progression of the original six hallmarks of 
cancer. Moreover, products of oncogenes and tumour suppressor genes are often 
potent transcription factors (Mees eta/. , 2009). A number of developmental stages, as 
well as cell type differentiation, are under the control of oncogenic transcription 
factors. Moreover, the loss of anti-oncogene TFs encoded by tumour suppressor genes 
has been known to result in carcinogenesis (Villard, 2004; Mees eta/., 2009). For 
example, germ-line mutations in TFs with tumour suppressor function have been 
shown to be responsible for various hereditary cancers, such as Li-Fraumeni 
syndrome, Wilms' tumour, and retinoblastoma (Villard, 2004). (Refer to Darnell, 
2002; Mees eta/., 2009 for more an in-depth review on transcription factors and 
cancer). 
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Table 1.1 Hallmark ascriptions of oncogenic transcription factors 
Table 1 Hallmark asaiption" of oncogenic transcnption factors 
Transcription factor Jlallmark /rafts 
Self-sufficiency in Insensitivity to growth· evasion of programmed Lm11tless Sustained nssue mvasion 
growth sgnals inhibitory Signal cell death rep/ie<1~ve ang~ogenesls and metastasis 
poten~al 
AP-1 X X X 
AR X 
ATF-1 
BRN-3b X 
C/ElJP> X 
CR 13 X X 
2F·I X 
TS· I X 
WSiETS X 
OX03a X 
HIF·hA~IF- III{ARfiiT) X 
Myc X X 
NF·KB X X X 
PEA3 
RARa X 
RO t X 
SP·1 X 
STAT3 X X X 
STAT5 X X 
TP53 X 
)> From Mees eta/. , 20093• 
3 License agreement between JC and Elsevier provided by Copyright Clearance Center. License Number: 
2391 090899689; License date: March 16, 2010 
X 
X 
X 
X 
X 
X 
X 
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Coregulators, which interact with and regulate TFs, have also been implicated 
in cancer. Numerous studies have revealed that the expression of selected 
coactivators is associated with tumourigenesis and/ or progression in both breast and 
prostate cancer, and further sensitize the tumours to estrogens and growth factors 
(Smith & O'Malley, 2004). Moreover, high levels of corepressor nuclear receptor 
corepressor 2 (NCOR2) and Silencing Mediator for Retinoid and Thyroid Hormone 
Receptors (SMRT) expression has been shown to be associated with poor patient 
outcome in breast cancer, independent of other prognostic factors. Conversely, other 
steroid receptor coactivator expression is generally associated with good prognosis 
(Green eta!., 2008). Such evidence has furthermore demonstrated that an imbalance 
of coactivators and corepressors may contribute to the acquisition of resistance to 
endocrine therapy in these aforementioned cancers (Schiff et a/. , 2003; Gururaj et a!. 
2006). 
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1.5 Mesoderm Induction Early Response 1 (mier 1) 
Mesoderm induction early response 1 (mierl) is a gene encoding a potent 
transcriptional regulator protein. This gene was first discovered in Xenopus laevis in 
response to fibroblast growth factor signalling (Paterno eta/., 1997). Fibroblast 
growth factor is highly implicated in cell differentiation, mitogenesis, motility and 
angiogenesis (Grose & Dickson, 2005). Capable of inducing embryonic cells to 
differentiate into mesodermal tissues, this particular growth factor has also been 
observed to cause phenotypic transformation in various cell lines when over-expressed 
(reviewed in Grose & Dickson, 2005; Sasada eta/., 1988). This succinctly 
demonstrates the potent regulatory function of this growth factor and consequently the 
regulatory potential of responding genes, such as mierl , which serve to further 
propagate this growth factor's signal throughout the cell at differing time points of 
development and during varying metabolic processes. 
Concordantly, after being characterized as an immediate early gene and target 
of the fibroblast growth factor signal transduction pathway (Paterno et a/. , 1997) in 
Xenopus laevis embryo explants, and later being cloned and characterized in humans 
using a human testes complementary DNA (eDNA) library (Paterno et al., 1998), 
mierl has ably demonstrated its puissant regulatory potential. Depending on the 
cellular context, the mier 1 protein product, MIER I, can act as either a repressor or 
activator oftranscription, functions of which are dictated by the underlying gene and 
protein structure. 
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1.5.1 mierl Gene, Transcripts, & Protein lsoform Structure 
mierl is a complexly organized 63 kilobase pair (kb) gene that is located on 
chromosome 1 at position p31.2 (Paterno et a/. , 2002). The intricacy of its structural 
organization stems from the fact that it contains 17 different exons which, following 
exon skipping, differential polyadenylation, and both facultative intron and alternate 
promoter usage, give rise to 12 different mRNA transcripts that can ultimately be 
translated into 6 distinct protein isoforms (refer to Figure 1.5 for a gene structure 
schematic) (Paterno et al., 2002). This vast assortment of protein isoform production 
derives from the aforementioned transcriptional and post-transcriptional processes at 
either the 5' or the 3' end of mierland its transcripts. 
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Figure 1.5: mierl Gene Structure 
This figure is adapted from Paterno el a/., 2002. Exons are numbered and the common region between 
all mierl protein isoforms is indicated by the red dotted bracket. 
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With respect to the 3' end of mierl , there are three possible polyadenylation 
sites which, depending on the specific site targeted, dictate the structure of the final 
transcript (Paterno et al., 2002). Figure 1.6 depicts the location and outcome of the 
polyadenylation of each site, which are marked polyadenylation site (PAS)i, PASii, 
and PASiii respectively. Differential polyadenylation does not, however, have an 
effect on the overall nature of the C-terminal protein domain, as the C-terminal coding 
region is not altered. This is unlike the most notable variation in the 3' transcript ends, 
which is facultative intron usage. The incorporation of the final intron, intron 15, as a 
facultative intron provides the final protein isoform with a distinct coding region that 
results in a 102 amino acid C-terminal domain. This facultative intron incorporation is 
the determining factor that demarks the protein as the beta (f3) isoform (Paterno eta/., 
2002). A protein harbouring this facultative intron domain is referred to as M I ER I f3, 
regardless of the location of polyadenylation and theN-terminal end composition. 
Proteins comprising the second C-terminal domain, termed alpha (a), have been 
translated from transcripts that do not use intron 15 as a facultative intron and 
therefore contain only 23 distinct amino acids in the C-terminal domain. All proteins 
translated from transcripts lacking the facultative intron are termed MIERla, 
regardless ofN-terminal composition and variable polyadenylation (Paterno eta/. , 
2002). Exons 4-15 are constitutive exons that encode 410 residues, which make up 
the common internal or core sequence of the mierl-derived protein isoforms (Paterno 
eta/., 2002). These exons do not contribute to transcript diversity; they do, however, 
contain important regulatory motifs implicated in MIER 1 ' s cellular function 
(discussed further in section 1.5.3.). 
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Another element affecting diverse transcript production is alternate promoter 
usage. Depending on which ofthe mierl promoters becomes activated, either MLP-PI 
or MAEP-P2, will dictate the organization of the 5' ends ofthe transcripts, and 
ultimately theN-terminal end of the respective protein isoform. Figure 1.6 delineates 
the possible 5' transcript ends produced by each separate promoter. Transcriptional 
activation at the MLP-Pl promoter will produce N-terminal ends "N I" and "N2", 
while activation at the MAEP-P2 promoter will produce N-terminal end "N3". The 
difference in the two N-terminal ends generated by MLP-PI are due to skipped exon 
usage, in which "N I" includes the skipped exon 3A (74bp in length), which is inserted 
after the first amino acid (M) encoded by exon 2A (Paterno eta/., 2002). 
As further illustrated by Figure 1.6, the twelve mRNA transcripts arise through 
the mixing and matching of the four possible 3' ends with the three possible 5' ends. 
Subsequently, the six possible protein isoforms are generated by individually 
combining each of the three possible N-terminal ends to either the a. or the P isoform 
specific C-terminal end (Fig 1.6). 
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This figure is adapted fTOm Paterno el a/., 2002. The 'gene structure' section can be used as a reference 
to the exon numbers. It also illustrates the alternate AUG start sites (ML, MAE) for both of mierl's 
promoters, whereby transcription initiation at the first promoter, MLP-Pl, results in N2 and the amino 
acids ML. Although not depicted in the above figure, N, which includes the alternate exon 3A results in 
the amino acid sequence MFMFNWFTDCL WTLFLSNYQ. Transcription initiation at the second 
promoter, MAEP-P2, results in N3 and the amino acids MAE. Furthermore, the al ternate poly A sites 
are marked by PASi, PASii, and PASiii. Below the "gene structure" diagram the alternate transcripts 
and their possible respective 5' and 3' ends are depicted. N I, N2, N3 represent the alternate N-termini 
and biii , bii, bi represent the structural outcome of the alternate poly A sites respectively. The a and ~ 
specific 3' ends are also indicated. 
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1.5.2 mierl Promoters 
Recently, the role of alternate promoter usage in gene regulation has become 
more apparent, as this regulatory phenomenon not only dictates tissue-specific 
expression, but has also been observed to be abnormally employed in various cancers 
(Agarwal eta!., 1996; Bulun eta!., 2009; Dehma & Bonham, 2004; Duan et a!., 2008; 
Li et at. , 2009; Miyazaki eta!., 2009; Renaud eta!., 2007; Benz et al., 2006). As 
described in section 1.3.1.2, an important aspect contributing to the diversity of the 
possible mierl mRNA transcripts is the alternate usage of either of the gene' s two 
promoters. 
1.5.2.1 MAEP-P2 
mierl's second promoter, MAEP-P2, which is named based on the three 
distinct N-terminal amino acids it encodes, was the first mierl promoter to be cloned 
and characterized. It is situated approximately 5.3kb downstream of the first promoter 
(Ding et al., 2004) (Refer to National Center for Biotechnology Information (NCBI) 
Reference Sequence: NT_032977.8). Transcriptional initiation at this promoter results 
in the inclusion of exon 1 B and the generation of the 'N3 ' N-terminal domain thereby 
resulting in the translation of the three amino acids MAE (methionine, alanine, and 
glutamic acid), which are incorporated at theN-terminal end of the protein (refer to 
Figure 1.6 for the structure of the transcripts and possible N-terminal ends). It is also 
important to note that MAEP-P2 specific transcripts contain completely distinct 5' 
UTRs compared to transcripts produced from mierl 's first promoter MLP-P1, due to 
the incorporation of exon 1 B. As briefly alluded to in section 1.3.1.2, the presence of 
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altering UTRs in promoter specific transcripts can potentially function to regulate 
gene expression. 
Full-length 5' ends of mierl were furthermore amplified using the 5' Rapid 
Amplification of eDNA Ends (RACE) PCR method, and following sequence analysis 
and Basic Local Alignment Search Tool (BLAST) comparison, the TSS of this 
promoter was found to reside 149bp upstream ofthe MAEP-P2 ATG translation start 
site (Ding, 2004; Ding eta/., 2004). The following figure illustrates the structure of 
this promoter. 
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Figure 1.7: MAEP-P2 promoter structure 
This diagram depicts the MAEP-P2 promoter region and the exon of mierl (exon I B) that results 
fo llowing transcription at this specific promoter. Exon I B, represented by the blue box, is 12 I bp long 
and encodes the UTR as well as the first three amino acids of the protein (MAE). The transcription 
start site, represented by + I, begins 149 bp upstream of the A TG translation start site. 
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Further examination and computer-assisted sequence analysis of this promoter 
region revealed that MAEP-P2 lacks any identifiable TAT A element, initiator 
sequence, and downstream promoter elements; the two latter of which are often found 
in TAT A-less promoters (Ding, 2004; Ding eta/., 2004). It does, however, contain a 
CpG island located 389 nucleotides upstream of the TSS and extending until the start 
of translation (Ding, 2004) (Fig 1.9). Previous studies have also mapped out the 
location of the minimal promoter (the minimal sequence that is necessary for promoter 
activity). Following a deletion series analysis using a luciferase reporter, the minimal 
MAEP-P2 promoter was observed to reside 68bp upstream of the TSS. Figure 1.8 
shows the different luciferase promoter constructs used, and their relative promoter 
activity following transient transfection into HeLa cells. 
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Figure 1.8: Characterization ofMAEP-P2 promoter activity 
This diagram, adapted from Ding et a/., 2004, depicts the relative luciferase activity fo llowing 
transfection of HeLa cells with various MAEP-P2 luci ferase reporter gene deletion constructs (Ding, 
2004; Ding et at., 2004). The counts in the diagram represent the sequences cloned into the reporter 
gene construct and are with reference to the TSS. For the purposes of the current study, four of these 
particular constructs were employed: +28, -68, -3 12, and -1 3 16 were used in this study. Refer to section 
2.2.3, 3.4.1 , and 4.6 for further details. 
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Furthermore, in silica analysis of this promoter region revealed several 
potential TFBSs, including multiple binding sites for the Specificity Protein I (Sp I) 
family (Ding eta/., 2004). Figure 1.9 illustrates the location of these putative TFBSs. 
The identified Sp I binding sites were further investigated with regards to their role in 
regulating mierl transcription from MAEP-P2 by electrophoretic mobility shift assays 
(EMSAs) using a probe consisting of the MAEP-P2 minimal promoter sequence and 
a Sp )-specific antibody against He La cell nuclear extracts. Results demonstrated that 
Sp I binds to the minimal promoter (Ding eta/. , 2004). Furthermore, this interaction 
induced transcription at the MAEP-P2 promoter, as revealed from results following 
co-transfection of MAEP-P I luciferase reporter gene deletion constructs and with Sp 1 
expression vectors (Ding et al., 2004). 
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l CpG Island Begins 
(-416/-565)caaggcataa ccgctttcaa agcacagttc ttgccgccgt tgcatcacag caacatccgt 
Elf-1 
( -356/-505)ttttcagcaa atgcatttca aaaacgacct acatgtaaaa tattacgta 
:Yi ERE 
(-296/-445)ctgtgtcaat gctggatgtg actcctttgg cactgttcct l .], · t ctct gatccgtaga 
(-236/-385)caaf cccctc cgcc ~ggagt ggcggatcag ctggagccag cgaagc4ccc cgcgcg~ttg 
TEF-2 H4TF-2 
(-176/-325)cccat ctcct c cca~accca ccttg{lctcc gccccc} ccg ctcttcccgg qqagqqctqg 
(-116/-265)ccgcp gggcc gcgc. cgcgc ccctgctccg gcgcglgctc gctggtcttt tccctccagt 
TEF-2 gct f:~ l (-56/-205) f cagcccapc cggggcgccg cgag+gggcg gagtf tgggcgc 
(+5/-145) CTCCTGCGCG TT{ ccGCCG4 GGCAGTGGCG GCGGGAGCGG CAGAGACGGC AGCGGCCGGA 
(+65/-85) GTCCCGTTGC TGAGTCTCAC ATCCGGGTTC TGGCCGTGAC CCAGCTGCGG CCGCCGCGGA 
(+125/-25) GATGTGACCC GGCAGTACGG CAAAH C G 
Figure 1.9: MAEP-P2 promoter CpG Island sequence & putative transcription 
factor binding sites 
This schematic illustra tes the nucleotide sequence of the MAEP-P2 promoter region. Sp l sites are 
denoted by the navy blue boxes. Other transcription factor binding sites were also found following in 
silica analysis and are labelled, and the nucleotides constituting the binding sites are italicized with 
distinct colors. The TSS is represented by + 1 and the beginning of the CpG island is specified by the 
red up-pointing arrow. Exon I B encoded fo llowing activation at the MAEP-P2 promoter is denoted by 
the capitalized nuclcotides. 
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1.5.2.2 MLP-Pl 
mierl's most 5' promoter, MLP-P1 , named based on the two distinct amino 
acids it encodes, had yet to be fully characterized prior to this study. Transcriptional 
initiation at this promoter results in the generation of two distinct N-terminal ends: 
N2, resulting from exon 1 A and 2A, and N I resulting from exon 1 A, 2A, and a third 
normally skipped exon denoted exon 3A (refer to Figure 1.6) that lies 2.58 kb 
downstream of the A TG translation start (Paterno et al. , 2002). Ex on 3A is 74bp in 
length and is inserted after the first amino acid (methionine) encoded by exon 2A. 
Inclusion of ex on 3A results in the generation of the following distinct N-terminal 
end: MFMFNWFTDCL WTLFLSNYQ. Further characterization with regards to the 
minimal promoter region, putative TFBSs, and the location ofthe actual TSS has yet 
to be fully investigated. Figure 1.10 depicts the MLP-P I promoter region structure, 
while Figure 1.11 illustrates the nucleotide sequence ofthe proximal promoter region. 
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Figure 1.10: MLP-Pl promoter structure 
This diagram depicts the MLP-PI promoter region and the two exons (represented by the blue boxes) of 
mier I that are incorporated into mier I transcripts following transcriptiona l activation at the MLP-P I 
promoter. Exon lA or UTR(a) is 137bp long, while exon 2A, which encodes for UTR(b) of MLP-PI 
specific mRNA transcripts, also encodes for the first two amino acids (methionine and leucine) of the 
protein. Exon 2A is I 0 I bp long. The putative transcription start site, or + I, is thought to be at the 
commencement of exon I A and is 1279 bp upstream of the A TG translation start site, if the size of the 
intron is inc luded. The intron, which is 1046bp long, resides between exon lA and 2A. Without the 
intron included in the count, the TSS is 232bp upstream of the A TG translation start site. Although not 
depicted in this schematic, exon 3A lies 2.58kb downstream of the MLP-P I translation start site. 
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(-249/-1528) gtggcgacca gctggggagt ggtgcaccac cccttttttt ggccgcctct gaagtccctg 
(-189/-1468) tacccccaag ctcctccgtt agcggctcgg gccgaggctc cggaatgttt gccgggcgtc 
(-129/-1408) atggcgacgg tggagccctg gctcaacaag cggccgcgcg gttggctggc ggcacgaggc 
(-69/-1348) cgaggaggag ggcggaggcg gaggggaggg cagagggttg gtggagctgg aggaagctcc 
(-9/-1288) 
Putative TSS ( + 1) I Exon 1A 
ggacgacg1EJ TGGAAGAAGG AGGCGGGCGG CCCGGGCCTC AGGCCCCTCC CAGGCTCTGA 
(+52/-1228) GTCTCCCGGC TGCAGGCGGA TGGATGGGGC TTCTTCAGGC GGTGGCGGCA GCAGCGAAGG 
(+112/-1168) TGGCGGCGGC AGCAGCGGCA GCGGCT . .. ... . . . ... 1046bp Intron .... .... . . . . .. . 
Exon 2A 
(+1181/-95) .. . TGGTGT GGTCGCTCGA TTCTCCCAGT GCCTGGCTGA GTTTCGGACG TGGTTAAGAA 
Translation Start Site 
(+1241/-38) CCAACTGGTT GAGGTTCAAT GCAGACAAGA CGGATGTGAT GCTG 
Figure 1.11: MLP-Pl proximal promoter sequence 
This figure illustrates the MLP-PI promoter prox imal region sequences. Uppercase letters represent the 
specific exons that are denoted by the boxes. The ATG translational start site, the putati ve TSS, and the 
I 046bp intron are also demarcated. 
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1.5.3 MIERl Function 
1.5.3.1 MIERl as a Transcriptional Activator 
Primary elucidation of MIER I function demonstrated its potential role as an 
activator of transcription through a series of transactivation assays using a CAT 
reporter gene vector (Paterno et a/. , 1997). Various regions of the Xenopus ortholog 
of mierl , xmierl, which displays 91% overall similarity to the human ortholog at the 
amino acid level, were fused to the DNA binding domain ofGAL4 and inserted into 
the chloramphenicol acetyltransferase (CAT) reporter gene vector (Paterno eta/., 
1997; Paterno eta/., 1998). Results following transient transfection of these reporter 
gene vectors into NIH 3T3 cells illustrated XMIERI 's ability to transactivate gene 
transcription as an increase in the level of transcription was observed following vector 
transfection (Paterno eta!., 1997). This activation arised from the presence of highly 
acidic regions or stretches that are clustered in the common region of the protein 
towards theN terminus (Fig 1.12) as the particular CAT reporter vectors harbouring 
this N-terminal region induced transcription 80-fold in this study (Paterno eta/., 
1997). These specific types of acidic activation domain regions, of which there are 
three in human MIER l , are highly conserved between both the Xenopus and human 
mierl orthologs. Moreover, such acidic activation domains have previously been 
implicated as putative trans-activating domains involved in transcriptional activation, 
and have been found in various TFs (Blair eta!., 1994; Ko eta!., 2008; Melcher, 
2000). 
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Figure 1.12: Structure of mierl protein isoforms including protein functional 
domains 
This schematic represents the structure of the mierl isoforms with emphas is on the varying structural 
and functional domains. The common region shared by both isoforms is represented by the orange, 
purple, blue, and black boxes and consists of 410 amino acids. The acidic acti vation domains, of which 
there are three in humans, are represented by the orange box and consist of amino acids 29-37, 72-94, 
and 150-160 of the 410 amino acid common internal region. The ELM2 domain, depicted by the purple 
box, consists of amino acids 169-272 of the common region, while the SW 13, ADA2, .!'-1.-CoR, and 
IFI liB (SA NT) domain, denoted by the blue box consists of amino acids 277-32 1. The a- speci lie C-
terminal end is made up of23 amino acids and the LXXLL domain is situated between the 3'd and 7'h 
amino acids of the C-terminal end. The ~-specilic C-terminal end consists of 102 amino acids whereby 
the nuclear localization signal (NLS) is located between the 64th and 70'h amino acids of this C-terminal 
end. 
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1.5.3.2 MIERl as a Transcriptional Repressor 
Further functional studies of MIER I have characterized this protein as not only 
having a role in gene transcription activation, but more frequently functioning as a 
repressor of gene expression (Ding eta/., 2003; Ding eta/., 2004; McCarthy eta/. 
2008). Moreover, this repressive role is exerted through various mechanisms, each of 
which employ distinct protein functional domains that are inherent to either the central 
core/ common coding region of all mierl protein isoforms, or to the C-terminal 
domain ofMlERla isoforms. 
1.5.3.2.1 Transcription Factor Tethering via the SANT domain 
The signature SANT domain of mierl is situated approximately 277 amino 
acids downstream of the start of the common internal region contained in all protein 
isoforms. This particular domain exhibits I 00% identity between human and Xenopus 
laevis, and following multiple genome base sequence analyses, also portrays 88% 
identity across nine different species, thereby highlighting its importance to MIERI 
function (Thorne eta/., 2005). First identified in transcription factors .S.Wl3, ADA2, 
N-CoR, and IFIIlB, the SANT domain is a protein motif that is implicated in DNA 
binding and protein-protein interactions, and is present exclusively in nuclear proteins 
that have an important role in the regulation of transcription (Aasland eta/., 1996; 
Ding eta/. , 2004). Moreover this domain or motif is also known for its repressive 
regulatory function, as it was found to be present and implicated in the functional 
activity of the corepressors and subunits of histone deacetylases (HDACs), nuclear 
receptor corepressor (NCoR), and SMRT (Boyer eta/. , 2004). 
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Ding eta!, 2004 further supported the SANT domain 's repressive regulatory 
potential in the context of MIER I function (Ding eta!., 2004). An intact SANT 
domain was required for the physical interaction between the Sp 1 transcription factor 
and MIERl, as demonstrated by glutathione s-transferase (GST)-pull down assays 
with various MIER 1 deletion constructs (Ding eta!., 2004). Moreover, this particular 
study demonstrated that both isoforms ofMIERI(a & p), through a SANT domain 
mediated interaction with Sp I , displace Sp I from its cognate binding sites and 
represses Sp 1- activated transcription from its own minimal promoter (the MAEP-P2 
minimal promoter) (Ding et al., 2004). Furthermore, overexpression ofMIERI 
resulted in the loss of detectable Sp I from this promoter (Ding eta!., 2004). Co-
immunoprecipitation (co-lP) and chromatin immunoprecipitation (ChiP) analysis 
additionally demonstrated that not only do Sp I and MIER I physically associated with 
one another, but that they also associated with the chromatin at the mierl MAEP-P2 
promoter endogenously (Ding eta!., 2004). 
The ability of MIER l to repress Sp !-mediated transcription clearly identifies a 
negative feedback loop regulating mierl isoforms and represents a novel mechanism 
for the negative regulation of Sp I target promoters (Ding et al., 2004). Sp 1 itself is a 
TF from the family ofSp/Krlippel-like factors (KLF) family ofTFs that bind to GC 
rich sequences, such as: GC boxes, CACCC boxes (also known as GT boxes), and 
basic transcription elements (collectively referred to as 'Sp I sites') in gene promoter 
regions (Black eta!., 2001). Sp and KLF proteins cooperatively interact with one 
another and other transcription factors on GC-rich promoters to either activate or 
inhibit multiple and diverse classes of mammalian genes that play a critical role in 
regulating cellular homeostasis (Black et al., 2001; Safe & Kim, 2004). Furthermore 
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Sp 1-specific signalling has been shown to be induced following a number of varying 
cellular processes and stimuli such as growth stimulation, oncogene overexpression, 
and anti-metabolites (Black et al., 2001). Thus, the nature ofSpl 's role in the cell 
only further emphasizes the importance of the repressive regulatory potential exerted 
by MIERI. 
1.5.3.2.2 Recruitment ofHDACl via the ELM2 Domain 
Another repressive regulatory function of MlERl was attributed to its EGL-27 
and Metastasis Associated Antigen 1 (MTA 1) homology 2 (ELM2) domain, which is 
situated approximately 169 amino acids downstream of the start of the common 
internal region ofmierl (Ding et al., 2003- refer to Figure 1.12). ELM2 was first 
described in Egl-27, which is a Caenorhabditis e/gans protein that plays a 
fundamental role in patterning and embryonic development (Ding et al., 2003; Solari 
eta/. 1999). This domain is often found N-terminally to a SANT- and a GAT A-
binding domain and thought to be involved in DNA-binding and/ or protein-protein 
interactions (Lakowski et a/., 2006). Moreover, the ELM2 domain and the SANT 
domain have been found to be present in several other important transcriptional 
repressors such as metastasis tumour antigen (MT A) (metastasis-associated family 
proteins), and CoREST (REI silencing transcription factor (REST) co-repressor) 
proteins (Wang eta/., 2008; Lakowski eta/., 2006). 
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Ding et al., 2003, showed that MIER I can function to repress transcription by 
recruiting a histone deacetylase I (HDACI). HDACs, such as HDACI, are chromatin 
remodelling enzymes that inherently function to inhibit transcription by decreasing the 
accessibility of essential transcription machinery to genomic DNA by increasing 
histone-DNA interaction the removal of acetyl groups. This consequently increases 
the histone's affinity for the DNA backbone, thereby making it less accessible. 
Results obtained from transient transfection experiments showed that both 
isoforms significantly repressed expression ofthe G5tkCAT reporter plasmid in a 
dose-dependent manner (Ding et al., 2003). lmmunoprecipitation (IP) assays revealed 
that both MTER I a and MTER 1 ~ induced transcriptional repression by recruiting 
HDACI in vivo. Moreover, addition of an inhibitor ofHDACI activity partially 
relieved the MIER I isoform-mediated repression, further providing evidence for a 
role ofHDACI in mediating transcriptional repression. The ELM2 domain is also 
implicated in the MIERl-induced recruitment ofHDACI as the minimum sequence 
sufficient for recruitment ofHDAC contained the ELM2 domain along with an 
additional C-terminal sequence that is often conserved in ELM2 containing proteins 
including MIER I protein isoforms (Ding eta/., 2003). 
1.5.3.2.3 Estrogen Receptor (ER) corepressor function ofMIERla and 
implications for the LXXLL & the SANT domains 
Recent studies further outlining the function of MfER I have concentrated on 
investigating a unique attribute of the MIER I a protein isoform: the presence of the 
nuclear receptor interaction LXXLL motif (Heery eta/., 1997; Heery eta/., 200 I; 
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Savkur & Burris, 2004). This particular motif, whereby "L" signifies the amino acid 
leucine, and "X" signifies any amino acid, is represented by the amino acids 
413LQMLL 417 in MIERia and is located just three amino acids downstream of the 5' 
start site of the alpha specific C-terminal end (refer to Figure 1.12). In addition to 
interaction with nuclear receptors, the LXXLL motif is also characteristic of 
transcriptional regulation as well as nuclear hormone receptor and other TF 
coregulators (Dobrzycka et al., 2003; Dong eta/., 2006; Li eta/., 2007; Plevin eta/., 
2005). 
In light ofthe involvement ofthe LXXLL motif in the regulation of nuclear 
receptors, McCarthy eta/., 2008 investigated whether MIERia is implicated in ERa 
signalling, and demonstrated that MIERia physically interacts with ERa 
endogenously. Additional studies from our lab have further illustrated that this 
molecular interaction surprisingly did not involve the LXXLL domain, but instead the 
C-terrninal portion of the SANT domain (Mercer eta/., unpublished data). Moreover, 
this phenomenon was ligand- independent, i.e. ERa & MlER I a interacted both in the 
presence and absence of estrogen, the interaction was stronger in the absence of ligand 
(McCarthy et a/. , 2008). 
Functional implications for the interaction between MIER I a and ERa were 
discovered following experiments involving the overexpression of MIER I a in 
estrogen-treated T47D breast carcinoma cell lines (McCarthy eta/., 2008). The 
increased presence ofthis isoform greatly hampered breast carcinoma cell growth in 
response to estrogen (E2) and revealed MIER I a as a possible corepressor of ER 
signalling (McCarthy eta/. , 2008). Further studies examining MI ER I a 's repressive 
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effects on ERa investigated how MTER1a affected the transcriptional regulation of the 
E2-regulated pS2 [trefoil factor 1 (TFF1)] promoter. Results demonstrated that only 
the MIERla isoform, not the MIERIP isoform, repressed both the ligand-dependent 
and ligand-independent transcriptional activation at this promoter through molecular 
interactions with its LXXLL domain (Mercer eta/., unpublished data). 
Further investigation into the ligand-independent corepressor function of 
MlER 1 a at the pS2 promoter showed, using ChiP assays, that MIER 1 a does not 
affect ERa recruitment to the promoter, nor does its repression involve the recruitment 
ofHDAC (Mercer eta/., unpublished data). These ChiP results did, however, show 
that MIER1a repressive function ofER-mediated transcription inhibited recruitment 
of steroid receptor co-activator 3 (SRC-3) and interfered with the dimethylation of 
histone H3 lysine 9 (H3K9), two processes involving epigenetic modifications that are 
strongly involved in transcriptional activation at this promoter (Mercer eta/., 
unpublished data). 
1.5.3.2.4. Negative Regulation of the Histone Acetyltransferase (HAT) activity of 
cAMP response element binding protein (CREB) binding protein (CBP) via 
MIERlf3's ELM2 Domain 
As MIER1 had previously been implicated in recruiting HDAC1 to the site of 
transcription initiation, Blackmore eta/, 2008 investigated whether or not MJERI was 
further involved in regulating HAT activity. GST pull-down assays using 35S labelled 
flag-tagged CBP constructs, full-length GST -MIER 1 p fusion proteins, and various 
deletion mutants of GST -MTER 1 p fusion proteins showed that MTER 1 interacted with 
CBP, a known HAT. This interaction involved theN-terminal half of the protein, 
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which includes the ELM2 and acidic activation domains. Moreover, HAT assays on 
extracts from HEK 293 cells co-transfected with myc-tagged full-length MIER 1 ~and 
flag-tagged CBP showed MIER1 ~inhibited CBP (Blackmore et al., 2008). 
1.5.4 MIERl Expression & Subcellular Localization 
Studies investigating mier 1 expression patterns have demonstrated that 
MIERl ~ is ubiquitously expressed at very low levels in most human tissues (Paterno 
eta/., 1998, Paterno et al., 2002). There are, however, tissues that displayed above 
average expression levels, including the spleen, adrenal glands, adult & fetal thymus, 
small intestine, colon, heart, ovary, thyroid glands and testis. Ofthese tissues, the 
testis exhibited the highest amount of expression in both reported studies (Paterno et 
a/., 1998, Paterno et al., 2002). Further investigation of MIER 1 a isoform-specific 
transcript expression revealed that it was not as ubiquitously expressed as its ~ 
counterpart. However, its expression patterns did support its role as a nuclear receptor 
coregulator as MIERla expression is restricted to endocrine and endocrine-responsive 
tissues. With respect to the mierl splice variants, various tissue-specific expression 
patterns were noted. For example, the lung and skeletal muscle only produced MIER~ 
transcripts harbouring the N3 N-terminal domain. Moreover, the generation of splice 
variant transcripts harbouring exon 3A across certain tissues was also shown to 
display tissue-specific expression patterns, as the brain, and skeletal muscle only 
expressed transcripts harbouring the 3A exon, and the lungs expressed transcripts 
lacking the 3A exon. These studies demonstrated that mierl undergoes differential 
promoter usage and tissue-specific regulation of transcription. 
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Analyses regarding the subcellular localization of the mierl protein isoforms 
have confirmed that both the a and p isoforms reside in the nucleus, an observation 
fitting with MIER 1 's role as a potent transcriptional regulator (Mercer et al., 
unpublished data; Paterno eta/., I997). Originally it was presumed that only the 
MIER I P protein isoform had the potential to be situated in the nucleus, as it contains 
the only functional putative nuclear localization signal (NLS) in humans (Ding eta/. 
2003; Post et al., 200 I). As delineated in Figure 1.I2, this NLS resides approximately 
64 amino acids downstream of the 5' starting point of the I 02 amino acid MIER I P 
specific C-terminal end. However, further examination has demonstrated that both 
forms are found in the nucleus, even though MIER I a does not contain a NLS. Ding et 
a/. , 2003 postulate that this may be due to a co-transport or piggyback mechanism 
used by the alpha isoform in order to locate to the nucleus, such mechanisms have 
been described elsewhere for other proteins (Kang eta!., I994; Zacksenhaus eta/., 
1999). 
1.5.5 Breast Cancer & MIERl 
Among Canadian women, breast cancer continues to lead in incidence, with 
22, 700 new cases expected in 2009 (Canadian Cancer Society 2009 Cancer Statistics, 
2009). Even though animal models have given us great insight into the molecular 
pathways involved in breast cancer development, there are still many remaining gaps 
in our understanding of the manifestations and progression of this disease (Jp & Asch, 
2000; Shackleton et a/., 2006; Sting) et al., 2006; Thompson et al., 2008). To date 
many signalling pathways have been extensively researched with respect to signal 
transduction in breast cancer, such as: the estrogen receptor, receptor tyrosine kinase 
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(RTK), and DNA repair pathways. However, knowledge concerning their regulation 
and interplay during breast cancer is incomplete (Britton eta!., 2006; Schiff eta/., 
2005; Speirs eta/., 2007). Furthermore there is a great need for the characterization of 
the causative factors and potential regulators underlying the invasive progression of 
breast cancer cells (reviewed in Gonzalez-Angulo et a/., 2007; Thompson et al., 
2008). 
Recent studies focusing on MIERia have implicated this mierl isoform as 
having a role in breast cancer progression. Overexpression of MIER I a in T4 70 breast 
carcinoma cells, in conjunction with estrogen treatment, significantly reduced the 
ability of estrogen to stimulate anchorage independent growth of these cells 
(McCarthy eta/., 2008). These results suggest that MIERI alpha may regulate breast 
carcinoma growth as the ability to proliferate without attachment is a distinct indicator 
of cell tumourigenicity (Fukazawa eta/. , 1995; McCarthy eta/., 2008). Moreover, the 
nature ofMIERla's corepressor function and interaction with ERa, as described in 
section 1.5.3.2.3, has strong implications for MJER I 's role in regulating ERa 
signalling, a receptor whose dysregulation has long been established as playing a 
fundamental role in breast cancer development and tumourigenesis (Chen eta/., 2008; 
Jones eta/., 2008; Speirs &Walker, 2007). 
These unique characteristics of MIER I a in association with breast cancer 
become even more pertinent, though, in the context of invasive disease. 
Immunohistochemical analysis of normal breast tissues and breast carcinoma tissues 
of varying stages demonstrated that as breast cancer cells acquire a more invasive 
phenotype, the subcellular localization of MIER I a changes dramatically (McCarthy et 
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a/., 2008). Instead of residing in the nucleus, whereby 77% ofthe normal breast 
samples examined contained nuclear MrERla, MIER1a was mainly situated in the 
cytoplasm of cells from invasive tissue, with only 4% of invasive ductal carcinoma 
(IDC) samples staining for nuclear MlER I a (McCarthy et a/., 2008). This striking 
change in subcellular localization in invasive breast cancer may have ramifications for 
MJER1a's pivotal function as a nuclear transcription factor coregulator. McCarthy et 
a/., 2008 hypothesized that the change in subcellular localization ofMJER1a from the 
nucleus to the cytoplasm may inhibit MIER I a from exerting its gene/chromatin 
repressor function and suppression of ERa, thereby ridding the cell of an inherent 
security mechanism and subsequentially increasing breast carcinoma cell proliferation 
(McCarthy et al. 2008). Moreover, the ability of MlER 1 a to regulate ERa in the 
absence of ligand strongly parallels the function of another gene with implications in 
breast cancer development, namely BRCA 1, which regulates ERa-stimulated and 
unliganded ERa activity (Gorski eta/., 2009; Zheng eta/., 200 I). 
1.5.6 The Regulation of mierl 
In order to fully understand the role of MIER 1 in the transcriptional regulatory 
network of the cell, it is necessary to characterize the regulatory factors that control its 
expression and that induce MIER 1 isoforms to exert their functional effects. To date 
several studies have elucidated various molecules that regulate mier 1 transcription, 
such as: fibroblast growth factor, Spl , and even mierl's own protein product, MIERI , 
which functions to inhibit Sp !-induced transcription in the form of a regulatory 
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feedback loop (Ding eta/., 2004; Paterno eta!., 1997). Most of the current knowledge 
about the regulation of mierl at the level of transcription has come from the 
characterization of the MAEP-P2 promoter. 
Regulatory mechanisms involved in MLP-P1 promoter- specific transcription 
have yet to be investigated. As described in section 1.5.4, expression analysis of 
transcript splice variants demonstrates that mierl promoters are under tissue-specific 
regulation, which further exemplifies that each promoter can be regulated by distinct 
transcriptional and environmental factors. Moreover, potential transcriptional 
activation at the MLP-Pl promoter can result in the incorporation of the commonly 
skipped exon, exon 3A. This phenomenon expands the network of converging factors 
implicated in mierl expressional regulation, as distinct factors can be involved in 
controlling the subsequent inclusion of this exon. 
1.6 The Aims and Principle Objectives of this Study 
The full characterization of promoter regions, by virtue of their function in 
transcriptional regulation, is not only key to understanding tissue-and stage-specific 
gene expression regulation, but is now increasingly becoming more important to 
understanding the development of diseases, such as cancer (Heintzman & Ren, 2007). 
The unique characteristics of the MLP-P1 promoter, and the possible outcomes of 
MLP-P1- driven transcription, suggest that this promoter may be implicated in the 
regulation of mierl in breast cancer. To this effect, several hypotheses have been 
made concerning mierl regulation at MLP-Pl and breast cancer: 
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I) If the putative NES and/ or putative transmembrane domain specified by exon 
3A functions to remove proteins from the nucleus, then MLP-PI-driven 
transcription can produce mier1 protein isoforms that reside in the cytoplasm. 
2) If during breast cancer progression there is a preferential activation of the 
MLP-P I promoter over the MAEP-P2 promoter of mier 1, then this can 
perpetuate the production of an increased number of cytoplasmic I non-
nuclear residing mier1 isoforms which may serve to explain the reported 
subcellular localization change of MIER I a from the nucleus to the cytoplasm 
in invasive breast cancer. 
The primary goal ofthis study was to characterize the MLP-PI promoter of 
mier1. Determination of the specific sequences required for activity at this promoter 
facilitated this study's additional aims, which were to investigate mier1 promoter 
activity in breast cancer cells, as well as to identify whether or not transcriptional 
activation at MLP-PI can affect the subcellular localization of certain mier1 isoforms. 
In order to meet these specific aims, this study focused on the following summarized 
objectives. 
Objective 1- Characterize the MLP-P 1 promoter, including the analysis and 
identification of the minimal nucleotide sequence necessary for promoter activity and 
the nucleotide sequence necessary for maximal promoter activity in breast cancer 
cells. 
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Objective 2- Search for putative human TFBSs residing in the MLP-P 1 promoter 
region in order to identify whether or not this promoter contains any putative TFBS 
that interact with transcription factors that are dysregulated in breast cancer. 
Objective 3- Characterize MLP-P 1 promoter activity in various eel/lines and 
determine if promoter activity is ER status dependent. 
Objective 4- Compare the activity of the two mier1 promoters in various cell lines to 
determine if there is preferential usage. 
Objective 5- Investigate whether or not the inclusion of exon 3A in mier 1 transcripts 
affects the subcellular localization of MIER1 a. 
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Chapter 2: Material & Methods 
2.1 Cell Culture 
2.1.1 Cell Lines & Cell Maintenance 
Four different cell lines were used in this study, as de picted by the fo llowing tab le: 
Table 2.1: Cell lines 
Cell line Descri tion Su tier J 
Human embryonic kidney American Tissue Culture 
HE K 293 Cells cells transformed with Collection (ATCC); A TCC® 
Adenovirus 5 DNA #: CRL-1573™ 
Mammary gland, carcinoma, A TCC; A TCC® #: HTB-
Hs578 T Cells ER negative 126™ 
Mammary gland, A TCC; A TCC® #: HTB- ----1 
MC F7 Cells adenocarcinoma, ER positive 22™ 
Mammary gland, ATCC; ATCC~#: HTB-
MDA MB 231 Cells adenocarcinoma, ER 26TM 
negative 
Mammary gland, ductal ATCC; A TCC® #: HTB-
T47D Cells carcinoma, ER positive 133™ 
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HEK 293 cells, MDA MB 231 cells, and Hs578T cells were grown and 
maintained in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen) 
supplemented with 10% Serum [75% calf serum (CS; Invitrogen) and 25% fetal 
bovine serum (FBS; Invitrogen)], 1% sodium pyruvate (Na-pyruvate; Invitrogen), and 
0.5% penicillin/ streptomycin (Pen/Strep; Invitrogen) as per recommendation of the 
American Type Culture Collection (ATCC). MCF7 cells were cultured in media 
containing DMEM supplemented with 10% Serum [75% CS and 25% FBS], 1% Na-
pyruvate, 0.5% Pen/Strep, and 0.001% of 4mg/ml insulin/ (Invitrogen). T47D cells 
were grown in RMP1-1640 media (Invitrogen) supplemented with 10% Serum [75% 
CS and 25% FBS], 2.383 g/L HEPES (Invitrogen), 0.00 I% of 4mg/ml insulin, and 
0.5% Pen/Strep. 
All cells were grown in 1 OOmL plates (Corning) containing 1 OmL of 
respective media as described above and kept in an incubator at a temperature of37°C 
containing 5% C02 levels. Cells were allowed to grow until confluency was reached. 
The optimal confluency (refer to Table 2.2) is different for every cell line and is 
dictated by their respective growth patterns and cellular structure. Following growth to 
optimal confluency (usually between 70-90% confluent; refer to Table 2.2), cells were 
subcultured at various dilutions depending on the cell line (Table 2.2). Briefly, media 
from each plate was aspirated and then cells were washed carefully with 5ml of 1 x 
phosphate-buffered saline (PBS; Sigma). The I x PBS was then aspirated off and 
1.5ml of 1% trypsin/ [ethylenediamine tetraacetic acid (EDTA)] (Invitrogen) in 1 x 
PBS (Sigma) was added. Cell culture plates were then rocked back and forth until all 
cells were no longer attached to the plate surface. Cells were then resuspended in the 
required amount of media that would yield the respective subcultivation ratio and then 
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added to a new cell culture plate containing enough media to result in a final volume 
of lOml. 
Sterile technique was strictly employed for all handling and subculturing of 
cells, which was performed in a laminar flow-hood (E-614, BioKione). Prior to any 
cell culture work, the laminar flow hood was exposed to ultraviolet (UV) light for at 
least 5 minutes and wiped down with 70% ethanol. All equipment, media, and 
reagents being brought into the laminar flow hood were wiped down with 70% 
ethanol. Only specifically designated laboratory coats were worn in cell culture and 
fresh new gloves were always employed. 
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Table 2.2: Cell line optimal confluency & subcultivation ratios 
Cell Line Maximum Confluency Sub-cultivation Ratios 
HEK 293 Cells 80-90% 1: I 0 
Hs578T Cells 70-80% 1:3 
MCF 7 Cells 60-70% 1:3 
MDA MB 231 Cells 70-80% 1:3 
T47D Cells 60-70% 1:2 
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2.2 Vectors & Constructs 
2.2.1 Experimental Control Plasmid Constructs 
Plasmid constructs were an integral part of this study. The following table 
details the pia mid constructs that were used as experimental control vectors for 
various employed experiments: 
Plasmid Construct 
Name & Manufacturer 
pGL3 empty vector 
(Prom ega) 
pRSV ~-Galactosidase 
(pRSVJ3-gal) 
(Prom ega): 
hERa pcDNA3 
Table 2.3: Experimental control plasmids 
Plasmid Construct Description 
This 4818bp plasmid vector contains luc + gene, which encodes 
for the firefly luciferase protein. The luc + gene,however, lacks 
eukaryotic promoter and enhancer sequences and; therefore, 
expression of the luciferase protein and subsequent luciferase 
activity depend on the insertion and proper orientation of a 
functional promoter sequence upstream of luc +. This particular 
empty vector, with no additional sequence inserted into its 
multiple cloning site, was used as a negative control for 
background luciferase activity. 
This expression plasmid construct contains the bacterial/acZ 
gene encoding the P-galactosidase enzyme inserted into the 
pRSV vector. It was used as control for monitoring transfection 
efficiency. The pRSV vector itself contains the rous sarcoma 
virus (RSV) promoter that drives transcription of the lacZ gene 
and subsequent production of the P-galactosidase (p-gal) enzyme. 
This expression plasmid construct (-kind gift from Dr. Christine 
Pratt, University of Ottawa) was designed to express the coding 
sequence of human Ra. In this particular study it was 
transfected into the ER negative HEK 293 cell line in order to 
verify whether or not any observed difference in promoter 
activity results between HEK 293 cells and the MCF7 ER 
positive breast cancer cell line was not a function of differing ER 
status (refer to section 3.2.3). The pcDNA mammalian 
expression vector is designed for high-level, constitutive 
expression in a variety of mammalian cell lines and includes the 
cytomegalovirus (CMV) enhancer-promoter for high-level 
expression as well, as an amp resistance gene. 
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2.2.2 pCS3+MTmierla & pCS3+MTmierla exon3A 
The expression vectors pCS3+MTmierla and pCS3+MT mierla exon 3A 
were used in order to investigate the effects of encoding exon 3A and the subsequent 
incorporation of the putative NES on the subcellular localization of mierl protein 
isoforms. Full length mierla-specific isoform genomic sequence stemming from the 
MLP-P 1 promoter (GenelD: 57708; accession number NM _ 00 l 077703) was 
engineered and cloned into the pCS3+MT empty vector Z. Ding in our laboratory 
(Ding, 2004). The pCS3+MT empty vector is a myc-tagged mammalian expression 
vector that was kindly provided by Dr. David Turner, University of Michigan, 
whereby the myc tag constitutes six N-terminal repeats of the amino acid residues 
MEQKLISEEDLNE from the c-MYC protein. 
Furthermore, the pCS3+MT mierl a exon 3A (GeneiD: 57708; accession 
number NM_OOl 077702) was constructed by Corinne Mercer in our laboratory and 
includes the full-length mierla-specific isoform genomic sequence stemming from the 
MLP-P I promoter and containing the encoding sequence of exon 3A. 
2.2.3 mier 1 Luciferase Reporter Gene Deletion Constructs 
Luciferase reporter gene constructs containing specific sequences of mierl 
promoter regions inserted into the pGL3 empty vector were used to analyze and 
compare mierl promoter activity. All constructs, except for MLP-Pl (-91) pGL3 and 
MLP-Pl (-44) pGL3, were cloned and engineered by Zhihu Ding, PhD (Ding, 2004). 
Briefly, this included the sub-cloning of mierl promoter specific eDNA, which was 
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originally isolated from human primary ectocervical cells, into the pCR2.1 vector. The 
isolated eDNA included 4077 bp ofmierl genomic sequence eDNA that spanned the 
MLP-Pl promoter region and 3045 bp ofmierl genomic sequence eDNA spanning 
the MAEP-P2 promoter region. Further deletion constructs were then generated 
through PCR- amplification of specific regions of each promoter using the primer 
pairs listed in Tables 2.4 & 2.5, and using the previously mentioned constructed 
plasmids as templates. These amplification products where then each cloned into 
separate pCR2.1 vectors. Each pCR2.1 vector was then digested with distinct 
restriction endonucleases in order to facilitate the directional cloning and ligation of 
the cloned sequences into the pGL3 empty vector to produce the final mierl-promoter 
specific luciferase reporter gene deletion construct (Ding, 2004). For further in-depth 
details on full cloning procedures performed in our laboratory, refer to either section 
2.4 or Ding, 2004. 
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Table 2.4: Primers used for cloning & engineering ofMLP-Plluciferase reporter 
gene deletion constructs 
MLP-PI Luciferase 
Reporter Gene 5' Primer Sequence 3' Primer Sequence 
Construct 
MLP-PI (-1708) 5'TGCAGGITGGT 5'TCCGTCITGTC 
pGL3 AGCCT AGAAGCAACA 3' TGCA TTGAACC 3' 
MLP-PI (-1077) 5'GCTGTGTGCTT 5'TCCGTCTTGTC 
pGL3 TTCT ACAGTCTTGITC 3' TGCA TTGAACC 3' 
MLP-P1 (-742) 5'CTCGAGTGCAA 5'TCCGTCTTGTC 
pGL3 CGGCACGA TCT 3' TGCA TTGAACC 3' 
MLP-PI(-185) 5'CCCAAGCTCCT 5'TCCGTCTTGTC 
pGL3 CCGITAGCG 3' TGCA TTGAACC 3' 
MLP-P1 (-91) 5'CGGTTGGCTGG 5'TCCGTCTTGTC 
pGL3 CGGCACG3' TGCATTGAACC 3' 
MLP-PI(-44) 5'GAGGGCAGAGG 5'TCCGTCTTGTC 
pGL3 GTTGGTGGAG 3' TGCATTGAACC 3' 
~ MLP-P1(+37) 5'CTCCCAGGCTCT 5'TCCGTCITGTC pGL3 GAGTCTCC 3' TGCA TTGAACC 3' 
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Table 2.5: Primers used for cloning & engineering ofMAEP-P2 luciferase 
reporter gene deletion constructs 
MAEP-P2 Luciferase 5' Primer Sequence 3' Primer Sequence 
Reporter Gene 
Construct 
MAEP-P2 (-1316) S'GACTGTCTGT AG S'CGTACTG CGGGT 
pGL3 ACTCTTTTCC 3' CACA TCTCC 3' 
MAEP-P2 (-312) S'ACGT A TTTTTCC S'CGTACTGCCGGGT 
pGL3 TCTGCTGTGTCA 3' CACATCTCC 3' 
MAEP-P2 (-68) S'TITCCCTCCAGT S'CGTACTGCCGGGT 
pGL3 CCAGCCCAGCCG 3' CACATCTCC 3' 
MAEP-P2 (+28) S'AGTGGCGGCGG S'CGTACTGCCGGGT 
pGL3 GAGCGGCAGAGA 3' CACATCTCC 3' 
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2.2.3.1 MLP-Pl Luciferse Reporter Gene Deletion Constructs 
Seven distinct MLP-PI promoter-specific luciferase reporter gene deletion 
constructs were used throughout the duration ofthis study. Each plasmid construct 
includes, inserted into the multiple cloning site of the pGL3 empty vector, the entire 
DNA sequence stemming from the respective 5' starting nucleotide (as dictated by the 
5' primer used for its construction, refer to Table 2.4) up until seven base pairs 
upstream of the ATG start site, as dictated by the 3' primer used to engineer each 
construct (refer to Table 2.4 for the exact sequences ofthe primers used to engineer 
these reporter gene constructs). It is also important to note that each MLP-PI 
Juciferase reporter gene deletion construct includes the 1 046bp intron in the MLP-P1 
promoter region, the exact location of which is illustrated in Figures 2.1 & 2.2 (refer 
to Appendix 2 for the exact nucleotide of this specific intron). The nucleotide counts 
represented in each Juciferase reporter gene deletion construct name are relative to the 
putative TSS ofMLP-Pl. As this promoter has yet to be completely analyzed, the 
actual TSS remains to be fully delineated. The putative TSS resides at the the first 
nucleotide incorporated into the MLP-P I 5' UTR, and thus the first nucleotide of exon 
1 A. Moreover, Figure 2.1 represents a schematic of the relative location of 5' starting 
position ofthe insertion sequences incorporated into each MLP-PI luciferase reporter 
gene deletion construct. The full nucleotide sequences of the construct inserts with 
reference to the overall MLP-Pl promoter region nucleotide sequence are depicted in 
Figure 2.2 for four of the plasmid constructs containing sequences of the proximal 
promoter area. Refer to Appendix 1 for the exact insertion sequences and 5' start 
positions ofthe three additional constructs not included in Figure 2.2 (-MLP-Pl(-
1708) pGL3, MLP-Pl(-1077) pGL3, and the MLP-PI (-742) pGL3 constructs). 
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MLP-P1 (-1708) pGL3 1 ~LP-P> (->on) pGL3 
1046 bp lntron 
1lit lA 
u ~LP-P1 (-44) pGL3 
MLP-P1 (-91) pGL3 
MLP-P1 (-185) pGL3 
MLP-P1 (-742) pGL3 
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Figure 2.1: Schematic of mierl MLP-Pl promoter region with reference to the 
sequences incorporated into tbe MLP-Pl luciferase reporter gene deletion 
constructs 
chematic depicts the MLP-P I promoter region, as well as the two exons (represented by the blue 
boxes) of mierl that are incorporated into mierl transcripts following transcriptional activation at the 
MLP-PI promoter. Exon lA or UTR (a) is 137bp long, while exon 2A, which encode for the 
untranslated region UTR(b) of MLP-P I specific mR A transcripts, is 10 I bp long. This exon also 
encodes for the first two amino acids (meth ionine and leucine) of the protein. The putative transcription 
start site, or+ I, is situated at the commencement of exon I A and is 1278 bp upstream of the A TG 
translation start site, if the size of the intron (represented by the yellow box) is incl uded. Without the 
intron included in the count, the TSS is 232bp upstream of the ATG translation start site. The 5' start 
positions of the nucleotide sequences contained in each respective luciferase reporter gene deletion 
construct are represented with the yellow arrows. 
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(-249/-1528} gtggcgacca gctggggagt ggtgcaccac cccttttttt ggccgcctct gaagtccctg 
(-189/-1468} 
cbMLP-P1(-185) pGL3 
tacc aag ctcctccgtt agcggctcgg gccgaggctc cggaatgttt gccgggcgtc 
(-129/-1408} atggcgacgg tggagccctg gctcaacaag 
r MLP-P1(-91) pGL3 
cggccgcgc gttggctggc ggcacgaggc 
MLP-P1(-44) pGL3 
(-69/-1348} 
(- 9/-1288} 
cgaggaggag ggcggaggcg gaggg aggg 
Putative TSS I Exon 1A 
ggacgacgaEJ TGGAAGAAGG AGGCGGGCGG 
cagagggttg gtggagctgg aggaagctcc 
t LP-P1(+37) pGL3 
CCCGGGCCTC AGGCCCCTCC CAGGCTCTGA 
(+52/-1228} GTCTCCCGGC TGCAGGCGGA TGGATGGGGC TTCTTCAGGC GGTGGCGGCA GCAGCGAAGG 
(+112/-1168} TGGCGGCGGC AGCAGCGGCA GCGGCT ... . ...... . . 1046bp Intron ....... . .. ... .. 
Exon 2A 
(+1181/-95) ... T GTGT GGTCGCTCGA TTCTCCCAGT GCCTGGCTGA GTTTCGGACG TGGTTAAGAA 
3Ci!nd of reporter gene inserts 
(+1241/-38} CCAACTGGTT GAGGTTCAAT GCAGACAAGA ! GGATGTGAT GCTG 
Figure 2.2: DNA sequence of the MLP-Pl promoter proximal region 
The above figure depicts the mierl nucleotide sequence (Entrez Gene ID: 57708) of the MLP-P I 
promoter proximal region spanning 1528bp upstream of the ATG translational start site and 249 bp 
upstream of the putative TSS. The first number on the left side is the nucleotide count with respect to 
the putative TS of MLP-P I where as the second number is the count with respect to the ATG 
translation start site. The sequence of the I 046bp intron is not included (Refer to Appendix 2 for the 
complete DNA sequence of the intron). Four out of the seven of the MLP-PI specific reporter construct 
5' sequence start sites are indicated. (Refer to Appendix I for the location of the other three constructs). 
The putative TS , as well as the start of exons I A and 2A, are denoted along with the ATG 
translational start site, which is typed in red. Uppercase letters demarcate the nucleotides in either exon 
lA or 2A. The location whereby all MLP-PI luciferase reporter gene deletion construct insertion 
sequences terminate at the 3'end is a lso denoted, and resides 7 bp upstream of the MLP-P I A TG 
translation start site. 
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2.2.3.2 MAEP-P2 Luciferase Reporter Gene Deletion Constructs 
There were four different MAEP-P2 luciferase reporter gene deletion 
constructs used in this study. These constructs include, in the insertional cloning area 
ofpGL3, all ofthe DNA sequence stemming from the respective 5' starting position 
(as dictated by the 5' primers used, refer to Table 2.5) to six nucleotides upstream of 
the ATG start site, as dictated by the 3' primer used in the engineering of each 
construct (Table 2.5). Figure 2.3 is a schematic of the MAEP-P2 luciferase reporter 
gene deletion constructs relative to the MAEP-Pl promoter region. The numbers 
incorporated into the name of each MAEP-P2 luciferase reporter gene deletion 
construct represent the count of the 5' nucleotide relative to the TSS ofMAEP-P2. As 
this promoter had been already characterized (Ding, 2004; Ding et al. , 2004), the 
actual known TSS is denoted (Fig 2.3 & 2.4). The actual nucleotide sequences 
inserted into the plasmid constructs with reference to the overall MAEP-P2 promoter 
region are represented in Figure 2.4 for three out of the four employed MAEP-P2 
luciferase reporter gene deletion constructs. Refer to Appendix 3 for the full 
nucleotide sequence of the insert cloned into the largest MAEP-Pl luciferase reporter 
gene deletion construct [MAEP-P2 (-1316) pGL3] with reference to the overall 
MAEP-P2 promoter region. 
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MAEP-P2 (-312) pGL3 
MAEP-P2 (-1316) pGL3 
Figure 2.3: Schematic of the mierl MAEP-P2 promoter region with reference to 
the sequences incorporated into the MAEP-P2 luciferase reporter gene deletion 
constructs 
Diagram depicts the MAEP-P2 promoter region, as well as the exon of mierl (exon I B) that results 
following transcription at this speci fie promoter. Exon I B, represented by the blue box, is 12 I bp long 
and encodes the UTR as well as the first three amino acids of the protein (methionine, alanine, and 
glutamic acid). The transcription start site, represented by + I, begins 148 bp upstream of the ATG 
translation start site. The 5' start positions of the nucleotide sequences contained in each respective 
luci ferase reporter gene deletion construct are represented with the yellow arrows. 
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(-416/-565)caaggcataa ccgctttcaa agcacagttc ttgccgccgt tgcatcacag caacatccgt 
MAEP-P2 {-312) pGL3 
( - 356/-505)ttttcagcaa atgcatttca aaaacgacct acatgtaaaa tatt · cgtat ttttcctctg 
(-296/-445)ctgtgtcaat gctggatgtg actcctttgg cactgttcct tgacctctct gatccgtaga 
(-236/-385)caaccccctc cgcctggagt ggcggatcag ctggagccag cgaagcgccc cgcgcggttg 
(-176/-325)cccacctcct cccacaccca ccttgactcc gccccctccg ctcttcccgg ggagggctgg 
MAEP-P2 {-68) pGL3 
(-116 / - 265)ccgcggggcc gcgcgcgcgc ccctgctccg gcgcgtgctc gctggtct tccctccagt 
(-56/-205) ccagcccagc cggggcgccg cgagggggcg gagtggggtg tggtgggcgc ch+l gctcgg GG 
MAEP-P2 {+28) pGL3 
(+5/-145) CTCCTGCGCG TTCCCGCCGA GGC TGGCG GCGGGAGCGG CAGAGACGGC AGCGGCCGGA 
(+65/-85) GTCCCGTTGC TGAGTCTCAC ATCCGGGTTC TGGCCGTGAC CCAGCTGCGG CCGCCGCGGA 
3r end of reporter gene inserts 0 
(+125/-25) GATGTGACCC GGCAGTACGt CAAATL::JC G 
Figure 2.4: DNA sequence of the MAEP-P2 promoter proximal region 
The above figure depicts the mierl nucleotide sequence (Entrez Gene ID: 57708) of the MAEP-P2 
promoter proximal region spanning 565bp upstream of the ATG translational start site and 4 16bp 
upstream of the TSS. The first number on the left side is the nucleotide count with respect to the TSS 
of MAEP-P2, where as the second number is the count with respect to the ATG start site. Three out of 
the four MAEP-P2 specific reporter construct 5' sequence start sites are indicated. (Refer to Appendix 3 
for the location of the additional upstream luciferase reporter deletion construct MAEP-P2 (-1316) 
pGL3 location.) The TSS/ beginning of exon Ibis indicated, along with the ATG translational start site, 
which is denoted in red. Uppercase letters demarcate the nucleoli des in exon I b. The location whereby 
all MAEP-P2 luciferase reporter gene deletion construct insertion sequences terminate at the 3' end is 
also denoted, and resides 6 bp upstream of the MAEP-P2 A TG translation start site. 
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2.3 Plasmid Construct Preparation, Purification, Quantification, & Storage 
In order to generate or replenish laboratory stocks of the various reporter gene 
deletion constructs, XL Blue chemically competent Escherichia coli (E. coli) cells 
(XL blue cells) (Stratagene Inc.) containing the respective reporter gene deletion 
construct were streaked on a Luria Broth (LB) ampicillin (amp; Sigma-Aldrich) 
plates [5g peptone (MP Biomedical), 2.5g yeast extract (Fisher Scientific), 5g NaCI 
(Fisher Scientific), 7.5g Agar (Oifco Laboratories), 500ml dH20, 50f..lg/ ml amp, 
autoclaved]. XL Blue cells containing respective reporter gene deletion constructs 
were obtained from either transforming new XL Blue cells with the reporter plasm ids 
or collecting bacteria from glycerol stocks [20% glycerol (Fisher Scientific), and 80% 
LB media (5g peptone, 2.5g yeast extract, 5g NaCI, 500ml dH20 , autoclaved)] 
harbouring bacterial cells previously transfected with the respective reporter plasmid. 
Briefly, XL Blue cell transformation involved incubating 5ng of reporter construct 
DNA with IOOf..ll of XL Blue cells for 30 minutes on ice. Cells were then heat-shocked 
at a temperature of 42°C for 45 sec and then put on ice for another 2 minutes. Two 
hundred and fifty microlitres of LB media was then added to the cells and shaken for I 
hour at 250 rpm at 37°C. One hundred microlitres of this LB/ cell mixture was then 
plated on aLB amp plate and incubated overnight at 37°C. In the case of collecting 
bacteria from glycerol stalks, approximately I drop of glycerol stock sample was 
streaked onto aLB amp plate and incubated overnight at 37°C. The reason why LB 
amp plates were used was because only bacteria harbouring the plasmid constructs, 
which encode an amp-resistance gene, would be able to grow in the presence of amp. 
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Following the overnight growth of the bacterial colonies, one or two colonies 
were inoculated into 150m I of LB media containing 750Jll of amp and were left to 
incubate over night at 37°C while horizontally shaking at 250rpm. The following day, 
the constructs were collected and purified using a Nucleobond® PC500 EF plasmid 
maxi prep kit (Catalogue# 740 550; Clontech Laboratories Inc.) as per manufacturer' s 
protocol. Maxi-prep kit purification expected yield is usually between 1 00-SOOJ.!.g of 
DNA that is then subsequently resuspended in TE-EF buffer supplied by the 
Nucleobond Maxi-Prep Kit. Reporter gene deletion plasmid constructs were then 
quantified using Quant-iT™ dsDNA BR Assay Kit (Q-Bit) (Invitrogen, Inc) following 
manufacturer's protocols. Following quantification, all reporter gene deletion 
construct stocks were either diluted or re-precipitated in order to be kept at a IJ.l.g/Jll 
DNA concentration and were then stored at 4°C. Furthermore, verification of the 
integrity of each plasmid construct was performed by DNA gel electrophoresis (refer 
to section 2.4.2) whereby both 80ng and 160ng of each plasmid was run on a 0.8% 
aragose gel and analyzed. 
2.4 Reporter Gene Deletion Construct Design, Cloning, & Construction 
For this study, two additional deletion constructs were engineered in order to 
further investigate the essential nucleotide sequences involved in MLP-PI promoter 
activity. These extra reporter constructs were MLP-PI(-91) pGL3 and MLP-Pl(-44) 
pGL3, which were illustrated in section 2.2.3. Figure 2.5 illustrates the steps 
involved in the design and generation of these additionalluciferase reporter gene 
deletion constructs. 
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a)Prlmer Design & In sllico 
promoter analysis 
e) Colony Screening, Mini-
preparation & purification, 
DNA quantification ,and 
sequencing of MLP-P1(-91) 
pGL3 & MLP-P1(-44) 
b) Polymerase Chain 
Reaction 
d) Restriction Digest, Gel 
excision, Ligation, and 
Directional Cloning Into the 
pGL3 basic vector 
b) TOPO Cloning Into the 
pCRZ.1 Vector 
c) Colony Screening, Mini-
preparation & purification, 
DNA quantification, and 
sequencing of MLP-P1 (-91) 
pCRZ.1 & MLP-P1 (-44) 
pCRZ.1 
Figure 2.5: Flow-chart for reporter gene deletion construct design, cloning, & 
construction 
Engineeri ng of the MLP-P I luciferase reporter gene deletion constructs MLP-P I ( -9 1) pGL3 and MLP-
P I (-44) p<ILJ fo llowed the steps depicted in this tigure. 
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2.4.1 in silica Promoter Analysis & Primer Design 
Four kilo base pairs of sequence upstream of the A TG translation start site, 
2722bp upstream ofthe putative TSS (-not including the 1046bp intron) ofthe MLP-
Pl promoter was subjected to in silica promoter analysis using the following 
programs: 
Algorithm Program 
Transcription Element Search 
System 
Website 
http://www.cbil.upenn.edu/cgi-bin/tess/tess 
Transcription Factor Binding 
Site (85% and 80% homology 
searches 
http:/ /mbs.cbrc.j p/research/dbffFS EA RCH .htm I 
Gene Regulation-Ali Baba 2.1 
CON SITE 
http://www.gene-regulation.com/ 
http:/ /asp. i i. u ib.no:8090/cgi-
bin/CONSITE/consite 
Following in silica analysis, and using previously collected preliminary results 
as a reference (refer to Appendix 4 for preliminary results), 5' primers and a 3' primer 
were designed to anneal to specific regions of the MLP-Pl promoter DNA sequence 
between the MLP-PI (-185) pGL3 and the MLP-PI (+37) pGL3 sequences. Table 2.6 
lists the exact sequences of the primers developed. To facilitate eventual directional 
cloning into the pGL3 empty vector, these primers were further engineered with a Bgl 
II restriction enzyme recognition site on the 5' primer and a Hindi II restriction enzyme 
site on the 3' primer (refer to Table 2.8). Furthermore, the newly designed primers also 
contained several 5' flanking nucleotides (either cytosine (C), guanosine (G), thymine 
(T), or adenine (A)) to enable the successful cleavage of the cloned product by the 
restriction enzymes as described by New England BiaLabs (New England BiaLabs 
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2009·1 0 Catalog & Technical Reference) with respect to the kinetic and enzymatic 
properties inherent to each respective restriction enzyme (Table 2.6). 
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Table 2.6: Primers designed for the construction ofMLP-Pl (-91) pGL3 and 
MLP-Pl (-44) pGL3 luciferase reporter gene deletion constructs 
MLP-PI Luciferase 
Reporter Gene Deletion 
Construct 
MLP-Pl (-91) pGL3 
MLP-Pl (-44) pGL3 
5' Primer Sequence 
5' C7TAGATCTCGGTT 
GGCTGGCGGCACG 3' 
5'AAGAGA TCTGAGGGC 
AGAGGGTTGGTGGAG 3' 
3' Primer equence 
5'CTAAGCTTGTCTT 
GTCTGCA TTGAACC 3' 
5'CTAAGCTTGTCTT 
GTCTGCA TTGAACC 3' 
Underlined sequences denote the restriction enzyme recognition sites (AGATCT= Bgl II 
restriction enzyme site; AAGCTT = Hindlll restriction enzyme site). The italicized letters 
represent the additional nucleotides incorporated to enable successful cleavage by the 
restriction enzymes. 
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2.4.2 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was performed using Platinum® Taq DNA 
Polymerase High Fidelity {Invitrogen) according to the manufacturer's protocol in 
order to produce the mierl MLP-Pl reporter gene deletion construct-specific insertion 
sequence. This particular enzyme, designed for cloning purposes, was chosen based 
on its ability to ensure the accuracy of the original DNA sequence template 
{Invitrogen). The template for the PCR reactions was the previously constructed 
pCR2.1 vector containing the originally isolated 4077bp eDNA insert from human 
primary ectocervical cells (refer to section 2.2.3). Primers used were the MLP-Pl (-91) 
pGL3- specific and the MLP-Pl (-44) pGL3-specific primers described in section 
2.4. 1. Briefly, 48J..Ll of master mix (refer to Table 2.7 for components of Platinum® 
Taq DNA Polymerase High Fidelity Master mix) was added to 2J..Ll of 1 ng/J..Ll template 
plasmid construct in a 0.5ml thin-wall PCR tube (Fisher Scientific). For negative 
controls, 2J..Ll of dH20 was used instead of the template plasmid construct. Contents 
were gently mixed, centrifuged, and then placed in a thermal cycler (Eppendorf 
Authorized Thermal Cycler) and subjected to the PCR program outlined in Table 2.8. 
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Table 2.7: Platinum® Taq DNA Polymerase High Fidelity master mix reagents 
Reagent Amount/tube (J.d) Amount/Master Mix (x 4.5) 
(ie: for 4 samr>les 
1 Ox High Fidelity PCR 5 22.5 
Buffer (Invitrogen) 
50mMMgS04 2 9 
(Invitrogen) 
10mM dNTPs 4.5 
nvitrogen) 
---
1 OOJ!g/Jll of 5' primer 1.25 5.6 
1 OOJ!g/Jll of 3' primer 1.25 5.6 
Sterile dH20 37.5 168.8 
Platinum® Taq High 0.2 0.9 
Fidelity 
Master Mixes were calculated using 4.5 in the hypothetical 4 sample master mix so as to account for 
pi petting error. Platinum High Fidelity Taq DNA Polymerase was added last to the master mixes. 
following mixture of the other reagents. 
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Table 2.8: Thermocycler parameters for PCR using Platinum Taq DNA 
Polymerase High Fidelity 
Temperature eq Time (sec) Number of Cycles 
94 120 1 
55 30 
68 33 30 
94 30 
55 30 
68 420 1 
30 1 
4 HOLD 
The 94°C temperature incubation was for denaturing of the template, the 55°C temperature incubation 
ensured annealing of primers, while the 68°C temperature incubation allowed lor extension. 
80 
Following the initial PCR reaction using Platinum® Taq DNA Polymerase 
High Fidelity, 0.2Jll of normal Taq DNA Polymerase (Invitrogen) was added to each 
sample thereby enabling an addition of a single deoxyadenosine (A) residue to the 3' 
ends of each eDNA product. This A-overhang is necessary for the TOPO TA cloning 
step described in the next section. The PCR products were incubated with Taq DNA 
Polymerase for I 0 minutes at 72°C. PCR product sizes were verified by DNA gel 
electrophoresis of 5J.!I of the PCR product diluted in 5J.!I of sterile dH20 and 2J.!I of ' I 
x blue juice' [Diluted from I 0 x blue juice: 0.25% bromophenol blue (BioRad), 0.25% 
xylene cyanol FF (BioRad), 25% Ficoll (Amersham GE Healthcare)]. All gels were 
made up of 1% agarose (Invitrogen) and 1 x TBE buffer [-diluted from I 0 x 
TBE{ 1 08g Tris base (Fisher Scientific), 55g boric acid (Fisher Scientific), and 40ml 
0.5M EDTA pH 8.0 (Sigma) per litre of 10 x TBE, autoclaved}]. Gels were run at a 
voltage of 115V for 40 minutes. 
2.4.3 TOPO Cloning of mierl MLP-Pl Promoter Specific Insertion Sequences 
into the pCR2.1 Vector 
Following verification of the PCR amplicon integrity and size using DNA gel 
electrophoresis, these products were then cloned into the pCR2.1 vector/ pCR®2.1-
TOPO (Invitrogen) using a TOPO T A Cloning® Kit (Invitrogen) as per manufacturer 
protocol. The pCR2.1 vector provided in this kit, pCR®2.1-TOPO , is designed 
specifically to contain overhanging 3' deoxythymidine (T) residues which are able to 
efficiently ligate with the (A) overhangs produced following addition of Taq 
Polymerase to the PCR-amplified inserts described in section 2.4.2. 
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- - - ------
Briefly, 2f.ll of freshly generated PCR product containing the MLP-P I 
promoter reporter gene deletion construct specific insertion sequence was each 
respectively added to a solution containing 2f.ll of salt solution [ 1.2M NaCI, 0.06M 
MgCh], 7f.ll of sterile dH20 , and lf.ll ofthe pCR®2.1-TOPO vector (-all ofwhich was 
provided by the TOPO TA Cloning® Kit (Invitrogen)). The reaction was mixed 
gently and then left to incubate for 5 minutes at room temperature. Following this 
incubation period, the reaction tubes were placed on ice and 2f.ll of each respective 
TOPO® Cloning reaction was added to a vial of chemically competent One Shot® INV 
E. coli and mixed gently. This reaction was then left to incubate on ice for 30 minutes 
and then heat-shocked for 30 seconds at 42°C. Immediately after the heat-shock step, 
the reaction tubes were placed on ice and then 250f.ll of room temperature SOC 
medium [2% tryptone, 0.5% yeast extract, I OnM NaCI, 2.5mM KCI, I OmM MgC12, 
I OmM MgS04, 20mM glucose] (Invitrogen; catalogue# 15544-034) was 
subsequently added to each respective tube. The tubes were then horizontally shaken 
at 200 rpm for 1 hour at 37°C. Following this incubation, both 50f.ll of transformation 
alone and lOf.ll oftransformation with 20f.ll of SOC media (used to ensure even spread 
of bacterial cells) for each respective transformation was spread on a pre-warmed LB 
amp plate and let to incubate overnight at 37°C. 
2.4.4 Colony Screening, Mini-Preparation & Purification, DNA Quantification, 
and Sequencing of MLP-Pl (-91) pCR2.1 and MLP-Pl (-44) pCR2.1 
Positive colonies containing the pCR®2.1-TOPO vector ligated with MLP-Pl 
promoter region DNA sequence were screened using conventional PCR with Taq 
DNA Polymerase (Invitrogen). The PCR 5' primer that was used was a primer 
designed specifically to anneal the vector exactly 39bp upstream of the insertion site 
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(Sequence: 5'GATCCACTAGTAACGGCCGCC 3'), where as the PCR 3' primer used 
was designed to anneal to the 3' end of both the MLP-PI reporter gene deletion 
construct specific insertion sequences (Sequence: 5 'CT AAGCTTGTCTTGTCT 
GCA TTGAACC 3') . Briefly, PCR was performed using 251-ll reactions whereby, 
while employing aseptic technique, the bacterial colony to be screened was touched 
by a pipet tip which was then submersed into an already prepared 251-ll PCR reaction 
(refer to Table 2.9 for description ofPCR Master Mix reagents). This same pipet tip 
was then used to gently streak a pre-warmed LB amp plate in order to grow up and 
store the possible positive colony. The streaked LB amp plates were placed in 37°C 
temperature and left to grow over night and the PCR reaction tubes were then placed 
in a thermal cycler and subjected to the PCR program outlined in Table 2.1 0. PCR 
amplicons were then analysed by DNA gel electrophoresis. 
83 
Table 2.9: Taq DNA Polymerase master mix reagents for colony screening 
Reagent Amount/tube (J.d) Amount/Master Mix (x 4.5) 
(ie: for 4 colonies) 
lOx PCR Buffer 2.5 22.5 
(Invitrogen) 
SOmMMgClz 0.75 9 
(Invitrogen) 
lOmM dNTPs 2 4.5 
(lnvitro en) 
100f.1g/f.1l of 5' primer 5.6 
I 
5.6 
----1 
lOOf.lg/Jll of3' primer 
Sterile dH20 17.65 168.8 
0.1 0.9 I Taq DNA Polymerase 
_j 
Master Mixes were calculated using 4.5 in the hypothetical 4 colony master mix so as to account for 
pi petting error. Taq DNA Polymerase was added last to the master mixes, followi ng mixture of the 
other reagents. Then, the pipet tip that came into contact with the bacterial colony to be screened was 
submerged in a tube containing 251-11 of the PCR master mix. 
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Table 2.10: Thermocycler parameters for PCR colony screening using Taq DNA 
Polymerase 
Temperature (OC) Time (sec) Number of Cycles 
94 120 
55 45 
72 45 30 
94 45 
55 30 
72 420 
30 1 
25 HOLD 
The 94°C temperature incubation was for denaturing of the template, the 55°C temperature incubation 
ensured annealing of primers, while the 72°C temperature incubation allowed for extension. 
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Bacterial colonies that resulted in the expected PCR product following colony 
screening were selected to further prepare and purify. Two positive bacterial colonies 
for each MLP-Pl reporter gene deletion construct were inoculated into 5ml ofLB 
media containing 25J.d of amp and left to grow over night at 37°C while horizontally 
shaking at 250 rpm. The following day, the MLP-Pl reporter gene deletion constructs 
in the pCR2.1 vector (-denoted separately as: MLP-Pl (-91) pCR2.1 and MLP-Pl 
(-44) pCR2.1) were purified using the Wizard® Plus SV Minipreps DNA Purification 
System (Promega; catalogue# A1460) following the manufacturer' s protocol. Each 
construct was then quantified using the Q-Bit as per manufacturer' s protocols. 
Verification of the integrity of each plasmid construct was performed by DNA gel 
electrophoresis whereby both 80ng and 160ng of each plasmid was run on a 0.8% 
agarose gel and analyzed. Following DNA construct quantification, the insertion 
sequences of MLP-P I ( -91) pCR2.1 and MLP-P I ( -44) pCR2. 1 were completely 
sequenced in order to verify the exact nucleotide composition of the newly generated 
constructs. All sequencing was performed at Memorial University' s Genomic and 
Proteomics (GAP) facility and using an Applied Biosystems 3730 (ABJ 3730) 
automated 48-capillary DNA analyzer (ABl 3730) (Applied Biosystems). 
2.4.5 Restriction Digest, Gel excision, Ligation, and Directional Cloning of MLP-
Pl (-91) pCR2.1 & MLP-Pl (-44) pCR2.1 inserts into the pGL3 empty vector 
Once MLP-Pl (-91) pCR2.1 and MLP-PI (-44) pCR2. 1 were confirmed as 
having the proper insertion sequence, they were digested with Bglll (Invitrogen) and 
Hind III (Invitrogen) restriction enzymes in order to isolate the insertion sequences in 
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these constructs. The pGL3 empty vector (the ligating vector), was also digested with 
the same enzymes. The total amount of DNA digested was 5J..Lg for the pGL3 empty 
vector and I2J..Lg for each respective pCR2.1 MLP-PI construct. Digestions were 
carried out in a total volume of 40J..LI , including: vector DNA, 3 x excess of each 
restriction enzyme, and I 0% of I 0 x React 2 Buffer (Invitrogen). Reaction 2 buffer 
was chosen as both enzymes where able to function optimally in this buffer. Each 
reaction was mixed and left to incubate at 37°C for 1 hour. The digested products for 
both the pGL3 empty and MLP-Pl pCR2. l vectors were loaded on a 1% agarose / 1 X 
TBE gel for 40 min at 115 volts. The gel was then visualized under low UV light and 
the area containing the desired DNA bands was excised from the gel. The digested 
inserts and digested pGL3 empty vector were then extracted and purified using a 
QlAquick Gel Extraction Kit (Qiagen, catalogue# 28704) as per manufacturer' s 
instructions. Following purification, the purified Bgl II and Hind 111 digested inserts 
from MLP-Pl (-91) pCR2.1 and MLP-PI (-44) pCR2.1 and the purified Bglll and 
Hind III digested pGL3 empty vector were quantified by the Q-Bit assay kit. Once the 
concentration of each was known, then these digested products were ligated using T4 
DNA Ligase (Invitrogen, Inc). Briefly, a molar ratio of3: 1 of Bgl ll and Hind IJI 
digested insertion sequence: Bglll and Hind lll digested pGL3 empty vector (approx. 
50ng of total DNA) was added to 4J..LI of 5 x T4 ligase buffer (Invitrogen), I J..LI ofT4 
DNA ligase, and enough dH20 to yield a final reaction volume of20J..LI. This reaction 
was incubated overnight at room temperature. The following day, ligation products 
were then transformed into XL Blue E. coli. using the same method as described in 
section 2.3. 
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2.4.6 Colony Screening, Mini-Preparation & Purification, DNA Quantification, 
and Sequencing ofMLP-Pl (-91) pGL3 and MLP-Pl (-44) pGL3 
Bacterial colonies were then screened in order to find the specific colonies that 
picked up the pGL3 vectors harbouring the MLP-Pl promoter sequence inserts using 
conventional PCR following the same procedure as described in section 2.4.4. The 5' 
primer used to screen these colonies was designed to anneal exactly 62 bp upstream of 
the multiple cloning site ofpGL3 empty vector (sequence: 5'CTAGCAAAATAGGCT 
GTCCC 3'), while the 3' primer used was the same as described in section 2.4.4. 
Once positive colonies were found the specific colonies were inoculated in LB media 
and collected and purified using the Wizard® Plus SV Minipreps DNA Purification 
System as described in section 2.4.4. The subsequent DNA quantification and 
sequencing were also performed as described earlier. Once sequencing confirmed that 
the final pGL3 constructs contained the desired sequence, these constructs, denoted: 
MLP-Pl (-91) pGL3 and MLP-Pl(-44) pGL3 respectively, were then further prepared, 
purified , quantified, and stored as described in section 2.3. 
2.5 Transient Transfection 
Transfection protocols were dependent on the cell line used, as conditions for 
optimal growth and transfection efficiency varied accordingly. 
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2.5.1 HEK 293, Hs578T, MDA MB 231, and T47D Cell Transfection 
Approximately 18 hours prior to transfection, either HEK 293 cells, Hs578T, 
MDA MB 231 cells, or T47D cells were seeded at various densities (refer to Table 
2.11) in 6-well plates (Corning) containing 2m I of either HEK 293 cell supplemented 
media, MDA MB 231 supplemented media, T47D supplemented media, or Hs579T 
supplemented media per well. Directly preceding transfection, the supplemented 
media was replaced with 1.5ml of fresh serum free media (SFM) depending on the 
cell line being used, ie: HEK 293, MDA MB 231 , and Hs578T SFM contained 
DMEM, and 1% Na- pyruvate, while T47D SFM contained RPMI, 1% HEPES, and 
0.00 I% of 4mg/ml insulin. Following media change, the plates were placed back into 
the incubator until time oftransfection. All media replacements involving HEK 293 
cells were performed under strict caution as not to dislodge the cells from the cell 
culture plate surface. 
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Table 2.11: Cell line seeding densities for 6-well plates 
HEK 293 Cells 
Hs 578 T 
MCF7 Cells 
Cell Line 
MDA MB 231 Cells 
T47 D Cells 
t 
Seeding Density 
(cells per well in a 6 well plate) 
5 x iO 
3 X 10 
3 x t 05 
3 x iO 
3 x l05 
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Each luciferase reporter gene deletion construct, along with the pRSVpgal 
construct, was transfected into 3 wells, therefore performed in triplicate for every 
experiment4 • Each well was transfected with 0.5~g of a specific luciferase reporter 
gene deletion construct and 0.25~g ofthe pRSVp-gal plasmid using 6~1 of plus 
reagent (Invitrogen) and 6~1 of lipofectamine (Invitrogen) according to the 
manufacturer' s protocol. Briefly, sufficient amounts of plus reagent were added to 
master mixes containing plasmid construct DNA diluted into appropriate amount of 
cell line-specific SFM, mixed, and incubated at room temperature for 15 minutes. 
Following this latter incubation, lipofectamine was diluted in ample SFM (800~.d per 
reporter construct included in the master mix) and was added to each master mix. The 
complexes were then incubated for another 15 minutes at room temperature. Then, 
additional SFM was added to the master mixes to make up the final volume so that 
each well received I ml of the DNA-Plus reagent-lipofectamine complex mixture. One 
millilitre of these master mixes was then each added to their respective wells and cells 
were placed into the incubator and left to incubate for 4 hours. Following this 4 hour 
time period, the DNA-Pius-lipofectamine complexes were aspirated off and replaced 
by fresh supplemented media corresponding to each respective cell line. Forty-four 
hours following this time point, cells were lysed and protein was extracted. 
4 Depending on the experiment, and along with the luciferase reporter gene constructs and the pRSV~-gal 
expression vector, cells were also transfected with e ither 0.5j.!g of either hE Ra pCDNA3 (for HEK 293 cells) or 
0.5j.!g of pCDNA3 empty vector (for breast cancer cell lines). For further information as to the rational for the use 
of these pCDNA3 constructs and as to when exactly these vectors were employed, refer to the results section of 
this thesis for each experimental data set. 
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2.5.2 MCF7 Cell Transient Transfection 
Approximately 18 hours prior to transfection, MCF7 cell lines were seeded at a 
density of 3xl05 cells/ well in 6-well plates containing 2ml ofMCF7 supplemented 
media per well. Directly preceding transfection, cell media was replaced with 1.5ml of 
fresh new MCF7 supplemented media and placed back into the incubator until time of 
transfection. Each luciferase reporter gene was transfected in triplicate with either I J..lg 
or 0.5J..lg5 ofluciferase reporter gene plasmid DNA, along with 0.25J..lg ofpRSVp-gal 
plasmid DNA6. For MCF7 cells, the Transl~-LTI transfection reagent (Mirius; 
catalogue # MIR 2300) was employed as a transfection reagent and all transfections 
were performed according to the manufacture's protocol using a ratio of3J..ll of reagent 
per lJ..lgofplasmid DNA. Briefly, the Transi~-LTI transfection reagent was brought 
to room temperature and gently mixed prior to use. Master mixes for each construct 
were prepared by adding ample amounts of luciferase reporter gene deletion construct 
DNA , Transi~-L Tl transfection reagent, and enough MCF7 SFM so that each well 
obtained 260J.!l from the respective master mix (MCF7 SFM: DMEM, I% Na-
pyruvate, and 0.00 I% of 4mg/ml insulin). These components were incubated at room 
temperature for 18 minutes, and then consecutively 260J..ll of each respective master 
mix was added to its respective well. The culture plates were then placed directly in 
5 Varying amounts of mier I promoter luciferase reporter gene deletion constructs were used depending on the 
experiment. For example, the characterization of MLP-P I activity in MCF7 cells employed lj.lg of each reporter 
construct because this was as lj.lg of DNA was an efficient amount as stated by the transfection reagent 
manufacturer (Mirius). Comparison ofMCF7 data to other cell lines though required 0.5j.lg of reporter construct as 
this was the same amount transfected into the other cell lines. 
6 For experiments whereby MCF7 data was compared to HEK 293 data, 0.5j.lg of pCDNA3 empty vector was also 
transfected in along with the luciferase reporter gene deletion constructs and the pRSY~-gal expression vector. For 
further information as to rational behind this inclusion refer to section 3.2.2 and 3.2.3. 
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the 37°C incubator and left for 48hours at which time the cells were then lysed and 
protein was extracted. 
2.6 Cell Lysis & Protein Extraction 
Forty-eight hours following transfection, cell media was aspirated from each 
well and the transfected cells were washed with I ml of I x PBS. Following aspiration 
of the I x PBS, protein extraction was performed by adding 400J.tl of I x Cell Culture 
Lysis Reagent (-prepared by adding 4 volumes of sterile dH20 to 1 volume of 5 x Cell 
Culture Lysis Reagent [Promega; l25mM Tris (pH 7.8 with H3P04) , 1 OmM DTT, 
50% glycerol, and 5% Triton X-1 00, stored at -20°C] to each well at room 
temperature. The plates were then incubated on ice for at least I 0 minutes to further 
enhance cellular lysis. Following this incubation, cells were scraped from each 
individual well using separate cell lifters (Fisher Scientfic) for each respective 
transient transfection, and Jysate was transferred to a chilled 1. 7ml eppendorf tube 
(Corning). Each lysate sample was then vortexed for 10 seconds and then centrifuged 
for 15 seconds at l2,000g in an Eppendorf Centrifuge model 5415C. Supernatant was 
transferred to a freshly chilled 1.7ml eppendorftube, and each sample was stored at 
-20°C until further use. 
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2. 7 Reporter Assays 
2.7.1 Beta-Galactosidase ((3-gal) Assay 
Twenty four hours following collection of cell lysate, samples were thawed, 
vortexed, spun down, and aliquoted into 1.7ml eppendorftubes in order to proceed 
with the P-galactosidase (p-gal) assay. This assay was performed in order to analyze 
the transfection efficiency of each well/sample by measuring the ability of p-gal to 
convert its substrate, o-nitrophenyi-P-0-galactopyranoside, to 0-nitrophenol, which 
proceeds as a calorimetric reaction. The amount of sample aliquoted in preparation 
for the assay depended on the cell line used and the transfection efficiency of each 
particular cell line (Refer to Table 2.12). Three separate tubes were additionally 
prepared as blanks/ negative controls by aliquoting lOJ..LI of I x cell culture lysis 
reagent instead of sample lysate. The assay itself was performed at either room 
temperature or 37°C, depending on cell line used and the nature of the experiment 
(Refer to Table 2.12). Two hundred microlitres of P-gal assay buffer [I 00% Z-buffer 
(-prepared using protocol from yeast protocol handbook-Ciontech: 4g/L of ortho-
Nitrophenyt-p-galactoside (ONPG)- the substrate of p-galactosidase enzyme (Sigma 
N-1127), and 0.27% ofbeta-mercaptoethanol (P-M-ETOH) (Bio-Rad)] was added in 
specific time intervals to each respective lysate sample and then vortexed for 1-2 
seconds. The time of when the P-gal buffer was added was recorded and the 
calorimetric reaction was left to proceed until a visible yellow colour was formed. 
Once the samples turned yellow, the reaction was stopped by adding 200J..LI of I M Tris 
pH 11.3 stop solution [121.1 g Tris Base, I litre dH20 , adjusted to pH 11.3 and 
autoclaved] in the same interval sequence as the lysate and the time of the sample 
incubation with the P-gal buffer alone was calculated. Two hundred microlitres of 
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each sample was then transferred to a 96-well plate (Corning) and the absorbance at 
415nm was read for each sample using a spectrophotometer. Raw beta gal data was 
then corrected for and normalized according to the value of the blank readings and 
time of assay duration by dividing the value of the 415nm sample reading minus the 
415nm blank reading by the p-gal incubation time period. 
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Table 2.12: Temperatures & sample aliquot amounts for P-Gal assay 
Cell Line Amount of Lysate Temperature of Assay (°C) Aliquoted (J.d) 
MLP-Pl Promoter MLP-P I Promoter 
Characterization Comparison between Cell Lines 
HEK 293 Cells 5 25 37 
MCF7 Cells 10 25 37 
MDA MB231 10 37 37 
Cells 
T47D Cells 10 37 37 
Hs578T Cells 10 37 37 
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2.7.2 Luciferase Assay 
Promoter strength, and thus the ability of a promoter to recruit RNA pol II for 
transcription initiation can be quantified using the luciferase assay system (Promega). 
This system employs reporter gene vectors harbouring a promoterless gene encoding 
the firefly luciferase enzyme, of which can be measured upon addition of the 
luciferase substrate and subsequent generation of light. It was this assay system that 
was employed throughout the majority of this project. Briefly, cell lysate samples 
were thawed, vortexed, and quickly spun down in preparation for the luciferase assay 
the day following protein extraction. Lyophilized luciferase assay substrate (Promega; 
catalogue # E 150 1) was then brought to room temperature, for at least a half an hour 
in an aluminum-covered plastic container, so as to prevent any exposure to light. Once 
the luciferase assay substrate was equilibrated to room temperature, 1 OJ.!I of each cell 
lysate sample was transferred to a luminometer tube (Simport; T405-3) and combined 
and gently mixed with the substrate for I 0 seconds. The amount of light produced 
following the enzymatic reaction between the luciferase protein and its substrate was 
read for 10 seconds by a luminometer (Mono light 20 I 0 luminometer; Analytical 
Luminescence Laboratory) and the relative luciferase units (RLU) values were 
recorded. RLU values where then normalized to transfection efficiency and the 
amount of protein in each sample, which was calculated by dividing the RLU values 
by the ratio of the corrected beta gal values (section 2.7.1) to the Bio-Rad values 
(section 2.7.3) for each respective sample. 
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2.7.3 Bio-Rad Protein Assay 
Bio-Rad Protein assays were completed in order to determine the amount of 
protein present in each cell lysate sample to facilitate the normalization of each RLU 
value to the level of protein of each respective sample. Cell lysate samples were 
thawed, vortexed, and quickly spun down prior to being aliquoted. Bio-Rad protein 
assay dye reagent (Bio-Rad) was then equilibrated to room temperature. Following the 
temperature equilibration of the Bio-Rad protein assay dye reagent, 790J.!I of sterile 
dH20 was added to I OJ.!I of cell lysate. Two hundred microlitres of Bio-Rad protein 
assay dye reagent was then added to the diluted cell lysate and vortexed. For a control 
or blank sample, in order to calibrate the spectrophotometer, 200J.!I of Bio-Rad dye 
reagent was added to 790J.!I of sterile dH20 and 1 OJ.!I of I x cell culture lysis buffer. 
Samples were then incubated for at least 5 minutes at room temperature and then 
transferred to 1.5ml cuvettes (Fisherbrand). The absorbance of each sample was 
measured at 595nm following calibration of the spectrophotometer (Pharmacia 
Biotech Ultrospec 2000). 
2.8 Immunocytochemistry (ICC) & Transient Transfection 
In order to investigate the nature of the putative NES encoded by ex on 3A and 
its effects on the subcellular localization ofMIERia in breast cancer cells and in the 
non-cancerous HEK 293 cell line, immunocytochemistry (ICC) was performed 
following transient transfection of expression vectors encoding MIER I a with and 
without the 23 amino acids encoded by exon 3A. In preparation of ICC, HEK 293, 
MCF7, T47D, and MDA MB 231 cells were seeded into either poly-L-Iysine hydro-
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bromide (Sigma) treated 8-well chamber slides (BD BioSciences) for MCF7 cell lines, 
or 0.1% gelatin (Fisher Scientific) treated 8-well chamber slides (BD BioSciences) for 
HEK 293 cells and MDA MB 231 cells7• All cells lines were seeded into their 
respective media at the densities outlined in Table 2.13 eighteen hours prior to 
transfection8. Transient transfections with either pCS3+MT empty vector, 
pCS3+MTmierla, or pCS3+MT mierla exon 3A were performed using Transi~-
LTl transfection reagent (for MCF7 & MDA MB 231cells) and Transl~-293 
transfection reagent (Mirius; catalogue# MIR 271 0) for HEK 293 cells. Each 
procedure followed was exactly the same as described in section 2.5.1 and 2.5.2 
respectively, with the exception of the various reagent volumes which were changed 
to coincide with volumes corresponding to 8-well chamber slides as per manufacturer 
protocol9• Briefly, the cell media of each well of each respective chamber slide was 
replaced by 200J.!I offresh MCF7, MDA MB 231, or HEK 293 supplemented media. 
Each well was transfected with 0.26j..lg of expression vector plasmid DNA. TransiT®-
LTl transfection reagent (Transl~-293 transfection reagent for HEK 293 cells) was 
employed at a 3:1 ratio of reagent to plasmid DNA for MCF7 and HEK 293 cells and 
a 8:1 ratio for MDA MB 231 cells. Master mixes for each expression vector were 
prepared so that each chamber slide well received 0.26j.!g of expression vector DNA, 
7 The reason why HEK 293 cells and MDA MB 231 cells were seeded into 0.1% gelatin treated chamber slides 
instead of the poly-1-lysine hydro-bromide treated slides used for the MCF7 cells was because the 0.1% gelatin 
treated chamber slides more efficiently kept the cells of these respective cell lines remaining on the chamber slide 
surface. Unlike MCF7 cells, which are readi ly adherent to the chamber slide surface following poly-I-lysine hydro-
bromide treatment, the HEK 293 and MDA MB 23 1 cells eiTortlessly dislodge from the surface when poly-1-lysine 
hydro-bromide is applied as a cell-adherent agent. 
8 Table 2.15 illustrates the optimal seeding densities for 8-well chamber slides of each cell line as dictated by the 
distinct growth patterns and cell structure of each respective cell line. 
9 The protocol employed for the TranslT®-293 transfection reagent was the same as that which was used for the 
Transl-r®-LTl transfection reagent. 
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0.8J!I of Trans I~ transfection reagent, and 24.68 J.tl of cell line-specific SFM. The 
master mixes were incubated at room temperature for 18 minutes, and then 
consecutively, 26J.tl of each respective master mix was added to the coinciding wells. 
The culture plates were then placed directly in the 37°C incubator. 
Forty-eight hours following transient transfection, the chamber slides were 
removed from the incubator and placed in a 250m I beaker of 1 x PBS (diluted from 10 
x PBS: 80g NaCI, 2g KCI (MP Biomedicals, LLC), 2.4g KH2P04 (Fisher Scientific), 
21.6g Na2HP04·7H20 (Fisher Scientific), adjusted to pH 7.4, final volume to I litre 
with dH20 , autoclaved) in order to wash and rinse the supplemented media from the 
cells. Cells were then fixed to the chamber slides by first removing the chamber slides 
from the 250m I beakers containing 1 x PBS so that each well was full with 1 x PBS. 
Half of the 1 x PBS was then aspirated and then 200J!1 of 4% paraformaldehyde 
solution [2g paraformaldehyde (Fisher Scientific), 5ml 10 x PBS, 40mL dH20 
warmed to 60°C in order to dissolve paraformaldehyde, adjusted to pH 7] to each 
chamber slide well and incubated for 5 minutes. Chamber slides were then again 
placed into 250m I beakers of I x PBS for rincing and then removed so that 1 x PBS 
solution remained in each well. Half of the I x PBS was then again aspirated and 
200J!l of 4% paraformaldehyde was added to each well and incubated for 10 minutes 
in a moist incubation or humidification chamber in order to prevent the cells from 
drying during incubation thereby allowing a total paraformaldehyde-incubation time 
of 15 minutes. The humidification chamber employed for these steps and future steps 
of the ICC protocol was prepared by inverting a small plastic gel tray and placing it in 
a larger sterile plastic container lined with paper towel napkins soaked in I x PBS. 
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Chamber slides were then washed twice in fresh lxPBS by submersing them in 
two fresh 250m! 1 x PBS filled beakers. The chamber slides were then placed in 
250m I beakers containing 0.1% TritonX-1 00/ I x PBS [1 00% TritonX-1 00 (Sigma) 
diluted in 1 x PBS] for 5 minutes in order to disrupt and perforate the cellular 
membrane. This step strengthens the access and subsequent recognition and staining 
of the antibody-specific antigens. The 0. 1% TritonX-1 00/ 1 x PBS was then aspirated 
off and 200J.ll of 5% blocking buffer was then added to each well and the chamber 
slides were incubated for l hour a humidification chamber. This step is essential in 
the ICC procedure as the blocking buffer binds to the non-specific sites inside the cell 
that could be recognized by the secondary antibody and therefore prevents future non-
specific staining from occurring. The blocking buffer is able to function in such a 
manner as it is made up of serum from the same animal source to which the secondary 
antibody was prepared. In the case of the experiments performed in this study, the 
secondary antibody, sheep-anti mouse horseradish peroxidase (SAM-HRP) 
(Amershan Bioscience), was engineered from immunization of a sheep against the 
mouse heavy chain antigen incorporated in the primary antibody that is of murine 
origin. Therefore, the 5% blocking buffer constituted 5% sheep serum in 1 x PBS. 
Following the I hour blocking buffer incubation, chamber slides were submersed in a 
250m! beaker containing 1 x PBS and then, following aspiration of the I x PBS, 200J.ll 
of0.6% H20 2 (Fisher Scientific) was added to each well and incubated for 30 minutes 
in a humidification chamber. Hydrogen peroxide treatment of the cells is essential as it 
degrades any endogenous peroxidases that would otherwise interact with the later 
employed secondary antibody reaction with SIGMA F AST™ 3, 3'- Diaminobenzidine 
(DAB) tablets (Sigma) and produce non-specific staining. 
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Following the latter incubatory period, chamber slides were washed in I L 
beakers containing 1 x PBS. Two hundred microlitres of primary antibody diluted at 
the optimal dilution determined for ICC of 1: 200 in 3% Bovine Serum Albumin 
(BSA) RIA grade (Sigma)/ 1 x PBS was added to each respective chamber well 
following the aspiration of the 1 x PBS. The primary antibody used in this study is a 
monoclonal antibody that was derived from murine hybridoma cells produced from 
the fusion of murine myeloma cells with the murine spleen cells from a mouse that 
had been immunized with the MYC tag epitope antigen, which is incorporated in the 
proteins expressed from the expression vectors used in this study: pCS3+MT empty 
vector, pCS3+MTmierla, and pCS3+MT mierla Exon 3A. This antibody will thus 
recognize and bind the specific proteins encoded by the transfected expression vectors 
in order to determine the subcellular localization of these specific mierl protein 
isoforms. The chamber slides were then left to incubate over night in a humidification 
chamber wrapped in paraflim at 4°C. At least one well for each chamber slide was 
used as a control containing no primary antibody, whereby 200J!I of only 3% BSA/ I 
x PBS was added. The non-primary antibody containing well is pivotal for 
performing ICC as it allows the investigator to ensure that the resulting final staining 
is due to the secondary antibody binding to the primary antibody and not due to non-
specific binding of the secondary antibody. 
The next day, the primary antibody was then aspirated off and each chamber 
slide was dipped into a 1L beaker containing 0.1% TritonX-1 00/ I x PBS and were 
then removed and incubated in 250m I beaker containing 1 x PBS for 5 minutes. 
Following aspiration of the 1 x PBS from each chamber slide well, the secondary 
antibody (SAM-HRP), specific for the primary antibody used, was diluted 1:200 in 
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3% BSA I I x PBS and was added and incubated for I hour at room temperature in a 
humidification chamber. After the 1 hour time point, chamber slides were then again 
dipped into the 1 L beaker containing 0.1% TritonX -I 00/ 1 x PBS and subsequently 
incubated in 250m I beaker containing I x PBS for 5 minutes. 1 x PBS was then 
aspirated and 200f..ll DAB (Sigma) solution, which was prepared as per manufacturer' s 
protocol, was added to each well. The DAB reacts with the horseradish peroxidase 
that is conjugated to the secondary antibody thereby producing a reddish- brown 
precipitate exactly where the secondary antibody binds to the primary antibody 
recognizing the protein antigen of interest. This reaction was left to proceed till 
staining was visible (approximately 15-30 minutes). DAB solution was then aspirated 
off each well and the chamber slides were submersed in a I L beaker containing fresh 
1 x PBS and incubated for 5 minutes. The gasket was then removed following 
aspiration of the 1 x PBS and 2 drops of 10% glycerol were gently added to each well. 
Slides were then mounted, a cover slip was added, and each slide was sealed with 
clear nail polish. Slides were then viewed and analyzed with a compound light 
microscope (Olympus) under the 1 OX, and 20X objective using both bright field and 
phase contrast microscopy. Stained cells were counted, and the percentage of nuclear, 
cytoplasmic, and whole cell staining for each experimental condition and chamber 
slide well was recorded. Specifically, staining was considered nuclear if only the 
nucleus was exclusively stained. Consequently, the cytoplasmic category consisted of 
cells that exclusively displayed cytoplasmic staining, where as the whole cell staining 
category constituted cells that contained both nuclear and cytoplasmic staining at 
approximately equal levels. Pictures of representative field ofviews were taken using 
103 
the Cool Snap system version 1.1 (Ruper Scientific). Slides were stored at 4°C in the 
dark in order to avoid bleaching and degradation of the staining. 
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Table 2.13: Cell line seeding densities for 8 well-chamber slides 
Cell Line 
HEK 293 Cells 
MDA MB 231 Cells 
MCF7 Cells 
Seeding Density 
(cells per well in an 8 well chamber slide) 
12, 000 cells/ well 
15, 000 cells/ well 
15, 000 cells/ well L 
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2.8.1 Leptomycin B Treatment 
Leptomycin B (LMB) (Alexis Biochemicals) was added to transfected MCF7 
cells at a concentration of IOng/ml in order to inhibit nuclear export. Non LMB 
treated transfected MCF7 cells were also used as negative controls whereby the LMB 
vehicle, 0.1% ethanol, was added in equal volume. LMB treatment was employed 40 
hours post transfection for 8 hours. 
2.9 Statistical & in silico Analyses 
All statistical analyses were performed using the INSTAT version 3.0 software 
program statistical program (GraphPad Software, San Diego, CA, USA) using the 
Student's t-test, p<O.O I. All data values analyzed were assumed to be sampled from 
Gaussian distributions using standard parametric methods. 
As briefly mentioned in section 2.4.1, all in silico analyses investigating 
putative TFBS present at specific regions of the MLP-P1 promoter were performed 
using algorithm tools on four separate websites (refer to section 2.4.1 ). In the case of 
the Transcription Factor Binding Site search system, only TFBSs with a score of at 
least 80% were finally considered as a putative TFBS. The algorithm system 'consite ' 
was employed using a "bit" parameter of 10 for its search. The 'bit' parameter 
measures specificity, whereby the higher the number, the more stringent the results. 
Mathematically, two bits refer to a precisely specified individual base. Therefore, a 10 
bit threshould would find an exact match to a 5 base site (Sandelin eta/., 2004). 
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Furthermore, the percentage of homology of between the human MLP-Pl 
promoter nucleotide sequences involved in minimal and maximal promoter activity as 
well as the nucleotide sequences upstream of and encompassed with exon 3A were 
compared to six different species [rhesus (monkey), dog, horse, mouse, rat, and 
chicken] using the VISTA Browser from the VISTA Comparative genomics website 
(http://genome.lbl.gov/vista/index.shtml). This specific program measures conserved 
regions of DNA from various pre-computed genome alignments of different species 
using multiple alignment, visualization, and statistical analysis tools (Brudno et al. , 
2007; Frazer eta/., 2004) 
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Chapter 3- Results 
3.1 Characterization of the MLP-Pl Promoter Region of mierl in Breast Cancer 
Cells 
Recent studies have implicated a role for MIERia in breast cancer, not only 
because this protein is a corepressor of ERa, but also because its overexpression 
inhibited estrogen-induced anchorage independent growth of an ER+ breast cancer 
cell line (Mercer et al. , 2008; McCarthy et al., 2008). Moreover, MIER I a may be a 
candidate contributing factor in invasive breast cancer as this protein is increasingly 
abnormally localized to the cytoplasm when tumours progress to a more invasive 
state. One hypothesis is that this change in subcellular localization may possibly 
enhance the progression of invasive breast cancer by interfering with or abrogating 
MIERla's potent transcriptional regulatory role in the cell, with the suppression of 
ERa being one of its more influential functions with regards to breast tumourigenesis 
(refer to section 1.5.5 and 1.5.3.2.3). 
As briefly alluded to in section 1.5.6, a possible mechanism for this 
documented change in subcellular localization could be preferential or increased 
transcription initiation at the MLP-Pl promoter, which potentially could result in 
proteins containing a putative NES and/ or transmembrane domain encoded by the 
MLP-Pl specific exon 3A. Therefore, in order to investigate whether abnormal 
transcriptional regulation of mierl 's MLP-Pl promoter is apparent in breast cancer, 
the promoter activity stemming from both the proximal promoter regions, as well as 
further upstream sequences of the MLP-PI promoter region, were characterized in 
breast cancer cells. 
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The proximal promoter of a gene, which typically lies within 250 bp upstream 
of the TSS, is the area of the promoter that contains elements critical to transcriptional 
regulation (Heintzman & Ren, 2007). Preliminary data investigating the MLP-Pl 
promoter region from our lab demonstrated that a stretch of nucleic acids residing 
between l85bp upstream and 37bp downstream ofthe putative MLP-Pl TSS (1463bp 
and 1241 bp upstream of the MLP-Pl translation start site) was involved in eliciting 
activation at this promoter (refer to Appendix 4)10 • In the case of this study, putative 
MLP-P I promoter regions of interest were inserted into the luciferase reporter gene 
plasmid upstream of the luciferase gene so as to act as the luciferase promoter. These 
luciferase reporter gene constructs essentially divided the aforementioned stretch of 
MLP-Pl putative proximal promoter DNA sequence between -185bp and +37 bp into 
three distinct parts, with MLP-P I ( -185) pGL3 containing the entire sequence 
downstream of -185 to seven nucleotides preceding the A TG translation start site of 
MLP-PI and MLP-Pl (+37) pGL3 only containing the entire sequence downstream of 
+37 up to seven nucleotides preceding the MLP-Pl ATG translation start site (Fig 2.1 
& 2.2). In order to divide the sequence between -185 and + 3 7 into further sections for 
a more thorough analysis, two further deletion constructs were engineered as 
described in section 2.411 : 
10 As the actual transcription start site of MLP-P I has not yet been officially characterized, all nucleotide counts 
are indicated with reference to the MLP-PI ATG translation start site. The first exon (exon I A) encoded by MLP-
PI lies 1279bp upstream of the MLP-PI ATG start site, and therefore the putative TSS of this promoter is 
hypothesized to lie at this position. Therefore with reference to the putative TSS of MLP-P I, this particular stretch 
of amino acids that was primarily analyzed extends from 185bp upstream to 37bp downstream of the MLP-Pl 
putative TSS. 
11 Refer to section 2.4 for further details on cloning, construction, and the exact sequences inserted into each 
respective luciferase reporter gene deletion construct. 
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I. MLP-Pl{-91); the sequence of which was cloned into the pGL3 
luciferase plasmid vector starts 94bp downstream of the MLP-Pl (-185) 
pGL3 inserted sequence and 125bp upstream ofthe MLP-Pl ( +37) 
pGL3 inserted sequence. 
2. MLP-Pl (-44); the sequence of which was cloned into the pGL3 
luciferase plasmid vector starts 14lbp downstream ofthe MLP-Pl (-
185) pGL3 inserted sequence and 8lbp upstream ofthe MLP-PI (+37) 
pGL3 inserted sequence. 
Furthermore, in addition to these four aforementioned MLP-PI luciferase 
reporter gene deletion constructs, the following three constructs were used: MLP-Pl (-
1708) pGL3, MLP-Pl (-1077) pGL3, and MLP-PI (-742) pGL3 12 (Fig 3.1). The 
reason for this additional incorporation was to include sequences further upstream of 
the MLP-Pl putative proximal promoter region in order to investigate whether mierl 
underwent regulation by distal regulatory elements, such as enhancers or silencers, 
which have been known to exert their regulatory activity considerable distances away 
from proximal promoter regions (Maston eta/., 2006). Acquisition of information 
with regards to such long range cis transcriptional regulatory elements would supply 
additional pertinent information with regards to the nature ofMLP-Pl regulation in 
breast cancer. 
One microgram of each of these MLP-Pl luciferase reporter gene deletion 
constructs (depicted in Figure 3.1 and furthermore described in section 2.2.3.1), 1 J.l.g 
of the pGL3 empty vector negative control, and 0.25J.1.g of the pRSVp-gal expression 
vector were each transiently transfected into MCF7 cells as described in section 2.5.2. 
12 The bracketed numbers denoting these luciferase reporter gene deletion constructs indicate how many base pairs 
upstream or downstream the 5' ends of the insertion sequences inserted into each respective construct lies with 
respect to the MLP-PI putative TSS. For further information about the location of these insertion sequences with 
relation to the MLP-P I promoter region refer to section 2.2.3. 1 & appendix I. 
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MCF7 cells express ERa and have long been used as a standard model for breast 
cancer (Kern eta!., 2004; Levenson & Jordan, 1997). For our purposes, they served as 
a suitable model to begin the MLP-PI promoter activity analysis. Forty-eight hours 
following transfection, cells were harvested and cell lysates were collected. Relative 
luciferase units (RLUs) were then measured using the luciferase assay protocol as 
described in section 2. 7.2. RLUs of each sample were normalized to P-gal assays 
values, which measured transfection efficiency, as well as to the protein level readings 
obtained following experiment-specific bio-rad. Bio-rad assays took into 
consideration the amount of protein in each sample which reflects the number of cells 
collected. 
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Figure 3.1: Schematic of luciferase reporter gene deletion constructs used for the 
characterization of the minimum and maximum promoter activity regions of 
MLP-Pl in MCF7 breast cancer cells 
Tills schematic depicts the :MLP-Pl promoter region and the 5' starting position of the :MLP-Pl putative 
promoter region inserts cloned into each individual :MLP-Pl luciferase reporter gene deletion construct 
that was used in section 3.1. Additional notation depicted in this schematic describes the :MLP-Pl 
proximal promoter region which is further described in section 2.2.3 .1. 
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3.1.1 The Minimal Promoter ofMLP-Pl in MCF7 Breast Cancer Cells 
Figure 3.2 illustrates results from five independent experiments in MCF7 cells, 
which recapitulated preliminary findings that the region between -185 and +37 does 
encompass an active promoter region driving transcription at MLP-P1 , as MLP-P I 
( -I85) pG L3 and MLP-P I ( -9I) pGL3 generated a significant increase in RLU 
production over the pGL3 empty vector (p<O.OO I and p<0.05 respectively). MLP-PI 
(+37) pGL3 though, as well as the construct harbouring the second smallest insert, 
MLP-PI (-44) pGL3, did not produce a significant increase above the RLU level of 
the pGL3 empty vector negative control (p>0.05) (Fig 3.2). These results denote 
MLP-PI(-91) pGL3 as the MLP-PI luciferase reporter gene deletion construct 
containing the smallest sequence able to produce a significantly higher level ofRLU 
over that of the pGL3 empty vector in MCF7 cells (Fig 3.2). 
3.1.2 Maximal Promoter Activity at MLP-Pl in MCF7 Breast Cancer Cells 
As clearly illustrated in Figure 3.2, the MLP-PI (-185) pGL3 construct 
generated the highest level of activity above the levels of the pGL3 empty vector 
negative control (p<O.OO I). Even the larger MLP-Pl luciferase reporter gene deletion 
constructs, which harboured further distal upstream MLP-P I sequences, as well as the 
same nucleic residues inserted in MLP-PI (-I85) pGL3, did not produce significantly 
higher luciferase activity levels than the MLP-Pl (-185) pGL3 construct (p>0.05). 
This marks MLP-P I ( -I85) pGL3 as the construct with the smallest insert resulting in 
the highest promoter activity. The rest of the constructs in the deletion series that 
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harbour smaller MLP-Pl sequence inserts revealed significantly lower luciferase 
activity than MLP-Pl (-185) pGL3, which is succinctly exemplified following 
analysis of the MLP-Pl (-91) pGL3 minimal promoter construct. This construct, 
which interestingly only contains 94 less nucleotide base pairs than MLP-P I ( -185) 
pGL3 significantly decreases in luciferase activity production by 2 fold (p<O.Ol) when 
compared to MLP-Pl (-185) pGL3 (Fig 3.2). 
The stretches of mier 1 MLP-P I sequence upstream of -185 did not produce 
higher levels of promoter activity than MLP-Pl (-185) pGL3. Figure 3.2 demonstrates 
that the promoter activity stemming from the construct harbouring the longest MLP-
Pl putative promoter insert, MLP-PI (-1708) pGL3, generated levels ofluciferase 
activity that were statistically lower than that ofMLP-Pl (-185) pGL3 (Fig 3.2). The 
p-value upon comparison of these two latter constructs was smaller than 0.00 I. 
Furthermore, MLP-Pl (-1708) pGL3 displayed approximately the same promoter 
activity level as the minimal promoter construct MLP-Pl (-91) pGL3 (p> 0.05). 
MLP-PI (-742) pGL3 and MLP-Pl (-1077) pGL3 also did not produce higher activity 
levels than MLP-P I ( -185) pGL3, but rather exhibited statistically comparable 
reporter activity levels to this latter construct (p>0.05) (Fig 3.2). 
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Figure 3.2: Characterization of the MLP-Pl promoter region of mier 1 in MCF7 
cells 
MCF7 cells were seeded at a density of 3 x I 05 cells/well of a 6-well plate and grown in DMEM for 
approximate ly 18 hour . Cells were then transfected with l11g of MLP-P I lucifcrase reporter gene 
deletion construct and 0.251-ig of pRSV~-gal. Cell lysates were collected 48 hours following 
transfection and relative lucife rase uni ts were measured. BioRad and ~-gal assay were preformed so 
as to collect necessary data in order to normalize the RLUs to the transfection efficiency as the amount 
of protein per sample as described in sections 2.7 .Each luciferase reporter gene construct was 
transfectcd into triplicate wells and the above data constitute a n=5. Statistically significant differences 
between speci tic constructs compared to the pGL3 empty vector are denoted by an asterisk whereby 
p<O.OOI for the MLP-PI(-1077) pGL3, MLP-PI(-742) pGL3, and MLP-PI(- 185) pGL3 1uciferase 
reporter gene deletion constructs. p<0.05 for the MLP-PI (-1708) pGL3 and MLP-PI(-9 1) pGL3 
reporter constructs. 
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3.2 Comparison of MLP-Pl Promoter Activity Patterns Across Multiple Breast 
Cancer Cell Lines Varying in ER Status and the Non-Cancerous Cell Line HEK 
293 
3.2.1 MLP-Pl Promoter Activity Patterns in HEK 293 Cells 
To demonstrate MLP-P I promoter activity from the proximal promoter region 
ofMLP-Pl in a non-neoplastic environment, HEK 293 cells were transfected with the 
pGL3 empty vector negative control and the following MLP-Pl luciferase reporter 
gene deletion constructs: MLP-Pl (-185) pGL3, MLP-Pl (-91) pGL3, MLP-PI (-44) 
pGL3, and MLP-PI (+37) pGL3 13. This human embryonic kidney cell line transfects 
very efficiently and, even though was primarily established by transfection with 
adenovirus (Graham & Smiley, 1977), ideally served for our purposes as a non-
cancerous control for comparison to breast cancer cells. 
It is also important to note that one of the key differences between the HEK 
293 cell line and the MCF7 cell line, apart from the neoplastic nature of MCF7 cells, 
is estrogen signalling. MCF7 cells are a well characterized ER+ cell line, and 
therefore consistently express the ERa. HEK 293 cells, on the other hand, do not 
express endogenous ERa. Therefore, in order to verify that any plausible differential 
in promoter activity between the two cell I ines was not affected by a lack of ERa 
expression, HEK 293 cells were also always transfected with 0.5J.Lg of the ERa-
expressing vector pCDNA3 14, along with 0.5J.Lg ofMLP-PI reporter gene deletion 
13 The location of the MLP-Pl putative promoter insert that was cloned into each of these specific luciferase 
reporter gene deletion constructs with respect to the MLP-P I proximal promoter region is depicted in figures 2.1, 
2.2, and 3.1. 
14 As briefly mentioned in the footnote of section 3.1. 1, an additional reason why hERa pCONA3 was used in the 
HEK 293 experiments was because the data obtained represent results extracted from the negative control groups 
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construct and 0.25~g pRSVp-gal. Consequently, allluciferase experimental data 
obtained using HEK 293 cells reflects not only transient co-transfection with MLP-P1 
reporter gene deletion constructs and pRSVp-gal, but also reflects co-transfection with 
a vector expressing ERa as well. Also, it is important to note that for the purposes of 
comparing data between HEK 293 cells and the breast cancer cell lines (such as: 
MCF7, T47D, and Hs578Ts), all the breast cancer cell samples that were used in each 
respective comparison were also co-transfected with 0.5~g ofthe empty vector 
pCDNA3 in addition to the other constructs. By transfecting the pCDNA3 empty 
vector into the rest of the examined cell lines, all cell line data could be compared 
equally as this step alleviated the variability that would have been created had only 
one cell line been transfected with the pCDNA3 vector. 
Fifty-two hours 15 following transfection, cells were harvested and celllysates 
were collected as described in section 2.6. Relative luciferase units (RLUs) were then 
measured and RLUs were normalized to transfection efficiency and protein levels. 
Figure 3.3 depicts results of seven independent experiments using HEK 293 cells and 
recapitulated the previously established MLP-P1 promoter activity pattern observed in 
MCF7 breast cancer cells whereby MLP-Pl ( -185) pGL3 produces a statistically 
higher luciferase activity level than all other constructs (Fig 3.3). Furthermore, the 
MLP-P1 (-91) pGL3 reporter activity levels were significantly lower than that of 
MLP-P1 (-185) pGL3 (p<O.OOl), consistent with previous observations in which the 
of experiments initially investigating the effect of estrogen on MLP-P I promoter activity (Refer to sections 3.2.2 
and 3.3.1.1 ). 
15 Cells were left to grow for 52 hours because originally these experiments were looking at estrogen treatment 
effects on MLP-Pl promoter activity. Estrogen treatment was performed 4 hours following transfection and both 
estrogen-treated and non-treated cells had to be left for 48 hours in the present of estrogen or treatment vehicle. 
The results presented in this section of the thesis are data from the non-estrogen treated cells. 
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94bp MLP-PI promoter region between -I 85 and -9 I harboured sequences which 
caused maximal reporter activation. Moreover, RLU values produced by the other 
MLP-Pl reporter gene deletion constructs sequentially decreased in luciferase activity 
levels from construct to construct coinciding with the length of the promoter region 
sequence insert of each MLP-Pl luciferase reporter. For example, the smallest insert, 
found in the MLP-Pl {+37) pGL3 construct, resulted in the lowest RLU values apart 
from the pGL3 empty vector (Fig 3.3). This pattern was also consistent with the MLP-
PI promoter characterization in MCF7 cells (Fig 3.2). 
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Figure 3.3: Characterization of the MLP-Pl proximal promoter region of mierl 
in HEK 293 cells 
HEK 293 cells were seeded aladensityof5 x 105 cells/well of a 6-well plate and grown in DMEM for 
approximately 18 hours. Cells were then transfected with 0.5 (.!g of MLP-P I promoter sequence 
luciferase reporter gene deletion construct, 0.25(.!g of pRSY~-gal, and 0.5j.lg ERa pCDNAJ. Cell 
lysates were collected 52 hours following transfection and relative light units were measured. BioRad 
and ~-gal assays were preformed so as to collect necessary data in order to normalize the RLUs to 
sample specific transfection efficiency and protein level as described in section 2.7. Each luciferase 
reporter gene construct was performed in triplicate and n=7. Statistically significant differences 
between all constructs compared to the pGLJ empty vector are denoted by an asterisk whereby p< 
O.OOifor MLP-PI(-185) pGLJ and MLP-PJ (-91) pGL3 and p<0.05 for MLP-PI (-44) pGL3 and MLP-
p I(+ 37) pGL3. Furthermore, all differences in luciferase activity between each respective construct 
were statistica lly significant with the exception ofMLP-PI(-44) pGL3 vs. MLP-P I (+37) pGL3. P 
values for these differences are as follows: a) MLP-P I (-185) pGL3 vs. all other constructs resulted in 
p<O.OOI b) MLP-Pl(-91) pGL3 vs MLP-PI (-44) pGL3 and MLP-P1 (+37) pGL3 resulted in p<O.Ol. 
119 
3.2.2 MLP-Pl Promoter Activity Patterns in Multiple Breast Cancer Cell Lines 
Varying in ER Status 
The estrogen receptor (ER) is presently the most powerful predictive marker in 
breast cancer management, and its pivotal role in breast tumourigenesis has been, and 
currently is, vigorously researched (Chen eta/., 2008; Payne el a/., 2008). MrER I a 
has been implicated in ER signalling as a corepressor of ERa, and as an inhibitor of 
estrogen stimulated anchorage independent growth in a breast cancer cell line 
following its overexpression (McCarthy el a!., 2008). This study further investigated 
how the MLP-Pl promoter is regulated in breast cancer by examining whether 
differing ER statuses, and consequently the neoplastic environment developed under 
the influence of such ER statuses, affect the transcription promoting ability of this 
promoter and its activity patterns in breast cancer cells. 
Three additional breast cancer cell lines varying in ER status [T47D (ER+), 
MDA MB 231 (ER-), and Hs578T (ER-)] along with the MCF7 ER+ breast cancer 
cell line were transiently transfected with 0.51-lg ofMLP-PI luciferase reporter gene 
deletion constructs and 0.251-lg ofpRSV~-gal expression vector. The MLP-Pl 
luciferase reporter gene deletion constructs used in this section of this study were the 
specific constructs that harboured MLP-PI proximal promoter sequences: MLP-PI (-
185) pGL3, MLP-PI (-91) pGL3, MLP-Pl (-44) pGL3, and MLP-Pl (+37) pGL3 16• 
Furthermore, in order to later compare this data with the previous HEK 293 data, these 
cell lines were also transfected with the empty vector pCDNA3 (refer to section 3.2.1 
for further explanation). All transfections, cell lysis procedures, and reporter assay 
16 The location of the M LP-P I putative promoter insert that was cloned into each of these specific luci ferase 
reporter gene deletion constructs with respect to the MLP-P I proximal promoter region is depicted in figures 2. 1, 
2.2, and 3.1 
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protocols were performed as previously described, and allluciferase values were 
normalized both to transfection efficiency and protein levels. 
Figures 3.4 A, B, C, & D individually depict results stemming from each ofthe 
four breast cancer cell lines examined. These data demonstrate that the promoter 
activity consecutively decreased similarly in each cell line from the maximum 
activity-producing construct as the MLP-Pl proximal promoter region inserts decrease 
in length from construct to construct (Fig 3.4 A -E). Furthermore, M LP-P I ( -185) 
pGL3 persistently produced the highest reporter activity level above the pGL3 empty 
vector negative control (p<O.OOI for each cell line). Moreover, the luciferase activity 
generated by the second largest deletion construct, MLP-Pl (-91) pGL3, s ignificantly 
decreased RLU levels when compared to MLP-P I (-185) pGL3 in each breast cancer 
cell line (p<O.OO 1 ). 
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Figure 3.4: MLP-Pl promoter activity across multiple breast cancer cell lines 
varying in ER status 
MDA MB 23 1 cells, Hs578T cells, T47D cells and MCF7 cells were seeded at a density of3 x 105 
cells/well and in a 6-well plate and grown in cell type specific supplemented DMEM for approximately 
18 h. Respective well s were then transfected with 0.5!Jg of MLP-P I luciferase reporter gene deletion 
construct, 0.5!Jg pCDNA3 empty vector, and 0.25!-lg ofpRSV~-gal. Cell lysates were collected 48 
hours following transfection, and relative luciferase units were measured. BioRad and ~-ga l assays 
were preformed so as to collect necessary data in order to normalize the RLUs to transfection efficiency 
as well as protein levels as described in section 2.7. Each luciferase reporter gene construct was 
transfecled into triplicate wells and the above data constitute: n= 4 (MB MDA 23 I cells), n=3 (T47D 
cells), n=3 (Hs578T cells), and n=S (MCF7 cells). Figure 3.4A represents relative luciferase units 
plotted with respect to the MLP-P I luciferase reporter gene deletion construct data on the X axis for 
Hs578T cells whereas Figure 3.4B depicts such results for the MDA MB 23 1 cells (please refer to 
Figure 3.5 which contains a di fferent y axis scale in order to further distinguish actual RLU values for 
thi s particular cell line), Figure 3.4C represents the T47D cell line, and Figure 3.40 represents data 
from the MCF7 cell experiments. 
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Figure 3.5: MLP-Pl promoter activity in MDA MB 231 cells 
MDA MB 23 1 cells were seeded at a density of 3 x 105 cells/well and in a 6-well plate and grown in 
cell type specific supplemented DMEM for approximately 18 hours. Respective wells were then 
transfected with 0.5!-lg of MLP-P I luciferase reporter gene deletion construct, 0.5!-lg pCDNA3 empty 
vector, and 0.25!-lg ofpRSVp-gal. Cell lysates were col lected 48 hours followi ng transfection, and 
relative luciferase units were measured. BioRad and p-gal assays were preformed so as to collect 
necessary data in order to normalize the RLUs to transfection efficiency as well as protein levels as 
described in section 2.7. Each luciferase reporter gene construct was transfected into triplicate wells and 
the above data constitute: n= 4 (MB MDA 23 1 cells), This figure represents the exact same data 
illustrated in Figure 3.4 B, however the values on Y axis are lower so that the MDA MB 23 1 relative 
luciferase units are more easily observable. Due to the low RLU values obtained in this specific cell 
line, when compared to scale with the other breast cancer cell lines, it is difficult to see the MLP-Pl 
promoter activity pattern. As in Figure 3.4, the RLUs are plotted with respect to the MLP-P I luci ferase 
reporter gene deletion construct data on the X axis. 
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3.2.3 MLP-Pl Promoter Activity Comparison in HEK 293 Cells and Multiple 
Breast Cancer Cell Lines Varying in ER Status 
Influences that the breast cancer cellular environment have on MLP-P I 
promoter activity, as well as influences of varying ER status can readily be observed 
following the combination and analysis of the previously performed experiments in 
HEK 293 cells and the multiple breast cancer celllines17• Figure 3.6 amalgamates and 
organizes data from the maximum MLP-P 1 promoter activity producing construct 
[MLP-P1 ( -185) pGL3] and the pGL3 empty vector negative control data in 
accordance to each respective cell line. As clearly illustrated by Figure 3.6, HEK 293 
cells produce much lower maximalluciferase activity levels than Hs578T (ER-) cells 
(with a ratio of 3.68:1 for the MLP-P1 (-185) pGL3 RLU values of Hs579T cells: 
HEK 293 cells), T47D (ER+) cells (with a ratio of 4.49:1 for the MLP-P I ( -185) 
pGL3 RLU values of T47D cells: HEK 293 cells), and MCF7 (ER+) breast cancer 
cells (with a ratio of 4.5:1 for the MLP-P1 (-185) pGL3 values ofMCF7 cells: HEK 
293 cells). Conversely, the maximal promoter activity stemming from these three 
latter breast cancer cell lines were very comparable to each other. Interestingly 
though, luciferase activity stemming from the MDA MB 231 (ER-) breast cancer cell 
line was much lower than that of the three aforementioned breast cancer cell lines, and 
was more comparable to the activity levels generated by the non-cancerous HEK 293 
cells. However, MDA MB 231 cell maximal promoter activity RLU values were still 
17 All cell lines for the experiments used for this specific promoter activity comparison were transiently 
transfected with 0.5)lg of respective MLP-P I luciferase reporter gene deletion construct, 0.5)lg of 
empty pCDNA3 vector (or 0.5)lg of ERa pCDNA3 in the case of the HEK 293 cells), and 0.25)lg of 
pRSV~-gal. Cells were harvested 48 hours following transfection (52 hours following transfection for 
HEK 293 cells) and reporter gene assays were preformed as described in section 2.7. 
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much lower than those generated by HEK 293 cells (with a ratio of 8.84: I for the 
MLP-P1 (-185) pGL3 RLU values ofHEK 293 cells: MDA MB 231) (Fig 3.6). 
The principal differences between the breast cancer cell line-specific activities 
did not always correlate specifically with ER status. Even though the ER+ cell line 
RLUs were quite proportional, the ER- Hs578T cells produced very distinct RLU 
levels from the ER- MDA MB 231 cells (p<O.OO I). 
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Figure 3.6: Comparison of the MLP-Pl promoter activity across multiple breast 
cancer cell lines varying in ER status and the non-cancerous HEK 293 cell line 
MDA MB 23 1 cel ls, Hs578T cells, T47D cells and MCF7 cells were seeded at a density of3 x 105 
cells/well and 1-I EK 293 cells were seeded at a density of 5 x I 05 cells/ well in a 6-well plate and grown 
in cel l type specific supplemented DMEM for approximately 18 hours. Respective wells were then 
transfected with O.S~g of MLP-PI luciferase reporter gene deletion construct, either O.S~g ERa 
pCDNA3 (for 1-IEK 293 cells) or pCDNA3 empty vector (for all breast cancer cell lines), and 0.25~g of 
pRSV~-gal. Cell lysates were collected 52 hours (for 1-IEK 293 cells) or 48 hours (for all breast cancer 
cell lines) 18 following transfection, and relative luciferase uni ts were measured. BioRad and ~-gal 
assays were preformed so as to collect necessary data in order to normalize the RLUs to transfection 
efficiency and protein levels as described in section 2.7. Each luciferase reporter gene construct was 
transfected into triplicate wells and the above data constitute: n=3 (293 cells), n= 4 (MB MDA 23 1 
cells), n=3 (T47D cells), n=3 (Hs578T cells), and n=S (MCF7 cells). 
18 MB MDA 23 1, Hs578T, T47D and MCF7 cell experimental data used for this particular comparison of MLP-PI 
promoter activity was not obtained from negative control groups investigating the effect of estrogen on M LP-P I 
promoter activity and therefore cells were left to grow 48 hours following initial transfection of the reporter gene 
deletion constructs and expression vectors. 
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3.3 In Silico Analysis of the MLP-Pl Promoter Proximal Region 
3.3.1 Putative MLP-Pl Transcription Factor Binding Sites (TFBSs) 
This study' s characterization of the MLP-P1 promoter proximal region clearly 
revealed that the mier 1 nucleotide sequence residing between positions -185 and -91 
from the MLP-PI TSS is involved in maximal activation at this particular promoter. In 
order to determine whether this specific region ofMLP-PI contains any putative 
human TFBSs that may be responsible for promoter activity in either a breast cancer 
setting specifically or within a normal physiological environment, in silico analysis of 
this region was performed. The analysis employed the following in silico search 
algorithms: transcription element search system, transcription factor binding site, gene 
regulation-ali baba 2.1 , and the consite algorithm program as described in section 
2.4.1 and 2.10. Table 3.1 lists the putative TFBSs that were specifically found within 
the 94bp sequence that is contained between the 5' starting end of the the maximal 
activation MLP-P1 reporter gene deletion construct MLP-P1 (-185) pGL3 and the 5' 
starting end ofMLP-P1 (-91) pGL3, the luciferase reporter gene deletion construct 
established to contain minimal promoter activity (section 3.1.1; refer to Figure 3. 7 for 
the full nucleotide sequence ofthe 94bp region between the 5' starting sites ofthe 
insertion sequences cloned into these two latter luciferase reporter gene constructs). 
Moreover, as the sequences stemming from -91 to -44bp upstream ofthe MLP-
PI TSS were shown to be necessary for minimal activity at this promoter, this 
sequence was also analyzed by the four previously described transcription factor 
binding site in silico analysis programs. Table 3.3 demonstrates the putative human 
TFBS found in these particular regions ofthe MLP-P1 promoter. 
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( - 249/-1528) gtggcgacca gctggggagt ggtgcaccac cccttttttt ggccgcctct gaagtccctg 
r MLP-P1(.18S) pGl3 
(-189/-1 4 68) tacc cccaag ctcctccgtt agcggctcgg gccgaggctc cggaatgttt gccgggcgtc 
(-129/-1408) atggcgacgg 
t MLP-Pl(-91) pGl3 
tggagccctg gctcaacaag cggccgcgcg gttggctggc ggcacgaggc 
Figure 3.7: The sequence of the 94bp stretch of nucleotides residing between the 
5' starting positions of the MLP-P1 promoter region inserts cloned into MLP-Pl 
(-185) pGL3 and MLP-P1 (-91) pGL3 
This fi gure depicts the mierl nucleotide sequence (Entrez Gene 10: 57708) of the MLP-P I promoter 
proximal region that resides between 249 to I 29 bp upstream of the putative TS of M LP-P I. The 
location of the 5' starting position of the MLP-P I promoter region insert cloned into both MLP-P I (-
185) pGL3 and MLP-Pl (-9 1) pGL3. As evident by this figure, the difference between these two 
constructs is that MLP-P I (- I 85) pGL3 contains 94 extra upstream nucleotides than does MLP-P I (-9 I) 
pGL3, the exact sequence of which is italized and printed navy blue. It is this 94bp sequence that results 
in the difference of activity stemming from these two respecti ve MLP-PI luciferase reporter gene 
constructs. With reference to the nucleotide count on the left side, the first number is the nucleotide 
count with respect to the putative TSS o f M LP-P I where as the second number is the count with respect 
to the ATG translation start site. 
128 
Table 3.1: Putative human transcription factor binding sites in the MLP-P1 
promoter proximal region residing between -185 and -91 bp from the MLP-P1 
putative TSS 
Transcription Element 
Search System 
AP-I 
E2F + p107 
CAC-Binding Protein 
c-Myc 
GCF 
Transcription 
Factor Binding 
Site19 
ZID 
AP-I 
Gene Regulation- CONSITE 
Ali Baba 2.1 
NRF-2 
TEF-I 
FREAC-4 
~ ~B I 
)> Human TFBSs found by at least two different search engine/algorithm programs that 
were located in the same position of the MLP-P I promoter region encompassing the 
same nucleotides are bolded, italicized, and outlined by a red box. 
19 This particular search engine was employed using 85% & 80% homology search parameters. 
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Table 3.2: Putative human transcription factor binding sites in the MLP-Pl 
proximal promoter region outside residing between -91bp to -44bp from the 
MLP-Pl putative TSS 
Transcription Element 
Search System 
c-Ets-2 
TCF-2 a 
PEA3 
GCF 
Transcription Factor 
Binding Site 
HSF2 {Sf I 
-Kappa 
Gene Regulation- CONSITE 
Ali Baba 2.1 
~ 
c-Ets-1 
C/EBPa 
Thing i-E47 
};;> Human TFBSs found by at least two different search engine/algorithm programs that 
were located in the same position of the MLP-Pl promoter region encompassing the 
same nucleotides are bolded, italicized, and outlined by a red box. 
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The exact sequences of the TFBSs listed in Tables 3.1 & 3.2 that were 
annotated with red boxes are depicted in Figure 3.8, which plots the TFBSs with 
reference to their respective location within the MLP-Pl promoter proximal region. 
These particular human TFBSs were detected by at least two different in silico 
sequence analysis programs. 
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SP1 
(-249/-1528) gtggcgacca gctggggagt ggtgcaccac cccttttttt ggccgcctct 
caag ctcctccgtt agcggctcgg gccgaggctc cggaatgttt 
Jl Ql<'t ggc 
CREB MLP-P1(-91) pGL 
(-129/-1408) 3tggcq acgg tggagccctg gctcaacaag 
(-69/-1348) cgaggagg. g gttg 
Putative TSS I Exon 1A 
(-9/-1288) J acgaEJ TGGAAGAAG:; AGGCGGGCO'G 
MLP-P1(+37) pGL1 
CCCGGGCCTC AGGCCCCTCC CA 
c-REL 
c..ftEL 
(+52/-1228) GTCTCCCGGC TGCAGGCGGA TGGATGGGGC TTCTTCAGGC GGTGGCGGCA GCAGCGAAGG 
(+112/ - 1168) TGGCGGCGGC AGCAGCGGCA GCGGCT .... . . ..... . 1046bp Intron .. . . . , . . ... . .. . 
Exon 2A 
(+1181/-95) 
. . ·PfGTGT GGTCGCTCGA TTCTCCCAGT GCCTGGCTGA GTTTCGGACG 
(+1241/-38) CCAACTGGTT GAGGTTCAAT GCAGACAAGA CGGATGTGAT GCTG 
Figure 3.8: Putative human transcription factor binding sites in the mierl MLP-
Pl promoter proximal region 
This tigure illustrates the location and sequences of the following putative human TFBSs: Sp I , CREB, 
USF, C/EBP~, and C-REL. These putative TFBS were found and described in at least two of the 
employed transcription factor in silica analysis programs as described in section 2.4.1 and 2.1 0. The 
locations of the 5' starting positions of the insertion sequence of each MLP-P I promoter proximal 
luciferase reporter gene deletion construct are also indicated. The first number on the left side is the 
nucleotide count with respect to the putative TSS of MLP-P I where as the second number is the count 
with respect to the M LP-P 1 A TG translation start site. 
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3.3.2 Analysis of the Percent Homology of the MLP-Pl Promoter Proximal 
Region Sequence Conservation Across Various Species 
The analysis of evolutionarily conserved sequences across multiple species 
allows scientists to determine the functional and/ or regulatory importance of specific 
genetic sequences (Dubchak eta!. , 2009). Sequence conservation highlights genetic 
segments or elements likely to mediate important biological function, as it is assumed 
that functionally important elements evolve more slowly than non-functional genomic 
regions due to selective constraints (Shah et al, 2004). In order to further stress the 
functional importance of the MLP-P1 sequences found to be involved in eliciting 
maximal and minimal promoter activity, this study analyzed the amount of sequence 
conservation that these particular regions of mier I portray across various species 
using the VISTA portal system computational tools as described in section 2.1 0. The 
species whose sequences were compared to the human MLP-Pl promoter region were 
as follows: rhesus (chimpanzee), mouse, rat, dog, horse, and chicken. 
Table 3.3 gives the exact percent sequence conservation between the denoted 
human MLP-P1 promoter sequences when compared to the analyzed species. It is 
important to note that the location on chromosome 1 whereby the maximal promoter 
activity region of MLP-P 1 (between -185 to -91 bp from the MLP-P I putative TSS) is 
chr I: 67, 163,045-67, 163,139. The location on chromosome 1 for the minimal 
promoter activity region ofMLP-Pl (between -91 to -44bp from the MLP-Pl putative 
TSS) is chr 1: 67, 163,139- 67, 163, 186. Figure 3.9 furthermore illustrates a graphical 
depiction of the sequence homology between these various species that was outlined 
in Table 3.3. Refer to Appendix 7 for the exact sequence nucleotides of each species 
sequence aligned to that of human MLP-Pl promoter sequences. 
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Table 3.3: Percent conservation of MLP-Pl maximal and minimal promoter 
regions across six species compared to human sequences 
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Figure 3.9: Graphical depiction of sequence homology of 
mierl's MLP-Pl promoter region across six different species 
compared to the human sequence 
Human mierl MLP-PI promoter sequences consisting of the established 
minimal and maximal promoter regions were compared to the following 
species: rhesus (chimpanzee), dog, horse, mouse, and chicken. This comparison, 
using the vista browser tool, aligned pre-computed and established genome 
sequences in order to calculate the percent conservation between these 
respective species as compared to the human sequence. The percent 
conservation is depicted on they axis of the graphs in this figure, which was 
obtained fo llowing the vista browser tool analysis. Further annotations 
appearing in this figure are explained in the legend located to the left. 
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3.4 Comparison ofMLP-Pl vs MAEP-P2 Promoter Activity in Breast Cancer 
Cells 
As previously discussed in section 1.3.1.2, alternate promoter usage is 
implicated in the generation of tissue specific expression of various gene protein 
isoforms and highly contributes to the diversity of a given proteome. Additionally 
there is growing evidence linking aberrant use of multiple promoters to cancer 
initiation and progression, as several oncogenes and tumour suppressor genes have 
multiple promoters. Moreover, the aberrant use of one promoter over another for 
various genes has been shown to be directly linked to cancerous cell growth (Agarwal 
eta/., 1996; Arce eta/., 2006; Davuluri eta/., 2008). As mierl contains two alternate 
promoters directing the transcription of its various protein isoforms, this gene can 
potentially be differentially regulated through aberrant promoter usage. Moreover, as 
briefly discussed in section 1.5.6 and further analyzed in section 3.5, there are 
significant possible implications to the preferential usage of MLP-P I, such as: an 
abnormal increase in transcription at MLP-P I may result in the generation of a large 
proportion of proteins harbouring putative NESs and/ or putative transmembrane 
domains. As such a phenomenon may help explain some of the molecular mechanisms 
contributing to the abnormal change in subcellular localization of Ml ER 1 a from the 
nucleus to the cytoplasm when breast cells progress to a more invasive state, it 
becomes even more pertinent to investigate and compare activation at both mierl 
promoters in breast cancer. 
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3.4.1 MAEP-P2 Promoter Activity Pattern in Breast Cancer Cells 
Many factors can induce alternate promoter usage, one of the principle 
governing components being triggers from the cellular environment; such as: tissue-
specific TFs, coregulators, and even abnormal regulatory factors present throughout 
chronic disease, such as cancer. In order to initially investigate whether or not either 
of the mierl promoters are differentially regulated in breast cancer cells, the luciferase 
reporter gene deletion construct approach used throughout this study was employed. 
As reported in section 1.5 .2.1 , the MAEP-P2 promoter had already been characterized 
by our laboratory prior to this study (Ding eta!., 2004). However, this characterization 
did not look at multiple sections ofthe MAEP-P2 promoter in various breast cancer 
cell lines. Therefore, this study's first step was to investigate MAEP-P2 promoter 
activity in breast cancer cells by initially transfecting MCF7 cells with four separate 
MAEP-P2 reporter gene deletion constructs that incorporated MAEP-P2 promoter 
proximal as well as promoter distal regions spanning up until 1316 bp upstream of the 
TSS ( -1464 upstream of the MAEP-P2 A TG translation start site). 
The constructs used for this initial characterization were as follows: MAEP-P2 
(-1316) pGL3, MAEP-P2 (-312) pGL3, MAEP-P2 (-68) pGL3, and MAEP-P2 (+28) 
pGL3 (Fig 3.10). For further details with regards to the exact MAEP-P2 promoter 
region nucleotide sequences inserted into these luciferase reporter gene deletion 
constructs refer to Figure 2.4 and Appendix 3. The pGL3 empty vector was used as a 
negative control for background luciferase activity. Forty-eight hours following 
transfection, cells were harvested and luciferase, p-gal, and bio-rad reporter assays 
were preformed as described previously (section 2. 7). Figure 3.11 depicts results of 
138 
luciferase activity measured, whereby the MAEP-P2 (-68) pGL3 reporter gene 
deletion construct is the smallest sequence significantly up-regulated above the pGL3 
empty vector control (p<O.OO I). Furthermore, Figure 3.11 demonstrates that MAEP-
P2 ( -312) pGL3 contained the MAEP-P2 nucleotide sequence that produced maximal 
promoter activity in MCF7 cells. Refer to Appendix 5 for results following these exact 
same experiments in HEK 293 cells, which further recapitulate this established 
promoter activity pattern. 
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Figure 3.10: Schematic of luciferase reporter gene deletion constructs used for 
the initial characterization of MAEP-P2 promoter activity in MCF7 cells 
This schematic depicts the MAEP-P2 promoter region and the 5' starting position of the MAEP-P2 
putative promoter region inserts cloned into each individual MAEP-P2 luciferase reporter gene deletion 
construct that was used in this current section (section 3.4. 1 ). Additional notation depicted in this 
schematic describes the MAEP-P2 proximal promoter region which is further described in section 
2.2.3.2. 
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Figure 3.11: Characterization oft he MAEP-P2 promoter region of mier 1 in 
MCF7 breast cancer cells 
MCF7 cells were seeded at a density of 3 x 105 cells/wel l of a 6-well plate and grown in DMEM for 
approximately 18 hours. Cell s were then transfected with l11g of MLP-P I luciferase reporter gene 
deletion construct and 0.25!lg of pRSVp-ga l. Cell lysates were collected 48 hours foll owing 
transfection and relative luciferase units were measured. BioRad and p-gal assays were prel'ormed so 
as to collect necessary data in order to normalize the RLUs to protein levels and transfection efficiency 
section 2.8. Each luciferase reporter gene construct was transfected into triplicate wells and the above 
data constitute an n=S. Astericks denote statistically significant differences between the RLUs 
stemming from the luciferase reporter gene deletion constructs and the pGL3 empty vector negative 
control (p<O.OO I for each comparison). 
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Similar to the investigation ofMLP-PI promoter activity described in section 
3.2.3, MAEP-P2 promoter activity was analyzed across multiple breast cancer cell 
lines in order to: I) initially investigate whether ER status could potentially affect 
activation at MAEP-P2 in breast cancer cells, and 2) investigate the MAEP-P2 
promoter activity patterns in breast cancer cells and to compare these results to a non-
cancerous cell line (HEK 293 cells). The procedure briefly outlined in section 3.2.3 
and extensively explained in sections 2.5-2. 7 was employed for these experiments, 
using the pGL3 empty vector as the negative control and the maximum MAEP-P2 
promoter activity producing construct, MAEP-P2 (-312) pGL3, in order to monitor 
MAEP-P2 promoter activity. Figure 3.12 depicts and compares results of these 
independent experiments across the HEK 293, MDA MB 231, T4 70, Hs578T, and 
MCF7 cell lines. Luciferase data demonstrates that MAEP-P2 was activated at 
different levels in these cell lines, with the ER- MDA MB 231 breast carcinoma cell 
line displaying the lowest level in relative luciferase activity. All MAEP-P2 (-312) 
pGL3 constructs in every cell line produced significantly higher promoter activity 
than the pGL3 empty vector negative control (p<O.OO I), which demonstrates that there 
is activity at this promoter in each cell line examined. This data also paralleled the 
observed pattern across cell line-specific MLP-PI promoter activity whereby MOA 
MB 231 and HEK 293 cells also generated lower amounts of promoter activity levels 
at the MAEP-P2 promoter than the T4 70, MCF7, and Hs578T cells. Contrary to the 
MLP-P1 promoter though, there was not as a prominent difference between the 
promoter activity levels of HEK 293 cells when compared to T4 70, MCF7, and 
Hs578T at the MAEP-P2 promoter (Fig 3.12). Furthermore, the differences between 
cell line-specific activities did not always consistently correlate with ER status, as the 
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ER- Hs578T cells produced very distinct RLUs levels from the ER- MDA MB 231 
cells. The ER+ cell line RLU levels; however, were comparable. 
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Figure 3.12: Analysis of the MAEP-P2 promoter activity across multiple breast 
cancer cell lines varying in ER Status and the HEK 293 non-cancerous cell line 
MB MDA 23 1 cells, Hs578T cells, T47D cells and MCF7 cells were seeded at a density of3 x 105 
cells/wel l and 1-1 EK 293 cells were seeded at a density of 5 x I 05 cells/ well in a 6-well plate and grown 
in cell type specific supplemented DMEM for approximately 18 hours. Respective wells were then 
transfected with O.SJ.!g of MA EP-P2 luciferase reporter gene deletion construct, either O.SJ.lg ERa 
pCDNA3 (for HEK 293 cells) or pCDNA3 empty vector (for all breast cancer cell li nes), and 0.25J.!g of 
pRSYI3-gal. Cell lysates were collected 52 hours (for HEK 293 cells) or 48 hours (for all breast cancer 
cell lines) followi ng transfection, and relative luciferase uni ts were measured. BioRad and p-gal assays 
were preformed so as to collect necessary data in order to normalize the RLUs to protein levels as well 
as transfection efficiency levels as described in section 2.8. Each luciferase reporter gene construct was 
transfected into triplicate wells and the above data constitute: n=3 (293 cells), n= 4 (MB MDA 23 1 
cells), n=3 (T47D cells), n=3 (Hs578T cells), and n=S (MCF7 cells). Astericks denote statistically 
significant difference between the MAEP-P2 (-3 12) pGL3 luciferase reporter gene deletion construct 
and the pGL3 empty vector for each respective cel l line (p<O.OO I). 
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3.4.2 MLP-Pl vs MAEP-P2 Promoter Activity in Breast Cancer Cells 
In order to: I) detennine whether one of mier 1's promoters is increasingly 
activated over the other in breast cancer cells compared to a non-neoplastic cells, and 
2) investigate whether the ER status of the breast cancer cell lines further affects the 
degree of promoter activity stemming from one mier1 promoter over the other, 
luciferase data following previously described transient transfections of four breast 
cancer cell lines and the non-cancerous HEK 293 cell line was compared. These 
experiments employed both the MAEP-P2 and MLP-Pl luciferase reporter gene 
deletion constructs used in sections 3.2.3 and 3.3.2 [MLP-Pl (-185) pGL3, MLP-Pl (-
91) pGL3, MLP-P1 (-44) pGL3, and MLP-P1 (+37) pGL3 for MLP-Pl and MAEP-P2 
(-312) pGL3 and MAEP-P2 (+28) pGL3 for MAEP-P2], as well as the pGL3 empty 
vector negative control. Along with these mier 1 luciferase reporter gene deletion 
constructs, the pRSV -~ gal expression vector, and either the human ERa pCDNA3 
(for HEK 293 cells) or pCDNA3 empty vector (all breast cancer cell lines) were also 
transfected into each well as described previously (section 2.5). For ease of 
comparison, Figure 3.13 displays the respective luciferase activities stemming from 
only the maximal promoter activity-producing luciferase reporter gene deletion 
constructs for each mier 1 promoter [MLP-P1 ( -185) pGL3 and MAEP-P2 ( -312) 
pGL3]20• This data precisely demonstrates that the MLP-Pl promoter produced 
significantly higher levels of luciferase activity above the MAEP-P2 promoter in each 
cell line tested (p<O.OOI) (Fig 3.13). The extent by which MLP-Pl was increasingly 
20 Data collected from the other MLP-Pl and MAEP-P2 luciferase reporter gene deletion constructs 
(MLP-PI (-91) pGL3, MLP-Pl (-44) pGL3, and MLP-PI (+37) pGLJ for the MLP-Pl promoter, and 
MAEP-Pl (+28) pGLJ for the MAEP-P2 promoter) are illustrated in figure 3.4 for the MLP-Pl 
promoter and in appendix 6 for the MAEP-P2 promoter. 
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. 
activated over MAEP-P2 did differ between the respective cell lines, and is succinctly 
illustrated by Figure 3.13 and Figure 3.14. Figure 3.14 specifically depicts the 
respective fold increases between these two constructs that generate maximum 
promoter activity at both mierl promoters. Interestingly, the degree to which MLP-P I 
was stimulated over MAEP-P2 was highest in ER+ cell lines. 
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Figure 3.13: Comparison ofMLP-Pl vs. MAEP-P2 promoter activity across 
multiple breast cancer cell lines varying in ER status and the non-cancerous 
HEK 293 cell line 
MB MDA 23 1 cells, Hs578T cells, T47D cells and MCF7 cells were seeded at a density of 3 x I 05 
cells/well and H EK 293 cells were seeded at a density of 5 x I 05 cells! well in a 6-well plate and grown 
in cell type specific supplemented DMEM for approximately 18 hours. Respective wells were then 
transfected with either 0.5~-tg of MAEP-P2 luciferase reporter gene deletion construct or MLP-P I 
luciferase reporter gene deletion constructs, and either 0. 5~-tg ERa pCDNA3 (for HEK 293 cells) or 
pCDNA3 empty vector (for all breast cancer cell lines), and 0.25J.lg ofpRSVp-gal. Celllysates were 
collected 52 hours (for HEK 293 cells) or 48 hours (for all breast cancer cell lines) following 
transfection, and relative luciferase units were measured. BioRad and P-gal assays were preformed so 
as to collect necessary data in order to normalize the RLUs to transfection efficiency and protein levels 
as described in section 2.7. Each luciferase reporter gene construct was transfected into triplicate wells 
and the above data constitute: n=3 (293 cells), n= 4 (MB MDA 23 1 cells), n=3 (T47D cells), n=3 
(Hs578T cells), and n=5 {MCF7 cells). 
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Figure 3.14: MLP-P1 (-185) pGL3 vs MAEP-P2 (-312) pGL3 luciferase activity 
comparison across various breast cancer cell lines and HEK 293 cells 
MB MDA 23 1 cells, l-l s578T cells, T47D cells and MCF7 cells were seeded at a density of3 x 105 
cells/well and 1-I EK 293 cells were seeded at a density of 5 x I 05 cells/ well in a 6-well plate and grown 
in cell type specific supplemented DMEM for approximately 18 hours. Respective well s were then 
transfected with either O.Sflg of MAEP-P2 lucilerase reporter gene deletion construct or M LP-P I 
luciferase reporter gene de letion constructs, and either 0.5j.!g ERa pCDNA3 (for H EK 293 cells) or 
pCDNA3 empty vector (for all breast cancer cell lines), and 0.25!J.g of pRSVJ3-gal. Celllysates were 
collected 52 hours (for HEK 293 cells) or 48 hours (for all breast cancer ce ll lines) following 
transfection, and re lative lucife rase units were measured. BioRad and J3-gal assays were preformed so 
as to collect necessary data in order to normalize the RLUs to transfection efficiency and protein levels 
as described in section 2.7. Each luciferase reporter gene construct was transfected into triplicate wells 
and the above data consti tute: n=3 (293 cells), n= 4 (MB MDA 23 1 cells), n=3 (T47D cells), n=3 
(Hs578T cells), and n=5 (MCF7 cells). This figure graphs the ratio of the normalized re lative luci ferase 
uni ts stemming from the maximum promoter activity producing mierlpromoter luciferase reporter gene 
de letion construct for each cell line. The ratio is as fo llows: MLP-P I (- 185) pGL3: MA EP-P2 (-3 12) 
pGL3 and is specified by they axis. The cell line is specified on the x axis. ER- cell lines are 
represented by the blue columns while the ER+ cell lines arc represented by the red columns. 
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3.5 Effect oflncorporation ofExon 3A on MIERla Subcellular Localization 
Section 1.5.6 briefly introduced a potential implication to preferential usage of 
MLP-P1, being the inclusion of mierl alternate exon 3A which may encode a NES 
and/ or transmembrane domain. Section 3.4 revealed MLP-Pl as eliciting higher 
levels of promoter activity than MAEP-P2 in HEK 293 cells and in each breast 
carcinoma cell line tested, an occurrence that was more pronounced in ER+ breast 
cancer cell lines. Due to such predominant promoter activity production at MLP-P1 in 
these cell lines, and because an increased inclusion of exon 3A could serve as a 
possible mechanism explaining MlER1a.'s aberrant subcellular localization in 
invasive breast cancer, this study included as a final objective to investigate the nature 
of the putative NES and/ or transmembrane domain of exon 3A and to observe 
whether it can perpetuate a change in subcellular localization from the nucleus to the 
cytoplasm and/ or plasma membrane. 
3.5.1 Subcellular Localization of mierl Isoforms derived from Transcripts either 
containing or lacking the 74bp Insert encoded by Exon 3A in MCF7 Breast 
Carcinoma Cells 
Transient transfections of expression vectors encoding MYC-tagged MJER 1 a. 
with or without the 74bp insert encoded by exon 3A (pCS3+MT mierlo. and 
pCS3+MT mierlo. exon 3A respectively), as well as a MYC-tagged control vector 
(pCS3+MT) were initially performed in MCF7 cells grown in 8-well chamber slides 
as described in section 2.8. Forty-eight hours following transfection, ICC was 
performed using antibodies specific for the MYC tag present in the specific proteins 
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produced by the transfected expression vectors. Stained cells were counted and the 
location of the staining, whether nuclear, cytoplasmic, or whole cell staining was 
noted. Specifically, staining was considered nuclear if only the nucleus was 
exclusively stained. Consequently, the cytoplasmic category consisted of cells that 
exclusively displayed cytoplasmic staining, while the cells were considered to exhibit 
whole cell staining when both nuclear and cytoplasmic staining appeared in the cell at 
approximately equal levels. The histogram of Figure 3.15 represents the respective 
proportion of cells that were observed in each category (ie: cytoplasmic, nuclear, or 
whole cell) for each mierl isoform and the tag control21 • Cells transfected with 
pCS3+MT mierla (denoted MIERI alpha in Fig 3.15) mostly resulted in nuclear 
staining (82%) followed by some whole cell staining (16%) and virtually no 
cytoplasmic only staining (2%). The MCF7 cells transfected with pCS3+MT mierla 
exon 3A (denoted MIER I 3A alpha in Fig 3.15), on the other hand, mostly displayed 
cytoplasmic staining (66%), with approximately 31% whole cell staining and virtually 
no nuclear only staining (3%). The MYC-tagged control displayed majority whole cell 
staining (76%), 22% cytoplasmic only staining and minimal nuclear only staining 
(2%). Representative pictures taken of these particular transfected MCF7 cells, as well 
as non-transfected controls stained or not stained with primary antibody are illustrated 
in Figure 3.16. Note that the non-transfected controls did not stain (Fig 3.16 M-P). 
21 The tag control is simply the MYC tag-containing pCS3 vector: pCS3+MT 
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Figure 3.15: Subcellular localization data of mierl isoforms derived from 
transcripts either containing or lacking the 74bp insert encoded by exon 3A in 
MCF7 breast carcinoma cells 
MCF7 cells were seeded at a density of 15,000 cells/ well in an 8-well chamber slide and grown in 
MCF7 specific supplemented DMEM for approximate ly 18 hours. Chamber slide wells were then 
trans fected with 0.26J,.tg of either pCS3+MTmierla, pCS3+MT mierla exon 3A, the MYC-tagged 
control vector (pCS3+MT), or were left untransfected. Forty eight hours following u·ansfection, cells 
were fixed with 4% paraformaldehyde and ICC was performed with an antibody specific for the MYC 
tag. Stained cells were counted and categorized as either having nuclear, cytoplasmic, or whole cell 
sta ining. The y axis represents the proportion of cells in each category whereby the x axis denotes the 
speci tic transfected mier I isoforms and the tagged control whereby the isoform produced from 
transfection w ith pCS3+MT mierl a is termed MI ERI alpha and the isoform produced from produced 
from pCS3+MT mierla exon 3A transfection is termed MI ERI 3A alpha. "Control" represents the 
MYC tagged-control pCS3+MT. n=4 for both MIERI alpha and MI ER I 3A alpha while n=2 for the 
control tag. Astrixes represent s ignificant differences between each category: MIER I alpha: nuclear 
staining vs cytoplasmic (p<O.OOI ), and nuclear vs whole cell staining (p<O.OOl); MI ER I 3A alpha: 
nuclear staining vs cytoplasmic (p<O.OOl), nuclear staining vs whole cell staining (p<O.OO I); tag 
control: nuclear vs whole cell staining (p<O.OO I), and cytoplasmic vs whole cell staining (p<O.OO I). 
Comparison between MI ERI constructs: I. MI ER I alpha nuclear staining vs MI ERI 3A alpha nuclear 
sta in in= p<O.OOI; 2. Ml ER I alpha cytoplasmic staining vs MI ER I 3A alpha cytoplasmic staining= 
p<O.OOI ; 3. MIER I alpha whole cell staining vs MI ER I 3A alpha whole cell staining= p>0.05. 
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Figure 3.16: Subcellular localization pictures of mierl isoforms derived from 
transcripts either containing or lacking the 74bp insert encoded by exon 3A in 
MCF7 breast carcinoma cells 
MCF7 cells were seeded at a density of 15,000 cells/ well in an 8-well chamber slide and grown in 
MCF7 specific supplemented DMEM for approximately 18 h. Chamber slide wells were then 
transfected with 0.261-lg of either pCS3+MTmierla, pCS3+MT mierla exon 3A , the MYC-tagged 
control vector (pCS3+MT), or were left untransfected. Forty eight hours following transfection, cells 
were fixed with 4% paraformaldehyde and ICC was performed with an antibody specific for the MYC 
tag. Stained cells were counted and categorized as either having nuclear, cytoplasmic, or whole cell 
staining. Fig 3.16 A, C, E, & G represent different cells transfected with pCS3+MTmierla (denoted 
MIERI alpha), Fig 3.16 B, 0 , F, and H represent different cells transfected with pCS3+MT mierla 
exon 3A (denoted MIER I 3A alpha). All these latter pictures were taken in bright field. Fig 3. 16 1-L 
represent the MYC-tagged control vector while Fig 3.16 M-P represent additional controls. 
Specifically, Fig 3.16 M & N consist of cells that were not transfected with any vector expression 
vector and that were not stained with a primary antibody (M= bright field, N=phase contrast), while Fig 
3.16 0 & P consist of cells that were not transfected but that were however stained with the anti-MYC 
primary antibody as described in section 2.8 (0= bright field, P=phase contrast). 
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3.5.2 Subcellular Localization of mierl lsoforms derived from Transcripts either 
containing or lacking the 74bp Insert encoded by Exon 3A following Leptomycin 
B Treatment in MCF7 Cells 
Nucleocytoplasmic trafficking, and thus the import and export of various 
molecules and proteins to and from the nucleus, is mediated by nuclear transport 
receptors belonging to the importin family (LaCour eta!. 2003). In the case of 
nuclear exportation specifically, proteins harbouring leucine-rich nuclear export 
signals (NESs) are translocated to the cytoplasm primarily through the CRM 1-
dependent pathway (Kosugi et a!., 2008; La Cour eta!. 2003). CRM I, which is a 
major cellular exportin, can be inhibited by the potent antifungal antibiotic leptomycin 
B (LMB) through direct alkylation of CRM I cystine 525 (Dong eta/. 2009, Kudo et 
a/.1998; Kudo eta!., I999). This function ofLMB has effectively allowed LMB 
treatment to serve as a means to verify whether or not subcellular localization is a 
function of nuclear export (Dong eta!. 2009). 
Therefore, in order to initially investigate whether or not mierl' s exon 3A-
encoded 74bp insert does translate into a functional NES, MCF7 cells transfected with 
either pCS3+MTmierla, pCS3+MT mierla exon 3A, or pCS3+MT tagged control 
were treated with I Ong/ml of LMB for 8 hours, forty hours post transfection (refer to 
section 2.8.1 for methodology). Following the eight hour time point of LMB 
treatment, ICC was performed and cells were counted for staining. Like the previous 
section, the staining pattern (ie: cytoplasmic, nuclear, and whole cell staining) was 
determined. 
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Figure 3.17 shows the percentage staining for both isoforms following LMB 
treatment in MCF7 cells. MIER I alpha was not affected by LMB treatment, as the 
percentage of stained cells did not significantly differ between the non-treatment and 
treatment groups (p>0.05). MIERJ 3A alpha staining in MCF7 cells did, however, 
change in response to the LMB treatment as 18% less cells displayed exclusively 
cytoplasmic staining following treatment when compared to the non-LMB treated 
control cells (Fig 3.17). This decrease in cytoplasmic staining of MIER I 3A alpha was 
followed by an increase in whole cell staining, whereby 8% more cells exhibited 
whole cell MIERI 3A alpha staining following LMB treatment than in the absence of 
LMB. Furthermore, nuclear staining also increased following LMB treatment, with 
10% more cells displaying nuclear MIER 1 3A alpha staining when compared to cells 
that were not treated with LMB (Fig 3.17). 
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Figure 3.17: Effect of Leptomycin B treatment on mierl isoform subcellular 
localization in MCF7 cells 
MCF7 cells were seeded at a density of 15,000 cells/ well , in an 8-we ll chamber slide and grown in cell 
line specific supplemented DM EM for approximately 18 hours. Chamber slide well s were then 
transfcctcd with 0.26J.1g of either pCS3+MTmierla, pC 3+MT mierla cxon 3A , the MYC-tagged 
control vector (pC 3+MT), or were I ell untransfecled. Forty hours following transfcclion I Ong/ml of 
LMB was added to each well (equal volume ofO. l% ethanol, which is the vehicle fo r the LMB, was 
added to non- treatment wells). Eight hours following LMB treatment (forty eight hours following 
transfection), cells were fixed with 4% paraformaldchyde and ICC was performed with an antibody 
specific for the MYC tag. Stained cells were counted and categorized as either having nuclear, 
cytoplasmic, or whole cell staining. They axis represents the proportion of cells in each category 
whereby the x axis denotes the specific transfected mier I isoforms and the tagged control whereby the 
isoform produced from transfection with pCS3+MTmier la is termed MI ER I alpha and the isoform 
produced from produced from pCS3+MT mierla exon 3A transfection is termed MIER I 3/\ alpha (n=7 
for all conditions except MIER I 3A alpha - LMB whereby n=6). 
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3.5.3 Subcellular Localization of mier Jlsoforms derived from Transcripts either 
containing or lacking the 74bp Insert encoded by Exon 3A following Leptomycin 
B Treatment in HEK 293 cells and MDA MB 231 cells 
The previous subsection of this study analyzed the subcellular localization of 
MIER 1 alpha and MIER 1 3A alpha in conjunction with LMB treatment in a well 
established ER+ breast carcinoma cell line. In order to further investigate MIER1a 
isoform localization in cell lines lacking ER signalling, the exact same experimental 
methodology (refer to sections 2.8 & 2.8.1) was utilized for HEK 293 cells and the 
ER- breast carcinoma cell line MDA MB 231. Figure 3.18 illustrates the proportion of 
transfected cells that displayed nuclear, cytoplasmic, or whole cell staining following 
-LMB and +LMB treatment in both HEK 293 cells (Fig 3.18 A) and MDA MB 231 
(Fig 3.18 B). 
The immunocytochemical staining, and thus subcellular localization, of both 
the MlERI alpha isoforms in the absence ofLMB treatment was prominently whole 
cell staining22for both cell lines independent of isoform type (90% whole cell staining 
for MIERI alpha in HEK 293 cells, 89% whole cell staining for MIER 1 3A alpha in 
HEK 293 cells, 90% whole cell staining for MIER 1 alpha in MDA MB 231 cells, and 
I 00% whole cell staining for MlERI 3A alpha in MDA MB 231 cells) (Fig 3.18 A & 
B). In HEK 293 cells, the amount of cytoplasmic staining for both isoforms was not 
significantly higher than the nuclear staining (7% of MIER I alpha-transfected HEK 
293 cells and 10% ofM1ER1 3A alpha-transfected HEK 293 cells portrayed 
cytoplasmic staining while 1% ofMlERl alpha- transfected HEK 293 cells and 3% of 
22 p<O.OO I when comparing whole cell staining to cytoplasmic and nuclear staining. 
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MIER 1 3A alpha- transfected HEK 293 cells portrayed nuclear staining)23 (Fig 3.18 A 
& B). Cytoplasmic and nuclear staining for MDA MB 231 cells was non-existent in 
MIER1 3A alpha-transfected MDA MB 231 cells and did not significantly differ 
among the MIER 1 alpha-transfected MDA MB 231 cells with 4. 7% of cells 
displaying cytoplasmic staining and 5.3% of cells displaying nuclear staining (p>0.05) 
(Fig 3.18 A & B). It is also important to note that these aforementioned staining 
patterns and trends for both HEK 293 cells and MDA MB 231 cells were not 
significantly affected by LMB treatment (p>0.05) (Figure 3.18 A & B). 
23 p>0.05 when comparing nuclear staining to cytoplasmic staining among both MlERla isoforrns. 
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Figure 3.18: Effect ofLeptomycin B treatment on mierl isoform subcellular 
localization in HEK 293 cells and MDA MB 231 cells 
HEK 293 cells were seeded at a density of 12,000 cells/ well and MDA MB 231 cells at a density of 
15,000 cells/ well in an 8-well chamber slide and grown in cell line specific supplemented DMEM for 
approximately 18 hours. Chamber slide wells were then transfected with 0.261-lg of either 
pCS3+MTmierla, pCS3+MT mierla exon 3A, the MYC-tagged control vector (pCS3+MT), or were 
left untransfected. Forty hours following transfection I Ong!m I of LMB was added to each well (equal 
volume of 0.1% ethanol, which is the vehicle for the LMB, was added to non- treatment wells). Eight 
hours following LMB treatment (forty eight hours following transfection), cells were fixed with 4% 
paraformaldehyde and ICC was performed with an antibody specific for the MYC tag. Stained cells 
were counted and categorized as either having nuclear, cytoplasmic, or whole cell staining. They axis 
represents the proportion of cells in each category whereby the x axis denotes the specific transfected 
mierl isoforms and the tagged control whereby the isoform produced from transfection with 
pCS3+MTmierla is termed MIER I alpha and the isoform produced from produced from pCS3+MT 
mierla exon 3A transfection is termed MIERI 3A alpha. Figure 3.18 A depicts results from HEK 293 
cells (n=4), and Figure 3.18 B represents results from MDA MB 231 cells (n=4). 
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Chapter 4: Discussion 
Early manifestations of specific events leading to neoplastic development 
prime a cell to be resilient and noncompliant to the cellular restraints and security 
networks that are pivotal to ensuring functional cellular homeostasis. Such security 
restraints and networks are essentially regulatory pathways governing fundamental 
physiological processes that, when altered or dysregulated, promote survival, 
proliferation, and cellular growth (Fig 1.1 , 1.2; Hanahan & Weinberg, 2000; Luo et 
a!., 2009). At the basic molecular level though, these alterations in regulatory 
signalling pathways that attribute a cancerous phenotype have a common converging 
point. This point of convergence is that of the fundamental process of gene expression 
whereby the production of every protein in the cell is tightly specified, controlled, and 
dictated by copious inter-related and inter-connected regulatory factors at multiple 
levels through a conglomerate of signalling pathways (sections 1. 2- 1.3). 
Over the past decade, mierl has been well documented as playing a role in the 
regulation of gene expression, as it encodes a potent nuclear transcriptional regulator 
protein (Ding eta/., 2003; Ding eta/., 2004; Paterno et a/., 1997). mierl transcript 
variants exert a transcriptional repression function in the cell using various 
mechanisms, with one isoform in particular (MJER I a) acting as a corepressor of ERa. 
By virtue ofMIER1 ' s transcriptional regulatory role in the cell, it is no surprise that 
this protein has also been implicated in breast cancer, as the MIERla isoforrn was 
revealed to undergo an aberrant subcellular localization switch from the nucleus to the 
cytoplasm as breast carcinoma progresses to a more invasive state (McCarthy et a/, 
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2008). Furthermore, the overexpression of MIER 1 a was shown to inhibit estrogen-
induced anchorage independent growth in an ER+ breast carcinoma cell line, a result 
consistent with MlERl a's role as a corepressor of ERa (McCarthy eta/, 2008). 
In efforts to study the regulation of mierl in breast cancer, such as the specific 
regulatory elements controlling expression of this gene and the mechanisms affecting 
subcellular localization of its protein isoforms, this study first took a step back to 
investigate the regulation ofmierl through a promoter activity analysis approach. As 
described in section 1.5.2, mierl has two distinct promoter regions, one of which, 
MAEP-P2, had already been characterized with regards to the precise nucleotide 
sequences involved in transcription initiation, as well as with regards to putative cis-
acting elements that could act to recruit various transcription factors involved in the 
regulation of mierl expression (section 1.5.2; Ding eta/. , 2004). mierl's most 5' 
promoter, MLP-P I; however, had yet to be analysed prior to this study. 
As outlined in this study' s objectives (section 1.6), the principle goal of my 
Masters research project was to characterize the MLP-Pl promoter and to find the 
sequences involved in maximal and minimal activation at this promoter. Once this 
information had been established, it was then an additional aim to analyze and 
investigate various aspects of mierl promoter activity in breast cancer cells, such as: 
1) whether the nucleotide sequences encompassing the MLP-PI promoter region have 
any putative TFBSs that interact with TFs that are dysregulated in breast cancer; 2) 
whether or not MLP-Pl is increasingly or preferentially activated in breast cancer 
cells; 3) whether the ER status of the particular breast cancer cell could potentially 
influence MLP-PI activity; 4) whether differential regulation persists at either of 
mierl's two promoters in breast cancer cells; and 5) whether there are true 
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implications for preferential activity at MLP-P I, such as: does the putative NES and/ 
or transmembrane domain act to remove MlER 1 a from the nucleus? As alluded to 
previously though, the key prerequisite in order to investigate these latter additional 
issues surrounding mierl transcriptional regulation at MLP-PI in breast cancer cells is 
the characterization of the sequences that are actively involved in eliciting 
transcription at mierl 's MLP-Pl promoter. 
4.1 mierl's MLP-P1 Promoter Region and Promoter Activity in Breast Cancer 
Cells 
4.1.1 The Minimal Promoter ofMLP-P1 
The minimalpromoterofMLP-Pllies between -9/bp and -44bpfrom the MLP-Pl putative 
TSS in MCF7 breast carcinoma cells 
Results from the transient transfection of luciferase reporter gene deletion 
constructs harbouring putative promoter regions of MLP-P I into MCF7 breast cancer 
cells revealed that, in these cells, the minimal promoter ofMLP-PI resides within 
-91 bp of the putative TSS (Fig 3.2). The smallest MLP-PI luciferase deletion 
constructs, MLP-P1 (-44) pGL3 and MLP-PI (+37) pGL3, did not produce 
significantly higher levels of RLUs above the pGL3 empty vector negative control 
(p>0.05) (Fig 3.2). We expected that this would not elicit significant levels of 
promoter activity as the 5' starting nucleotides of this construct' s insertion sequence 
reside 37bp downstream ofthe putative TSS ofMLP-PI and are thus situated in the 
first exon (Exon lA) ofmierl. Conventionally, active promoters are not intrinsic to 
exonic or intronic regions, and as such, these regions do not normally serve to recruit 
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transcription initiation machinery (Bajic eta/., 2006; Carninci eta/., 2006; Trinklein 
eta/., 2002). However, with that being said, some studies have found that promoter 
regions can exist in exons and/ or introns (Carninci eta/., 2006; Gaildrat eta/., 2005; 
Kaku & Rothstein, 2009; Singaraja eta!., 200 I). Consequently, as both intronic and 
exonic promoter regions have been described, this study employed the pGL3 empty 
vector lacking any putative MLP-PI promoter sequence upstream of the luc + gene as 
a negative control for promoter activity. 
Interestingly, the construct MLP-PI (-44) pGL3, which contains 44bp of 
sequence upstream ofthe putative MLP-PI TSS (47bp less than the MLP-PI (-91) 
pGL3 construct), also did not produce significantly higher levels of luciferase activity 
than the pGL3 empty vector. The significance of this finding is that it indicated that in 
MCF7 breast cancer cells, the nucleotide sequence between positions -91 and -44 
contained the necessary cis-elements required to initiate transcription at this promoter, 
thereby enabling the generation of the reported luciferase activity levels. The 
nucleotide sequence downstream ofthe -44 position, and therefore the sequences 
cloned into MLP-PI (-44) pGL3 that produced luciferase activity at the same level as 
the empty control vector, must not have contained ample cis-acting elements required 
to sufficiently recruit the essential transcriptional machinery needed to produce high 
levels of detectable luciferase activity. Refer to Figure 2.2 for the actual nucleotide 
sequence of this 47bp region (between the positions of -91 and -44) as well as the 
location of this particular sequence with regards to the MLP-Pl putative TSS. 
Moreover, the benefit of narrowing down this aforementioned sequence involved in 
minimal MLP-Pl promoter activity is that it can be furthermore analyzed for putative 
TFBSs, some of which may recruit TFs that could possibly be dysregulated 
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throughout cancer development & progression (refer to sections 3.3 & 4.3 for further 
discussion and analysis of the TFBSs found in this particular area of the MLP-PI 
promoter region). 
4.1.2 Maximum Activity Promoter Region ofMLP-Pl 
The maximum promoter of MLP-P I lies between -185bp and -91 bp from the MLP-PI 
putative TSS in MCF7 breast carcinoma cells 
As previously described in sections 1.2.1.1 & 1.3.1.1 , promoter activity levels 
are a function of the interplay between the inherent cis-elements within the nucleotide 
sequences of a given promoter region and the trans-regulatory factors (such as TFs 
and coregulators) that perpetuate signal transduction pathways in a given cellular 
environment at specific time points (Cao et a/., 2008: Trinklein et a/., 2003). 
Therefore, the difference between maximal promoter activity regions and minimal 
promoter activity regions of a specific promoter is dictated by the extent of this 
interplay and the cis-elements that constitute the promoter nucleotide sequences. 
(Kininis & Kraus, 2008; Levine & Tijan, 2003; 0 Barrera & Ren, 2006). Upon 
comparison of the luciferase activity levels produced following transient transfection 
ofMLP-Pl luciferase reporter gene deletion constructs, Figure 3.2 illustrates that the 
maximum activity promoter region ofMLP-PI resides between -185 and -91 bp from 
the putative MLP-P I TSS in MCF7 breast cancer cells. As this data demarks this 
94bp region between the -185 and -91 positions as constituting sequences resulting in 
the maximum activity at MLP-P I, it also further suggests that encompassed in this 
particular 94bp sequence are certain cis-elements that are more actively and 
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stringently involved in the recruitment of the transcriptional machinery than the 
apparent elements residing in the minimal MLP-PI promoter region (between 
nucleotides -91 and -44 with reference to the MLP-P1 TSS). Refer to Figure 2.2 in 
order view the exact 94bp sequence between the MLP-P1 ( -185) pGL3 and the MLP-
Pl ( -91) pGL3 construct 5' sequence insert starting positions. 
Furthermore, the investigation for further distal-acting enhancer or repressor 
elements in the MLP-P1 promoter upstream region showed that a repressor element 
may exist between -1708 and -1077 bp upstream of the MLP-P I putative TSS. Figure 
3.2 demonstrates that MLP-Pl (-1708) pGL3, the largest engineered MLP-P1 
luciferase reporter gene deletion construct, had significantly lower luciferase activity 
levels than MLP-Pl (-185) pGL3 (p<0.001) and comparable RLUs to MLP-P1 (-91) 
pGL3 (p>0.05). This data suggests that putative repressor elements, rather than further 
activation or enhancer elements, are present in these upstream, distal sequences. 
Although this particular study only continued to investigate and focus on the proximal 
promoter region ofMLP-P1 , the potential presence of a repressor element implicates 
the necessity of further study and investigation of these regions. 
Primary future studies investigating this distal downstream repressive 
phenomenon could employ further MLP-Pl luciferase reporter gene deletion 
constructs that divide the 631 bp region between MLP-P 1 ( -1708) pGL3 and MLP-P1 
(-1077) pGL3 (a construct that generated RLU levels comparable to MLP-P1 (-185) 
pGL3) into additional segments. The sequences found to be highly involved in the 
generation of the reported decrease in luciferase activity could be further analyzed for 
putative cis-elements and repressor sequences via in silico examination. Subsequent 
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steps that could be utilized in order to investigate whether or not any of the putative 
TFBSs found are implicated in the regulation ofthis distal upstream region are 
discussed at the end of section 4.4. 
4.2 Effect of ER Status on MLP-Pl Promoter Activity in Breast Cancer Cells 
As briefly introduced in section 1.1.1 , the complexity of cancer is not easily 
rivalled, as this disease is considered one of the most complex and intricate 
phenomena in biology (Edelman eta/., 2008; Grizzi & Chiriva-lnternati, 2006). Even 
among the vast plethora of individuals that develop a given type of cancer, there exists 
multitudes of different subtypes; each subtype of which can even have unique 
qualities and attributes that manifest differently from individual to individual (Grizzi 
eta/., 2006). In breast cancer specifically, an important factor that is used to 
distinguish between the predominant mammary neoplasia subtypes is that ofER status 
(Lopez-Tarruella & Schiff, 2007). Accordingly, the importance of ER' s state in 
developing breast tumours stems from its powerful predictive ability with regards to 
the success of breast cancer's mainstay therapy (endocrine therapy) (Clark, 1995; 
Grizzi eta/., 2006; Gruvberger eta/. , 2001; Osborne, 1998). Recently, the 
heterogeneous nature of the ER subtypes has become even more and more evident, as 
tumours have been shown to present widely different percentages of ER+ cells that 
express the receptor protein at mixed intensities (Lopez-Tarruella & Schiff, 2007). 
Furthermore, ER+ and ER- tumours display remarkably different gene expression 
phenotypes that are not solely explained by differences in estrogen responsiveness, 
thereby highlighting the dynamic differences in the cellular environments developed 
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in these neoplastic subtypes (Gruvberger eta/., 2001; Lopez-Tarruella & Schiff, 
2007). 
In order to enhance the understanding of MLP-Pl-specific promoter activity in 
breast cancer cells, this study addressed the issue of varying breast cancer cell ER 
status by investigating whether MLP-Pl promoter activity differs significantly in 
breast cancer cells either containing or lacking ER. Intriguingly, cell lines with the 
same ER status (ER- cell lines MDA MB 231 and Hs578T) generated significantly 
different levels of luciferase activity (p<O.OO I) from the maximum promoter activity 
producing construct MLP-Pl (-185) pGL3 (Fig 3.5). Specifically, MDA MB 231 cells 
produced 33 times less luciferase activity from MLP-Pl (-185) pGL3 than did Hs578T 
cells (Fig 3.5). This suggests that there must be other elements inherent to these 
particular cell lines that dictate the extent of the overall MLP-Pl promoter activity. 
Conversely, the MLP-Pl ( -185) pGL3 luciferase reporter gene construct 
transfected into ER+ cell lines (MCF7 and T47D cells) generated comparable levels 
of RLUs (Fig 3.5). This suggests that the regulating factors influencing the overall 
promoter activity level ofMLP-Pl must either be present in both these cell lines, or 
cell line-specific regulatory factors must induce transcriptional activation at MLP-Pl 
to a similar extent. Moreover, Figure 3.5 also demonstrates that RLU levels generated 
from the MLP-Pl ( -185) pGL3 construct transfected into the ER- cell line Hs578T 
produced analogous levels of luciferase activity to the ER+ cell lines. This 
furthermore suggests that this ER- cell line may contain common regulatory elements 
and activated signalling pathways as the employed ER+ cell lines. 
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The key limitation with regards to this latter type of comparison across 
different cell lines is that even though the ER status of each cell line is known, the 
status of the other MLP-Pl putative regulatory pathways and elements in these cell 
lines is not entirely characterized. This is mainly because mierl specific 
transcriptional regulation has not been fully analyzed to date, and also because 
different cell lines constitute distinct transcriptomes and have diverse cellular 
environments encompassing varying activated signalling pathways. As noted in Table 
2.1, the exact origins and even level of cancer progression for each of these cell lines 
vary. This adds to the possible variation of each respective cellular environment 
composition and the exact activated signalling networks in these cells and; therefore, 
cell lines lacking ER differ from ER+ cells in more respects than merely the lack of 
this receptor (Angus eta/., 1999). For example, T47D cell lines portray classic 
epithelial cell-like morphologies, while the MDA MB 321 cells are typically 
fibroblast-like and have been demonstrated to behave in a more advanced malignant 
and metastatic nature (Angus eta/. 1999). These cell lineages thus introduce 
differences in many additional regulatory processes, such as growth factor and plasma 
membrane receptor expression (refer to Angus eta/., 1999 for a further detailed 
review on further differing attributes among the commonly established human breast 
cancer cell lines). 
Furthermore, these different cell lines also each have distinct transfection 
efficiencies that dictate the extent of MLP-P 1 luciferase reporter gene deletion 
construct uptake. This study controlled for transfection efficiency by co-transfecting a 
beta galactosidase expressing vector with the luciferase reporter gene deletion 
constructs. An obstacle with this particular control, however, is that one cannot be 
169 
certain that the luciferase reporter gene deletion constructs are being transfected 
exactly the same extent as the beta galactosidase vector or whether they are both even 
entering the same cell. In order to verify whether this is truly a confounding variable, 
these experiments could be repeated using a dual-luciferase reporter system (Promega: 
Dual-Luciferase® Reporter Assay System: Technical Manual - Instructions for use of 
products E 1910 and E 1960). This particular reporter system is designed to contain two 
reporter enzymes in a single system with each reporter vector constituting an 
experimental reporter enzyme (firefly luciferase, which would indicate the extent of 
promoter activity) and a control reporter enzyme (renilla luciferase, which would 
serve as the baseline response) (Promega). Measurements from the experimental 
reporter and the internal control reporter would then not only be originating from the 
same cell, but would stem from the exact same reporter vector. 
Consequently though, as it is clearly evident that there are numerous factors 
that contribute to the heterogeneity among these breast cancer cell lines, it cannot 
directly be deduced through these studies that the differences in MLP-P1 promoter 
activity obtained are absolutely correlated with the cell line-specific ER status alone. 
The reason these specific experiments were employed though, was so that reporter 
activity data could be compared across breast cancer cell lines differing in ER status 
and serve as preliminary support for the possible implications ofER status on the 
activation at the MLP-Pl promoter in breast cancer cells. In order to firmly and 
accurately investigate whether or not estrogen, and consequently ER signalling, 
affects activation at this particular promoter, experiments comparing the effect of 
estrogen within the same cell line either containing or lacking ER would be more 
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conducive to narrowing down the exact functional implications ofER signalling on 
the activity at a particular promoter. 
This type of comparison experiment can be performed using various 
approaches. One possible approach could be by knocking down ER expression using 
short interfering RNA (si -RNA). These si-RNA-ER specific treated cells could then 
be compared to the same cell line that was treated with a control si-RNA. Some 
groups have even been known to use ER inhibitors (such as the anti-estrogen ICI 182, 
780) in order to analyze the affect ofER signalling in various ER+ cell lines (Dauvois 
eta/. , 1993; Fawell eta/., 1990). Other research groups, in order to minimize 
differences in cell lineage, have even developed stable clones of already established 
cell lines with a newER status instead of transiently changing the ER status. For 
example, in efforts to analyze the effect of ER on activity of cytochrome P450 1 B 1 
(CYPI B I) and cytochrome P4501A I (CYPIA I) across a variety of breast cancer cell 
lines, Angus eta/. , 1999 developed paired cell lines deriving from the same 
background, but which differed in ER status (Angus et a/., 1999). Furthermore, an 
ER- clone T47D:C4:2W (T47D-) had previously been derived from normal ER+ 
T47D cells by long-term culture in estrogen-free medium (Pink el a/., 1996). These 
cell lines could then be used for further promoter activity analysis as performed in this 
current study. 
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MLP-P 1 promoter activity patterns of relative luciferase activity levels remained constant 
when compared between MLP-Plluciferase reporter gene deletion constructs in all 
examined cell lines independent of ER status 
Finally, even though this set of data was unable to fully reveal whether or not 
ER status truly affects transcriptional activation at MLP-Pl, there was one very 
important finding that these experiments did exhibit. This is that across all the 
examined breast cancer cell lines, the relative promoter activity (measured as relative 
luciferase activity levels) stemming from each MLP-Pl luciferase reporter gene 
deletion construct remained constant when the activities of these constructs were 
compared within a particular cell line (Fig 3.4). This invariable pattern, which was 
observed independent of ER status, was first characterized in section 3.1 whereby the 
the MLP-Pl ( -185) pGL3 construct consitently generated the highest level of 
promoter activity in each cell line with the other MLP-Pl luciferase reporter gene 
deletion constructs consecutively decreasing in RLU levels as the size of the putative 
MLP-PI promoter insert shortened (Fig 3.2 & 3.4). This phenomenon insinuates that 
these areas of the MLP-Pl promoter are activated in a similar manner with respect to 
each other across breast cancer cell lines, and therefore demonstrates that there is a 
commonality with regards to the response of the sequence areas of the MLP-Pl 
proximal promoter in breast cancer cells. In conclusion, with regards to MLP-Pl 
promoter activity in breast cancer cells, that which varies between breast cancer cell 
lines with respect to MLP-Pl promoter activity is the intensity or efficiency by which 
these areas of the MLP-Pl promoter can recruit the transcription initiation machinery. 
Relatively though, within a given cell line, the specific sequences of the MLP-Pl 
promoter are similarly activated with respect to one another, thereby generating 
consistent promoter activity patterns (Fig 3.4). 
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4.3 MLP-Pl Promoter Activity in Breast Cancer Cells vs. the Non-Cancerous 
HEK 293 Cell Line 
Over the past few decades, breast cancer research has revealed numerous genes 
that are either associated or dysregulated throughout mammary neoplastic 
development (Polyak, 2007). In order to initially investigate as to whether mierl 's 
MLP-Pl promoter is differentially regulated in a breast cancer cellular environment 
compared to a non-cancerous cellular environment, data from reporter gene analysis 
experiments following transfection ofMLP-Pl luciferase reporter gene deletion 
constructs was compared between the non-cancerous cell line HEK 293s and an 
assortment of breast cancer cell lines (MDA MB 231, Hs578T, MCF7, and T47D 
cells). The HEK 293 cell line generated significantly lower levels of luciferase 
activity than the ER+ breast cancer cell lines and the ER- Hs578T breast cancer cell 
line (Fig 3.6). This observation supplies preliminary support that MLP-PI is activated 
at a higher level in these breast cancer cells than in non-neoplastic human embryonic 
kidney cells. Even more interestingly though, was that HEK 293 cells had higher 
promoter activity levels than the ER- MDA MB 231 cell line. This suggests that the 
extent of activity at this promoter in MDA MB 231 cells is even lower than that of the 
non-cancerous HEK 293 cells, thereby further indicating that the signalling 
environment developed in this cell line is not conducive to increasing MLP-PI-
mediated promoter activity. 
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This type of comparison though, because it similarly uses analytical methods 
discussed in section 4.2, also succumbs to the same pitfalls. Such pitfalls are that we 
can only primarily hypothesize and not directly deduce that the lack of a neoplastic 
mileu, as is the case with the HEK 293 cells, is the only reason for these differences in 
overall promoter activity levels at the MLP-Pl promoter. Other factors that are 
specifically inherent to embryonic kidney cells, but not to mammary epithelial cells, 
may potentially function together in order to give the observed results. Ideally, in 
order to accurately study and investigate whether or not MLP-Pl is being 
differentially activated in cancer vs. normal cells, one would use the same type of cells 
(ie: mammary epithelial cells); one population which would constitute normal 
mammary epithelial cells, and another population composed of cancerous mammary 
epithelial cells of the neoplastic phenotype. 
To date, various " normal-like" mammary epithelial cell lines have been 
developed, such as: MCF 10, MCF 1 OA, MCF 1 OF, MCF 12, etc ... (www.atcc.org). 
The term ' normal-like ' is required for the description of these cell lines as they cannot 
truly be classified as ' normal ' cells due to either the original source of the cells or 
cellular adaptations following immortalization- a necessary step in the establishment 
of cell lines (Singhal eta/., 1999). For example, MCF 10 cells do not have a normal 
karyotype consequent to immortalization and, furthermore, were collected from a 
patient presenting with fibrocystic disease following a mammoplasty (Singhal eta/., 
1999). However, in spite of these characteristics, this particular cell line is considered 
a normal mammary control and a good model to study the carcinogenic process using 
chemical carcinogens and oncogenes for induction of malignant transformation (Hu et 
a/., 1998; Ismail eta/., 1999; Wang eta/., 2000; Wei eta/. 1998). 
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Additionally, the Hs578T ER- breast cancer cell line could also be used for the 
purpose of evaluating MLP-P1 promoter activity between cancerous and non-
cancerous mammary epithelial cells by comparing Hs578T-specific experimental 
results to its non-tumourigenic counterpart cell line, Hs578BsT. Hs578BsT was 
derived by Hackett et al. 1977 from normal breast tissue peripheral to the infiltrating 
ductal carcinoma source for Hs 578T (Hackett eta/. 1977). Consequently, future 
studies could compare results following MLP-P I reporter gene deletion construct 
transfection from the non-tumourigenic 'normal-like' mammary epithelial cell lines to 
developed breast carcinoma cell lines. Using this same cell type and/ or cell origin 
diminishes cell-type specific variability in result interpretation. 
HEK 293 cells exhibited similar promoter activity paUerns when compared between the 
MLP-Plluciferase reporter gene deletion constructs, just as the previously analyzed breast 
cancer cells. 
Finally, even though HEK 293 cells resulted in different overall MLP-P1 
luciferase activity levels when compared to multiple breast cancer cell lines, the HEK 
293 results did recapitulate the same MLP-P I promoter activity patterns as the breast 
cancer cells (Fig 3.5). This pattern, as first described in section 3.1 , illustrates that the 
nucleotide sequence between -185 and -91 elicits the highest amount of activity 
followed sequentially by the other MLP-P1 luciferase reporter gene deletion 
constructs in order of insert size. The significance of this observation in these 
particular cells is that it shows that this activity pattern is present regardless of cell 
type and lineage, thereby further highlighting the functional importance of these 
175 
nucleotides and their putative regulatory role in the generation of MLP-Pl specific 
mierl transcripts. 
A final point to note is that the HEK 293 cells used for these experiments were 
transfected with ERa along with the MLP-Pl and/ or MAEP-P2 luciferase reporter 
gene deletion constructs and the p-gal expression vector. HEK 293 cells intrinsically 
do not express ERa; therefore, this latter step served as a control to ensure that the 
obtained results were not affected by a lack in expression of this nuclear hormone 
receptor. Due to this particular control, ER+ breast cancer cell lines and HEK 293 
cells results can be more directly compared as they have one less confounding 
variable. However, the principal overall confounding variable is still present as HEK 
293 cells and MCF7 cells are not only completely distinct cell lines, but are as well 
completely distinct cell types. 
The capacity to control the ER status in HEK 293 cells through transient 
transfection though provides a great opportunity to further investigate whether or not 
ER status can affect the overall level of promoter activity at MLP-Pl , as one can 
observe MLP-Pl activity in the presence and absence of ER in the same cell line. 
Therefore, future experiments with these cells could repeat this same type of 
experimental procedure, but also have a set of cells lacking transient transfection with 
ERa. In this case, as results containing or lacking ER would stem from the same cell 
line, the investigator would be able to efficiently investigate the effect ofER on MLP-
Pl promoter activity in these cells. 
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4.4 Putative Transcription Factors involved in the Regulation of mier 1 at the 
MLP-Pl Promoter 
What is truly causing these aforementioned alternating overall MLP-PI 
promoter activity levels across different breast cancer cell lines and the non-cancerous 
HEK 293 cell line, though? As described in sections 1.2 & 1.3, the expression of a 
particular gene is dictated by the interaction between the inherent cis-elements of the 
gene' s promoter region and the active transcriptional regulators present in the cellular 
environment (Frith eta/., 2008; 0 Barrera & Ren, 2006). As the cellular 
environments, and therefore the level of various activated TFs, coregulators, and 
signalling pathways of each respective cell line differ, the interplay between these 
regulatory molecules and the cis-acting response elements residing in a given gene 
promoter region changes in correlation. Therefore, one would expect the ensuing 
differences in cell line-specific environments to mediate distinct signalling networks, 
some of which may diversely affect gene transcriptional activation via differential 
interaction with the gene promoter, and especially with regard to this project, the 
MLP-Pl promoter. 
Transcription factors such as Spl, CREB, CIEBPp, USF, and c-Rel may play a pivotal role 
in MLP-Pl specific transcriptional regulation. 
In order to fully understand how the MLP-PI promoter is being affected and/ 
or regulated in breast cancer cells, it is not only important to investigate the various 
signalling pathways and TFs that are activated, but as well to delineate the cis-
response elements residing in the particular sequences involved in generating 
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promoter activity at this promoter. This study demonstrated that the nucleotide 
sequence spanning position -185 to -44 from the MLP-P 1 putative TSS are involved 
in promoting transcriptional activation of mierl from MLP-P1 in breast cancer cells 
(Figures 3.2 & 3.4, sections 3.1 & 3.2). Encompassed in this sequence was an area 
involved in eliciting maximal promoter activity (nucleotides spanning -185 to -91) and 
a region harbouring the nucleotides necessary for minimal promoter activity 
(nucleotides spanning -91 to -44) (Fig 3.2). Table 3.1 demonstrates that Spl and 
CREB are the main candidate transcription factors affecting the maximal promoter of 
MLP-Pl and that Sp 1, C/EBP~, USF, and c-REL are candidate transcription factors 
activating the minimal MLP-PI promoter region. The following subsections outline 
these TFBSs and discuss whether or not the particular TF that binds to the established 
putative MLP-P1 specific TFBS is dysregulated in cancer and/ or has a role in breast 
cancer progression specifically. 
1) Specificity Protein 1 (Sp1) 
Putative TFBSs for this particular transcription factor were found in both the 
maximal and minimal promoter activity producing areas ofMLP-PI (Fig 3.8). 
Interestingly this transcription factor, which binds to the GC rich core consensus 
sequence of 5'-GGCGGG-3 (Risili et al., 1995), was also characterized as regulating 
transcription from mierl's MAEP-P2 promoter, a function that was even shown to be 
negatively regulated by MIERI in a negative feedback loop mechanism (sections 
1.5.2.1 & 1.5.3.2.1; Ding eta/., 2004). The presence of Sp 1 sites in the MLP-Pl active 
promoter region further insinuates that MIERI could further negatively repress 
transcription at MLP-P1 , as well as MAEP-P2. 
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In terms of the neoplastic cellular environment, Sp I has been intimately linked 
to growth-related changes in transcription (Kim eta/., 2005). There is also emerging 
evidence that Sp 1 protein expression may be a critical factor in tumour development, 
growth, and metastasis (Safe & Abdelrahim, 2005). Moreover, Sp 1 has been found to 
maintain cell proliferation through various mechanisms. One such mechanism is by 
sustaining expression of fatty acid synthase (FAS), which allows cancer cells to 
constantly biosynthesize their plasma membrane, a step critical to continual cell 
propagation (Lu & Archer 2009). Another mechanism is that Spi also plays a role in 
regulating cell cycle via regulation ofCDC25A expression, which is a pivotal cell 
cycle checkpoint mediator and regulator of both the G I /S and G2/M transitions (Ray 
eta!. , 2007). 
ln the case of breast cancer specifically, one study showed that Sp l protein 
expression was elevated in 1I out of 14 breast carcinomas, whereas only I in 5 benign 
breast lesions expressed detectable Sp I protein levels (Black eta!., 2001 ). 
Furthermore, an additional recent study demonstrated, by analyzing normal breast and 
breast cancer tissues and specimens, that Sp I staining in cancer tissue was positively 
correlated to TNM stage, tumour invasion, and lymph node metastasis. This group 
specifically proposed that Sp 1 maybe participate in the invasion and metastasis of 
breast cancer, and is one of the valuable markers indicating poor prognosis of breast 
cancer (Wang et al., 2007). 
Finally, another principle interest with regards to Sp I 's role in breast cancer 
progression is its interactive synergy with the ERa receptor, whereby ERa has been 
found to tether to the Sp l TF and activate transcription following the binding of the 
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ERa/Sp I complex to cognate Sp I sites. This pivotal interaction can even occur in the 
absence of ligand (Kim eta/., 2005; Porter eta/., 1997). 
2) cyclic AMP (cAMP) Response Element Binding Protein (CREB) 
A CREB binding site [cyclic AMP (cAMP)-response element (CRE)] was the 
second key putative TFBS that was found in between positions -185 to -91, and thus 
may potentially be involved in eliciting maximal activity at MLP-Pl (Fig 3.7). CREB 
is a member of a family of transcription factor proteins involved in stimulus-
transcription coupling, and as such generally functions as a classic second messenger 
(Mayr & Montminy, 200 I). More specifically, CREB-mediated transcription regulates 
genes and processes involved in glucose homeostasis, growth-factor-dependent cell 
survival and growth (Mayr & Montminy, 2001). Interestingly though, this TF is best 
characterized in the brain where it is best known for its roles in learning and memory 
to which it mediates experience-based neuroadaptations (refer to the comprehensive 
review by Carlezon Jr eta/., 2005). 
Various roles for CREB activity in cancer development and signalling 
pathways though have also been revealed following investigation into the regulatory 
mechanisms behind aromatase expression, as well as pathways preventing cellular 
migration (Ghosh eta/, 2008; Hansen eta/., 2009). In the case of aromatase, which is 
the rate-limiting enzyme in estrogen biosynthesis and a key target in breast cancer 
treatment, Ghosh eta/. 2008 demonstrated that CREB indirectly regulates its 
expression (Ghosh eta/, 2008). They revealed that CREB actually negatively 
regulates aromatase basal expression by maintaining constitutive BRCA 1 expression 
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levels and proposed that inhibition ofCREB activity would decrease BRCAl 
expression thereby leading to elevated aromatase basal expression. In terms of 
cellular migration, Hansen et al., 2009 showed that Wnt-5a induces a cAMP response 
leading to Thr34 phosphorylation ofDARPP-32 and a subsequent downstream 
activation ofCREB. This CREB-specific activation resulted in the inhibition ofbreast 
cancer cell migration (Hansen eta/., 2009). 
Mechanistically, CREB mediates transcriptional regulation by dimerizing and 
binding to the cyclic AMP (cAMP)-response element (consensus sequence: 
TGACGTCA) and thereby inducing transcription of its downstream targets (Carlezon 
eta!., 2005; Mayr & Montminy, 2001). Molecular studies of this activation pathway 
have revealed that phosphorylation, and subsequent activation of the CREB TF, 
recruits a cascade of associated proteins such as CREB-binding protein (CBP), which 
in turn promotes the assembly of a larger transcriptional complex involved in altering 
the conformation of nearby chromatin thereby enabling RNA synthesis via RNA 
polymerase II (Bannister et al., 2002; Carlezon eta/., 2005; Walker eta/., 1996). 
The presence of a putative CRE in the MLP-PI promoter region is further 
interesting in the case of mierl regulation, as it was previously discovered that the 
MIER I~ isoform inhibited CBP and its HAT activity (Blackmore et a/., 2008). This 
suggests that perhaps mier 1 MLP-Pl specific transcription could be involved in a type 
of negative feedback mechanism towards CREB-mediated transcriptional activation. 
Further studies with regards to such a role in regulating this specific pathway are 
needed. 
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3. The CCAAT/Enhancer Binding Protein Beta (C/EBPfl) 
C/EBPP is a member of a family of basic leucine zipper (bZIP) transcription 
factors which bind specific DNA sequences as either homo-or heterodimers 
(consensus C/EBP= AIG ITGCGcrrAAcrr) (Grimm et al. , 2003). This study' s in silica 
analysis ofthe functional regions ofMLP-Pl found that such a TFBS resides between 
-91 and -44bp upstream of the putative MLP-PI TSS (Fig 3.7). The C/EBP family of 
TFs in particular have been implicated in regulating transcription and functioning of 
various critical cellular processes such as cellular proliferation, differentiation, 
survival and/or apoptosis, metabolism, inflammation, and oncogene-induced 
senescence and tumourigenesis (Zahnow, 2009). The study ofC/EBP regulatory 
effects in the cell has been quite cumbersome though, as in general these transcription 
factors exert pleiotropic effects based on many factors such as: tissue- and stage-
specific gene expression, alternative translation of various protein isoforms, 
interaction with other transcription factors, and variable DNA-binding specificities 
(Zahnow, 2009). 
Furthermore, the C/EBPP isoforms have been reported as playing distinct and 
important roles in the development of many tissue types, and as such, have also been 
associated with the neoplastic state (Grimm eta/., 2003). With respect to breast cancer 
in particular, C/EBPP mRNA levels are mostly non-elevated compared with normal 
tissue, but are increased in a more-aggressive subset of tumours versus the less-
aggressive tumours (Grimm et a/., 2003). Moreover, significant increases in the LIP: 
LAP ratio (-a ratio oftwo specific C/EBPP isoforms) have been observed in estrogen 
receptor-negative, aneuploid, and highly proliferative breast tumours that are 
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associated with a poor prognosis (Zahnow, 2009). Additionally, some researchers 
attest that C/EBPWs role in cancer may be due to its mediated role in regulating cell 
survival and apoptosis. Studies to this effect, however, have showed conflicting results 
which further illustrate this TF's complex signalling characteristics, as it has the 
potential to promote the survival of some transformed cells while inducing growth 
arrest in others (Zahnow, 2009). 
4. Upstream Stimulatory Factor (USF) 
The TFBS for this TF was also found in the MLP-P1 proximal promoter region 
spanning -91 bp to -44bp upstream of the MLP-PI putative TSS (Fig 3.7). There are 
two distinct USF genes in humans that encode for the USF-1 and USF-2 TFs 
respectively, which are both members of the eukaryotic evolutionary conserved basic-
Helix-Loop-Helix-Leucine Zipper transcription factor fam ily (Corre & Galibert, 
2005). Downstream targets of these transcriptional regulators have been implicated in 
various key cellular processes, such as: stress and immune responses, cell cycle and 
proliferation, and lipid and glucid metabolism (Corre & Galibert, 2005). Molecularly, 
USF TFs interact with DNA as dimers and recognize E-box elements characterized by 
a central CACGTG or CACATG sequence, an action ofwhich has also been shown to 
mediate recruitment of chromatin remodelling enzymes to the transcription pre-
initiation complex (Corre & Galibert, 2005; Corre & Galibert, 2007; Ismail eta/., 
1999; North eta/., 1999). Furthermore, they display strong similarities with the Myc 
oncoproteins both in their overall protein structure and DNA-binding specificity 
(reviewed in Ismail eta/., 1999). 
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Interestingly though, in terms of possible implications with carcinogenesis, 
USF proteins have been found to exert antiproliferative effects whereby 
overexpression ofUSF was demonstrated to prevent Ras and c-MYC- dependent 
cellular transformation and the proliferation of various transformed cells (Corre & 
Galibert, 2007; Ismail eta/., 1999). Furthermore, loss of USF function is common to 
not only breast cancer cells, but as well as in prostate hyperplasia and carcinoma 
(Chen et al., 2006; Corre & Galibert, 2007; lsmail et al., 1999). Moreover, distinct 
tumour suppressor genes, including p53, BRCA2 and APC, have also been shown to 
be direct targets of the USF TFs (Corre & Galibert, 2005). 
5. c-Rel 
e-Re! is one of five subunits ofthe TF NF-KB (Gaspar Pereira & Oakley, 
2008). This study found that a putative binding site for this particular subunit resides 
between the MLP-Pl minimal promoter region -91 bp and -44bp. The significance of 
the appearance of this particular TFBS in the MLP-Pl promoter stems from the fact 
that NF-KB is a critical regulator of many cardinal cellular processes, and more 
particularly has been implicated in and contributes to each of the hallmarks of cancer 
development described in section 1.1 (Naugler & Karin, 2008; Ravi & Bedi, 2004). Its 
regulatory influence spans over 200 genes involved in these pertinent pathways, as 
countless studies have and still are investigating its functional role and downstream 
targets in the context ofneoplasic development (Gaspar Pereira & Oakley, 2008; 
Naugler & Karin, 2008). Furthermore, some research groups claim that NF-KB may be 
highly involved in conferring resistance of human cancers to apoptosis as it is 
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frequently activated consequent to various genetic aberrations and the subsequently 
developed stress stimuli (Ravi & Bedi, 2004). 
c-Rel in particular is a proto-oncogene first identified as the cellular 
counterpart ofthe v-Rel avian reticuloendotheliosis retrovirus (REV-T) derived 
oncogene (Liou & Hsia, 2003). This subunit is furthermore one ofthree NF-KB 
subunits that contains a trans-activation domain thereby facilitating direct gene 
transcription activation (Gaspar Pereira & Oakley, 2008). With respect to a role for 
this specific subunit in tumourigenesis, many human breast cancer tissue samples and 
derived cell lines express abnormally high levels of c-Rel and activation of this 
subunit has even been shown to be involved with mesenchymal to epithelial transition 
induction in mammary cells (Belguise et al., 2007). Moreover, along with the 
cooperation ofCK2A, a ubiquitously expressed serine/theorine kinase, c-rel has been 
shown to promote a more invasive gene profile in vitro (Belguise et al., 2007). 
With the finding of these putative TFBSs in the sequences involved in activity 
at the MLP-Pl promoter, future studies should now look at confirming a role for the 
respective TFs in the regulation of mierl at MLP-Pl. More specficially, putative 
TFBSs could be mutated using site-directed mutagenesis. These ' mutated ' MLP-Pl 
promoter sequences could then be cloned and inserted into the pGL3 empty vector 
thereby creating new MLP-Pl luciferase reporter gene deletion constructs; the 
experimental data from which could be compared to results collected from the non-
mutated MLP-Pl luciferase reporter gene deletion constructs. For further confirmation 
following these MLP-P1 luciferase reporter gene promoter analysis experiments, 
additional experiments employing either transient transfection of vectors expressing 
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one of the six candidate TFs, or treatment with compounds or molecules that would 
activate the TF-specific signalling pathway, could be performed in conjunction with 
assays from the MLP-Pl-specific luciferase reporter gene system. Levels ofMLP-PI 
activity could then be compared across the different treatment groups, for example: 
cells transiently expressing the TF vs. cells not expressing the TF. Western blots, 
would also be necessary following the transient transfection experiments in order to 
verify that the vectors were adequately and efficiently expressing the TF of choice. 
Additionally, if the cell line being studied endogenously expressed the TF in question, 
one could even knock down the particular TF using si-RNA. In conjunction with the 
si-RNA induced knockdown ofthe TF expression, luciferase reporter gene assays 
could then detect MLP-PI promoter activity in the absence or presence of the si-RNA 
mediated TF specific knockdown. 
Another type of approach that could be used that does not employ reporter 
gene technology is that of electromobility shift assays (EMSAs). Such an approach 
would assist in determining whether or not the candidate TF binds to the MLP-Pl 
promoter region. This specific method was utilized previously when investigating how 
Spl affected transcription at MAEP-P2 (Ding eta/., 2004). Briefly, these particular 
EMSAs would use a P32 labelled probe specific to either the maximal or minimal 
MLP-Pl proximal promoter region. This probe would then be incubated with nuclear 
cell extracts. These extracts would then be stained with an antibody specific for the TF 
and the event of a shift due to antibody binding would be recorded. Moreover, the 
CHIP assays would be another very efficient method for revealing whether or not the 
candidate TFs do actually bind to the putative TFBSs found at the MLP-Pl proximal 
promoter. 
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Finally, in addition to analyzing whether or not the candidate TFs affect MLP-
Pl promoter activity, and whether or not they are capable of binding to the MLP-Pl 
promoter, one could also verify whether or not the TF affects endogenous mier1 
expression. In this case, the particular cell line in question could be transiently 
transfected with expression vectors specific for the candidate TF. Forty-eight hours 
following transfection, total RNA could be isolated. Reverse transcriptase (RT) PCR 
could then be performed followed by either PCR or quantitative PCR (qPCR) with 
primers specific for the various mier1 transcripts. The significance of these 
experiments is that they would demonstrate whether or not endogenous mier 1 
transcription is affected by the particular TF. Furthermore, as all 12 possible 
transcripts stemming from mier1 are characterized (Paterno et al., 2002), transcript-
specific primers could be utilized in order to monitor the effect of the candidate TF on 
each respective transcript. This would furthermore distinguish at which promoter the 
TF in question is acting, thereby furthermore verifying the MLP-P I putative TFBS 
function, as transcriptional activation at both MLP-Pl and MAEP-P2 produce very 
distinct mier1 transcripts. 
Information obtained from such experimental assays validating the functional 
effects of the candidate TFs on MLP-Pl promoter activity would be markedly useful 
in delineating the regulatory network of mier 1. All of the candidate TFs have been 
found to be either involved in or dysregulated throughout cancer growth and 
progression (with the exception ofUSF, which demonstrates antiproliferative and 
tumour suppressor properties). This suggests that MLP-PI has the potential to become 
activated aberrantly throughout cancer progression, as these TFs may be abnormally 
activated or regulated. Of additional interest is with regards to the TFBSs for Sp I and 
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CREB found in the MLP-PI maximal promoter area (between -91 and -44bp from the 
putative MLP-P1 TSS). Both ofthese transcription factors have not only been found 
to contain implicated roles in breast cancer, but as well have been previously found to 
either be involved in mier 1 regulation (-with Sp 1 already established as regulating 
mierl transcription at MAEP-P2) or affected by MIERI function (-with CREB 
requiring CBP for downstream signalling and transcriptional activation; CBP being a 
molecule harbouring HAT activity to which MIERI~ inhibits) (Blackmore eta/., 
2008). Therefore, ifthese TFs do regulate MLP-Pl specific transcription, then further 
regulatory negative feedback loops involving MIER 1 isoforms could possibly be 
revealed. 
4.5 MLP-Pl Promoter Proximal Sequence Conservation Across Various Species 
Sequence alignment comparison of the human MLP-P 1 promoter region to various species 
further reinforces functional importance of the MLP-Pl promoter proximal region. 
Sequences that mediate gene expression tend to be evolutionarily conserved 
(Loots, 2008). Consequently, data from inter-species genomic sequence comparison 
alignments are primed to aide in the decoding and identification of the sequences 
responsible for gene regulation (Pennacchio & Rubin, 2001). Out ofthe six species 
analyzed, MLP-P1 proximal promoter regions were highly conserved among four: 
rhesus (chimpanzee), mouse, rat, and dog (section 3.3.2; Appendix 7). The fact that 
there is such a high degree of conservation amongst these species furthermore 
reinforces the functional importance of these nucleotides. 
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4.6 MLP-Pl vs. MAEP-P2 Promoter Activity 
The regulatory influence that alternate promoter usage exerts on gene 
expression is becoming more and more apparent, not only because of the increased 
discovery of genes that are regulated at more than one promoter, but due to the further 
characterized role of alternate promoter usage in tissue-specific gene expression 
regulation (Baek et al. , 2007; Bharti et al. , 2008; Davuluri et al., 2006; Kakizawa et 
al. , 2007; Kimura eta/., 2006; Puomila eta/., 2007; Sehgal et al., 2008). Moreover, 
the abnormal preferential usage of one promoter over the other for certain genes has 
been revealed to contribute to cancer development in various tissues (Bulun et al. , 
2009; Davuluri eta/., 2006). Possible implications for preferential usage ofthe MLP-
Pl promoter has raised questions with regards to whether or not the cellular 
environment indicative of breast cancer cells and tumours preferentially activates 
transcription of mier 1 isoforms at the MLP-P I promoter over the MAEP-P2 promoter. 
As previously noted in sections 1.5.6 and 3.5, this possible phenomenon is the basis 
for a promising mechanism serving to explain MIERla' s aberrant subcellular 
localization in invasive breast tumours and cancer cells. 
The MLP-Pl promoter is consistently activated at a higher level titan MAEP-P2 in all cell 
lines examined, the extent of wlticlt is highest in ER+ breast cancer cell lines. 
Results from section 3.4.1 demonstrate that MAEP-P2 RLU levels varied 
across the examined cell lines (Fig 3.1 L). Moreover, these reporter activity levels did 
not correlate specifically with cell line ER status as the two ER- cell lines produced 
considerably distinct RLU levels, an observation consistent with the MLP-P I 
promoter results. It is evident from Figure 3. 12 though, that the MLP-P I promoter is 
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consistently activated at a higher level than MAEP-P2, thereby incessantly producing 
more luciferase activity than mier1 ' s second promoter in each cell line. This suggests 
that, in general, the MLP-P I promoter is the prominently active promoter of mier 1. 
Intriguingly though, implications for a possible role of ER status in the 
regulation of mier 1 transcription surfaced when the luciferase activity data obtained 
from the aforementioned experiments between the two mier 1 promoters was 
compared (Fig 3.12 & Table 3.4). The degree to which MLP-PI is activated over 
MAEP-P2 increases in ER+ breast cancer cell lines. This striking pattern is clearly 
evident upon the calculation of the ratios between the RLU levels stemming from the 
maximum activity- producing luciferase reporter gene deletion construct of each 
promoter [MLP-P1 (-185) pGL3 for MLP-Pl and MAEP-P2 (-312) pGL3 for MAEP-
P2] as outlined in Table 3.4. This suggests that in ER+ breast cancers, which already 
contain heightened ER signalling, MLP-P1 would become even more activated over 
the MAEP-P2 promoter. A key potential repercussion ofthis preferential activation is 
discussed in the following section. 
Furthermore, it is interesting that this phenomenon is prominent in ER+ breast 
cancers thereby suggesting that perhaps ER signalling may play an accessory role in 
dictating the degree to which MLP-PI is activated over MAEP-P2. There are various 
ways to investigate this point. A promoter analysis approach similar to the approach 
used in this study could be employed in order to assay the effect of either inducing or 
abrogating ER signalling in these cells, such as with either estrogen treatment to 
activate estrogen signalling, and estrogen inhibitor treatment or si-RNA technology to 
knock downER expression in order to impede ER signalling. This would then allow 
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one to monitor the promoter activity ratios between MLP-Pl and MAEP-P2 under 
these various conditions that either induce or disruptER signalling. 
Intriguingly, previous in silico analysis of the MAEP-P2 promoter revealed 
that a ~ ERE resides -256bp from the MAEP-P2 TSS. Moreover, numerous studies 
have found that Spl, a TF that was previously shown to regulate transcription at 
MAEP-P2 specifically, can function in concert with ER and its cognate~ ERE sites to 
induce transcription of downstream target genes (Kim eta/., 2005; Porter eta/., 1997). 
Therefore one would postulate that the MAEP-P2 promoter would be more active than 
MLP-Pl (which does not harbour any such ~or full EREs) in the presence of ER 
signalling. This study showed the exact opposite; thereby suggesting that the 
previously described MLP-Pl TFBS, or any possible non-characterized MLP-Pl 
TFBS, must be more conducive to attracting the transcription machinery at this 
promoter than the MAEP-P2 specific TFBS are for the MAEP-P2 promoter in the 
examined cell lines. 
Finally, a key goal to studying promoter activity levels is to investigate how 
transcription is regulated at a particular gene of interest. With the finding that MLP-
Pl is the predominantly activated promoter of mierl , the next pivotal step would be to 
examine whether or not this preferential activation affects the level and type of 
endogenous mierl transcripts in a particular cell line. It would be interesting to see 
whether or not ER+ breast cancer cells generate a higher percentage ofMLP-PI 
specific vs. MAEP-P2 specific transcripts than ER- breast cancer cell lines. 
Furthermore, transcript type and level could be investigated in the absence or presence 
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of estrogen treatment or estrogen signalling inhibition in these various breast cancer 
cell lines. 
These types of analyses can be performed by first extracting the total RNA 
from a number of the examined breast cancer cell lines, either directly or following 
treatment with either estrogen or estrogen inhibitors (specifically in the case ofER+ 
breast cancer cells) and then performing reverse transcription (RT)-PCR to obtain 
sufficient cell line specific eDNA. This eDNA could then be run through various PCR 
reactions using primers designed specifically to anneal to each of the promoter-
specific transcripts (for reference to all possible mierl transcripts, refer to Figure 1.6). 
A very important consideration with this method, however, is primer design. Each 
primer must be engineered so that they each anneal to the eDNA with equivalent 
efficiency thereby ensuring that any differences in the final observed PCR products 
are representative of the extracted RNA and not a function of differential primer 
annealing. Therefore, the stringent design of the transcript specific primers is very 
important, and should take into consideration any possible secondary structure formed 
by each primer, the annealing and denaturing temperatures of the primers, primer 
nucleotide content, and the sizes of the amplicons produced by each transcript specific 
pair. Following RT-PCR and PCR results, qPCR should then be performed to further 
verify and confirm the result trends, using new and carefully designed primers for 
each promoter specific transcript as corresponding to qPCR primer requirements. 
Other methodological approaches could be employed for this transcript 
analysis, however, these also intrinsically contain certain caveats. For example, one 
could perform a northern blot using a probe that binds to the common region of all 
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transcripts. This northern blott analysis would then directly detect the extracted RNA 
and the differences in the sizes of the transcripts could then be use to distinguish a 
particular promoter specific transcript. However, as previously illustrated by Paterno 
et al. 2002, this assay would not be able to distinguish between all of the different 
mierl transcripts as the 5' transcript ends produced by either MLP-PI and MAEP-P2 
are not sufficiently different enough to resolve on a gel. Finally, an RNAse protection 
assay could be performed with probes specific for each mierl transcript. This would; 
however, inherently require the careful and assiduous planning and design of 
efficiently annealing probes, not unlike the primer design needed for the previously 
proposed RT-PCR method. 
4. 7 Implications for Preferential Transcriptional Activation at MLP-Pl and the 
Effect ofMLP-Pl Specific Exon 3A Inclusion on the Subcellular Localization of 
MIERla. 
As described in section 1.5.6, transcriptional activation at MLP-PI can 
potentially result in the incorporation of the alternate exon, exon 3A, in the nascent 
MLP-Pl specific transcript. Exon 3A specifies a 74bp nucleotide sequence that 
translates into the following amino acid sequence: MFMFNWFTDCL WTLFLSNYQ. 
The alternate N-terminal end resulting from exon 3A inclusion harbours many 
hydrophobic amino acids that, as predicted by in silico algorithms, could possibly 
function as a transmembrane domain, which could serve to anchor the resulting 
protein isoform to the plasma membrane. Additionally, there is also a putative nuclear 
export sequence (NES) that contains the consensus L(X2- 3) L(X2- 3) LXL (whereby 
193 
"L" represents leucine or any other large hydrophobic residue, namely valine, 
isoleucine, phenylalanine, or methionine and "X" represents an amino acid) 
(Dong et al. , 2009; Kosugi et al., 2008; LaCour et al., 2003; Rosas-Acosta & Wilson, 
2008). In the amino acid sequence encoded by exon 3A this putative NES resides 
between the 7th and 16th amino acids and constitutes the following sequence: 
ETDCL_WTL_Ff:t.. 
These two aforementioned putative characteristics of theN-terminal domain 
encoded by exon 3A have significant implications for the regulation of MIERI 
isoform function. It is currently hypothesized that in order for MIER I isoforms to 
fully exert their general regulatory role in the cell, they should be present in the 
nucleus. Therefore any action that would evoke a change in subcellular localization 
causing MIER I to be removed from the nucleus, such as plasma membrane anchorage 
or nuclear export, could possibly abrogate or change MIERI ' s transcriptional 
regulatory functions. Furthermore, as discussed in section 1.5.5, with regards to 
MIER 1 and breast cancer development, MIER I a has shown to undergo a subcellular 
localization switch to the cytoplasm as breast carcinomas progress to a more invasive 
state. The inclusion of exon 3A, with either its putative transmembrane or nuclear 
export domains, may serve as a possible explanation as to why this isoform is no 
longer localized to the nucleus as breast cells become more malignant. 
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The 74bp insert specified by exon 3Afunctions to localize MIERla to the cytoplasm in 
MCF7ce/ls 
Results outlined in section 3.5.1 following transient transfection of MCF7 cells 
with MYC-tagged mierl isoform expression vectors showed that the 74bp insert 
specified by exon 3A does in fact function to localize MIER I a to the cytoplasm 
(Figures 3.15 & 3.16). This finding has significant implications, not only for the 
importance of regulation at MLP-P I, but for further describing the state and location 
ofMIERia in various stages of breast cancer. These results suggest that if some 
event or cue from the cellular environment throughout breast cancer progression 
causes increased transcriptional activation at MLP-PI , and thus an increased 
production oftranscripts harbouring exon 3A, then the protein isoforms subsequently 
produced could become localized in the cytoplasm. 
An important future direction to this effect though, would be to analyze the 
actual transcript profile in breast cancer cells at different levels of breast cancer 
progression in order to determine whether there is a switch to the production of 
transcripts containing exon 3A. These analyses could be performed like the previously 
proposed transcript analysis, but instead of focusing on discriminating between the 
promoter specific isoforms, one would have to further distinguish between the MLP-
PI specific isoforms containing and lacking exon 3A. This would be possible by either 
designing primers that specifically span this particular exon, or by simply using 
amplicon size as a marker for exon 3A incorporation. For example, all MLP-PI 
transcripts could be detected by using a specific 5' primer in the MLP-PI UTR. 
Transcripts containing exon 3A, and therefore the PCR products generated from such 
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transcripts following RT-PCR and subsequent PCR reactions, would not run as far 
down an agarose gel as the transcripts lacking exon 3A as these PCR products would 
contain 74 extra nucleotides. 
Further characterization of the subcellular localization, as well as the level of 
MLP-Pl specific mierl isoforms at various stages of breast cancer, could be 
investigated using immunohistochemical approaches employing tissue microarrays 
constituting various breast cancer tumour samples varying in grade and/ or degree of 
neoplasia (such as hyperplasia vs. carcinoma in situ). Antibodies specific for MlliRla 
isoforms harbouring the amino acid sequence encoded by the exon 3A-specified 74bp 
insert could be developed in order to stain these tissues. One could then directly 
observe the subcellular localization of such isoforms in these various tissues. 
Moreover, co-staining of MIER 1 a isoforms that originate from transcripts either 
containing or lacking the 74bp insert with antibodies specific for each separate 
isoform could be performed and analyzed using confocal microscopy. This technique 
would be extremely beneficial, as it would allow the investigator to compare the 
location of both ofthese MIERla isoforms in the same cell, at the same time, and in 
the same tissue. Then, such as with the previously proposed immunohistochemical 
analysis, confocal analysis comparing the isoforms could be utilized on distinct tissues 
of varying cancer grade, even in invasive breast cancer. 
McCarthy eta!. 2008 is currently the only study to have directly investigated 
MIER!a in invasive breast cancer. As described in section 1.5.5, that particular study 
revealed that MIER I a was predominantly localized in the cytoplasm as breast cancer 
cells progressed towards an invasive state. It would be interesting to examine whether 
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or not the MIER 1 a isoforms that are found in the cytoplasm contain the amino acid 
sequences encoded by the 74bp insert specified by exon 3A. This would specifically 
be revealed following the immunohistochemical and confocal analysis described 
earlier. lfthese isoforms were discovered to contain such amino acids, then a role for 
the MLP-Pl promoter in invasive breast cancer progression; and as such, the 
mechanism of how these specific isoforms are getting localized to the cytoplasm in 
this particular stage of breast cancer would be further revealed. 
LMB treatment further supports the hypothesis that the 74bp insert does contain a 
functional NES which is responsible for the subcellular targeting of MJERlo. 74bp-
containing isoforms to the cytoplasm in MCF7 cells. 
The ability of LMB to efficiently inhibit nuclear export has greatly advanced 
the current knowledge surrounding nucleocytoplasmic trafficking (Kosugi et a/. , 
2008; LaCour et a/. 2003). LMB treatment has furthermore been relentlessly utilized 
to confirm the functionality of putative leucine rich nuclear export signals (Amazit et 
a/., 2003). Researchers are able to use LMB treatment to help specifically pinpoint 
whether or not a putative NES can function as a true NES, as LMB treatment 
abrogates the functioning of a key exportin involved in the prime nuclear export 
signalling transduction pathway (Dong et al. 2009, Kudo et a /.1998; Kudo eta/., 
1999). In theory, if a molecule harbouring the putative NES in question was found to 
localize to the cytoplasm, then LMB treatment would further support the functionality 
of the putative NES as a true NESby causing a decrease of cytoplasmic accumulation. 
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This exact phenomenon was exemplified in this study. LMB treatment of 
MCF7 cells caused a decrease in cytoplasmic accumulation of the mierl isoform 
harbouring the putative NES (MIER 1 3A alpha) and reciprocally induced a higher 
percentage of nuclear and whole cell staining for this particular isoform (Fig 3.17). 
This finding fundamentally supports the hypothesis that the MLP-PI driven alternate 
incorporation of exon 3A results in the expression of a NES which does contain 
nuclear export function via the CRM I exportin-dependent nuclear exportation 
pathway in this ER+ breast carcinoma cell line. 
The subcellular localization patterns of the MIERla isoforms in ER- MDA MB 231 cells 
and the non-cancerous ER- HEK 293 cells did not recapitulate the subcellular localization 
patterns observed in the ER+ MCF7 eel/line 
Interestingly, the subcellular localization results ofthe MIERia isoforms in 
ER- MDA MB 231 breast cancer cells and ER- HEK 293 cells did not parallel that 
which was found in the ER+ MCF7 breast cancer cells. In both cell lines, whole cell 
staining was the most prominent outcome following immunocytochemical staining for 
the different MIER I a isoforms. This suggests that the MIER 1 3A alpha isoform 
containing the amino acids encoded by the exon 3A-specified 74bp insert does not 
induce exclusive cytoplasmic subcellular localization of these particular proteins in 
these cells. Moreover MIERia isoforms are not predominantly localized in the 
nucleus in these cell lines, as is the case in MCF7 cells. 
This finding raises a lot of pertinent questions, the most evident being: what is 
causing this substantial localization pattern difference across these cell lines? The 
most obvious feature that differentiates MDA MB 231 cells and HEK 293 cells from 
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MCF7 cells is ER signalling thereby suggesting that the ER may play a role in 
MIER I a isoform localization. What is also interesting though, is a further question of 
how the MIERla isoform can localize to the nucleus in MCF7 cells in the first place, 
as MIERla isoforms do not have intrinsic nuclear localization signals (section 1.5.1 , 
1.5.3, 1.5.4). Ding eta/, 2003 first addressed this issue by suggesting that MIERla 
may be cotransported to the nucleus through regulated interactions with another 
nuclear protein(s) through a type of piggyback mechanism (Ding et al, 2003). Such a 
mechanism has been revealed for many different proteins such as Hsp90, 
retinoblastoma (RB) gene product, mitogen activated protein kinase (MAPK), p53, p 
catenin (Davis et a!., 2006). 
Could it be possible that this specific piggybacking protein is the ER? Such an 
occurrence may explain the observation of the exclusively nuclear staining in ER+ 
MCF7 cells but not in the ER- MDA MB 231 cells and the ER- HEK 293 cells. There 
are various experiments one could set up to investigate th is. One option would be to 
perform the exact same type of immunocytochemistry experiment in MCF7 cells as 
described in this study, but to furthermore investigate whether knocking down ER 
expression in MCF7 cell lines, such as discussed in section 4.2, would abrogate 
MIER I a ' s nuclear localization. Furthermore, one could even transfect the ER into the 
ER- MDA MB 231 and HEK 293 cell lines to observe whether or not MIERia 
localizes and accumulates in the nucleus. In addition, another more direct option 
would be to coanalyze the subcellular localization ofboth the ER and MIERla 
isoforms in the same cell using confocal microscopy. 
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Confocal microscopy would not only be extremely useful for this particular 
proposed project, but would also serve to further confirm results from section 3.5 
concerning the subcellular localization of the MIERla isoforms in MCF7 cells. Even 
though LMB treatment did adequately support a case for the putative NES as the 
functional component of the 74bp insert that induced MJERI 3A alpha isoforms to 
move out of the nucleus, while also ruling out membrane anchorage as the functional 
mechanism, confocal microscopy could serve as an additional tool to further validate 
LMB treatment experiments. Using this specific technique one could effectively 
observe not only nuclear and/or cytoplasmic subcellular localization but more 
specifically plasma membrane anchorage accumulation much more clearly than would 
be possible using conventional immunocytochemical techniques. 
Another important point with regards to the proposed ICC and the previously 
performed ICC experiments of this study is that future investigation needs to employ 
western blot analysis of the transiently transfected MIERia isoforms. This step is 
critical to these types of assays in order to confirm that the transfected MJER 1 a 
isoforms are effectively being produced in the cells. 
Finally, the incorporation of exon 3A may not solely be a function of 
preferential activation at MLP-PI. Another pivotal step involved in alternate exon 
incorporation is RNA splicing. As briefly described in section 1.2.2, like most 
cellular processes, RNA splicing is very complex and is intricately orchestrated by a 
variety of regulatory molecules and interconnecting pathways. In fact, some groups 
even attest that the spliceosome may represent the largest and most complex 
macromolecular structure in eukaryotic cells (Skotheim & Nees, 2007). In terms of 
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splicing profiles in tumourigenesis, there is increasing evidence that alternative and 
aberrant pre-mRNA splicing may play an important functional role in human cancers 
(Skotheim & Nees, 2007). Accumulating evidence suggests that the cellular splicing 
machinery is changed during oncogenic transformation and that a variety of candidate 
genes involved in RNA-processing are known to be up-regulated (Skotheim & Nees, 
2007). Morever, several tumour-specific splice variants have been characterized and it 
has been found that each of the classical "hallmarks of cancer" discussed previously 
are affected or sustained by at least a few known cancer associated splice variants 
(Skotheim & Nees, 2007). 
Therefore, it is a wonder whether or not aberrantly functioning splicing 
machinery may be perpetuating exon 3A incorporation in MLP-Pl specific mierl 
transcripts. Regulation ofmierl- specific splicing mechanisms has yet to be 
investigated, as research surrounding RNA splicing mechanisms in cancer 
development in general is still in its infancy (Pajares eta/., 2007). Future projects 
focusing on this particular research question though would not only reveal pertinent 
information surrounding the mierl regulatory network in cancer, but would further 
contribute to current knowledge surrounding the role of alternative splicing with 
regards to cancer progression. 
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4.8 Final Summary of Conclusions & Implications 
This study successfully characterized the nucleotide sequences that are 
involved in eliciting minimal and maximal activity at mierl's MLP-Pl promoter. The 
results from this promoter activity mapping analysis facilitated the identification of 
candidate active cis-elements inherent to this promoter via in silico examination. The 
discovery ofSpl, CREB, C/EBPp, USF, and c-REL TFBSs as candidate MLP-PI 
promoter cis-elements suggests that MLP-Pl may be under the regulation of these 
TFs. Moreover, each of the aforementioned TFs, except USF, have been characterized 
as in playing a role in cancer, whether solely being dysregulated or serving directly to 
perpetuate the neoplastic phenotype. Therefore, an abnormal level of expression or 
activation of these particular TFs in cancer may serve to dysregulate mierl at MLP-Pl 
thereby ensuing abnormal production ofMLP-PI specific transcripts. 
Further investigation ofMLP-Pl specific regulation in a variety breast cancer 
cell lines and the non-cancerous HEK 293 cell line via promoter activity analysis 
reconfirmed the promoter activity ofthe established MLP-PI minimal and maximal 
promoter sequences, as each cell line displayed similar promoter activity patterns. 
This finding implies that, in all ofthese cell lines, each section of the promoter is 
respectively being activated to the same extent, even though the overall levels of 
promoter activity differed across each cell type. The functional importance of the 
stretches ofnucleotides involved in maximal and minimal activity at MLP-PI were 
even further supported following conservation analysis across six different species 
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whereby four out of the six species analyzed displayed high levels of conservation and 
homology. 
Analysis of mierl promoter activity across four different breast cancer cell 
lines showed that the MLP-Pl promoter is the predominant promoter in these cells. 
This observation further implicated breast cancer ER status in mierl transcriptional 
regulation as the ratio ofMLP-P1 activation to MAEP-P2 activation was highest in 
ER+ breast carcinoma cell lines. The significance of this preferential transcriptional 
activation of MLP-P1 over MAEP-P2 lies in the alternate inclusion of mierl's exon 
3A, which is only possible following MLP-P1 specific mierl transcription. 
MlERla's subcellular localization changes from the nucleus to the cytoplasm 
as breast cancer cells progress to a more invasive state (McCarthy eta/., 2008). Exon 
3A had recently been described as encoding for a 74bp sequence that harbours either a 
putative NES and/ or putative transmembrane domain, which suggests that the 
incorporation ofthis exon into mierl transcripts may produce mierl isoforms (refered 
to as MIERI 3A alpha in this study) that abnormally localize to the cytoplasm. ICC 
results specifically showed that MIER I 3A alpha is forms do reside in the cytoplasm in 
ER+ MCF7 breast cancer cells. In contrast, MTER 1 a isoforms produced from 
transcripts lacking exon 3A, termed MIER 1 alpha, localized to the nucleus in these 
particular cells. This subcellular localization pattern changed following LMB 
treatment whereby cytoplasmic localization of MIER I 3A alpha decreased. This was 
furthermore followed by an increase in nuclear localization ofMIERI 3A alpha, 
which suggested that this event was a function ofNES mediated nuclear export. 
Interestingly though, when ER- MDA MB 231 cells and ER- HEK 293 cells were 
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analyzed, such subcellular localization patterns were not observed. Instead, both 
MIER1a. isoforms were found in both the cytoplasm and nucleus of these cells. These 
findings suggest that ER may play a role in the localization of these isoforms, as ER 
status is the prominent difference between these cell lines thereby necessitating further 
investigation. 
This ICC data furthermore provided evidence that transcriptional activation of 
MLP-P 1, and the subsequent generation of MIER 1 a isoforms containing ex on 3A, can 
result in sequestering ofMIERla in the cytoplasm ofER+ breast cancer cells. Could 
this be a mechanism explaining what is happening to MIER 1 a in invasive breast 
cancer? And if so, could cytoplasmic accumulation of this isoform directly enhance 
progression to invasive breast carcinoma? Is there a specific stage leading to the 
acquisition of invasive cancer cell characteristics whereby subcellular relocation of 
MIER I a takes place? Could the change in subcellular localization of MIER 1 a be used 
to indicate further transformation of a pre-existing benign carcinoma to invasive 
breast cancer? If so, is this correlation directly due to an abnormal function of an 
aberrantly localized MIER 1 a and its interaction with ERa.? More inquiry and further 
investigation, like that which is discussed in the future directions suggested 
throughout this chapter, is undoubtedly needed to address these questions. 
Fortunately, significant implications for such further investigation arise as pertinent 
clinical relevance may be revealed for this particular protein isoform in breast cancer 
patients. IfMIERia cytoplasmic accumulation can be used as a prognostic factor 
indicating transformation to invasive cancer, clinicians may be able to more accurately 
diagnose and even possibly predict breast cancer stage, which would help selection of 
the most appropriate therapeutic regimes. Furthermore, if it is shown that there is a 
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functional correlation between the MLP-Pl MIER 1 a-specific isoform and invasive 
breast cancer progression, mierl could be targeted using therapeutic modalities 
whereby transcriptional activation at MLP-P1 could be suppressed. 
In conclusion, this study performed significant preliminary analyses that have 
revealed MLP-P I as a very important component in the regulation of mier 1. Future 
studies need to focus on investigating whether the differential promoter activity 
established in this study is reflected by transcript production. Furthermore, confocal 
microscopy and immunohistochemical analysis following the staining ofMLP-P1 
specific isoforms (MIER1 alpha and MJERI 3A alpha) in breast cancer tissues 
varying in tumour grade are needed to efficiently investigate the functional 
implications of exon 3A inclusion on invasive breast cancer progression. Finally, 
investigation is also required to delineate why subcellular localization patterns differ 
with respect to ER status. Results stemming from such further investigation and 
characterization ofthese important isoforms in different stages of breast cancer may 
thus reveal MlERla as a prognostic factor or even a therapeutic target in breast cancer 
development. Such a serendipitous discovery would then add MIER 1 a to the 
repertoire of molecules vigorously trying to be collected in our efforts to make 
personalized medicine a reality in oncology and cancer treatment. 
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Appendix 1 - mierl MLP-Pl Promoter Region showing Location of 5' Starting 
Points for Insertion Sequences that were cloned into MLP-Pl Luciferase 
Reporter Gene Constructs 
(-1849/-3128) . .. .. . . .. . . . .... • . . . ... atgtttacat acacaaatact tagcattgtg ttacaattgc 
(-1809/-3088)ctacagtatt cagtacagta 
raMLP-Pl{-1708) pGl3 
acatgcta g caggttggta gcctagaagc aacaaatgca 
(- 1749/-3028)ttttcatcat tatgcaaaca ccatttagtg tacttacaca aacctagatg tatagcctac 
(- 1689/-2968)tatagcttag gtgtacagtc tactatacaa ttgtagccta ggtgtatagt agcccataca 
(-1629/-2908)tctacgtttg tgtaagtaca ctagaagata tttgcaaaat gctgaaattg gctaacaagg 
(-1569/-2848)tatttctcag aaggtatcac catcgatgca tgactgtatt tagttatggt agtgaggaac 
(-1509/-2788)agataccagc aaaggatctg ggaaaggtga aaccatgaac caagacaaga actaggaaga 
( - 1449/-2728)gtggtttctc agaacccaaa taaagctttt caaagatcga gaagcgataa acccgaccga 
(-1389/-2668)cactgcttca ttcaaaaaga atgaaactgt ggatcagcca ttgtatttgg ttgcatggct 
(- 1329/- 2608)attgctggct t t catagaag ctgttttgat ggagtggtag gatggacaaa agcgtgagta 
(- 1269/-2548)ccatattcaa gagagaatgc aaggttctct cccaagaact ctcaacaagt tccgctgaag 
(-1209/-2488)aaagattagc tgaggtggag gagattggag aggggaagag aaaacaaatt acttagggaa 
( - 1 149/-2428)ttttggggga acttagtggg cagcattacg ggcagcgcta aggaaccatt taaagtaaga 
MLP-Pl(-1077) pGl3 
(-1089 / -2368)caagtccaca ca~gtgtg cttttct aca gtcttgttca actgctgcat aacaacagaa 
(-1029/-2308)tgttggaagc aggaattagt tttaaagtaa gatggtattg acgagacgac aataaaatac 
(-969/-2248) ctctactaca gagcacagca atgttcggcc tggtggctca cagaagctga ggctcttgaa 
(-909/-2188) cgtctgggca cagcatgaaa gcatcaagct tgagagactg caggccttaa caaactagaa 
( - 849/-2128) gtgctagaac gatggttcta aaccaggtct tttctcacac agcaagcaca gcaatagaga 
(-789/-2068) tttattttat cttatttttt agacagagtc 
MLP-Pl(-742) pGl3 ::J 
tcgctctgtt gctcagg tc gagtgcaacg 
(-729/ -2008) gcacgatctc ggcttactgc aacctccgcc ttccgggttc aagggattct cctgcctcag 
(-669/-1948) cctcccaagt agctgggatt acaggcatgt gccaccacgt ccggctaact ttttgtattt 
(-609/- 1888) ttagtacaga cggggtttca ccatgttggc cagcctggac gctaacttct gacctcaggt 
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(- 549/-1828) gatccacccc actcggcctc ccaaagtgcc gggattacag gtgtgagcca ccgcgcccag 
(- 489/-1768) cccagtagag attcttttaa agactgcggt aggtcgataa aggagacatt gtggcctagg 
(- 429/ -1708) agcttcaagg tct acagact gaacccagtt agggtagggc ccctttccaa atccagaaat 
(-369/-1648) ggtatctatt aatagaaggg ctccctccgg gtcccagggg gatggactac ggtttttagc 
(- 309/-1588) gccggaactt acaacccgaa gttctgctgc ttgtgactgc ctgccggaga gactggcatg 
(- 249/-1528) gtggcgacca gctggggagt ggtgcaccac cccttttttt ggccgcctct gaagtccctg 
LP-P1(-185) pGL3 
(- 189/-1468 ) tac cccaag ctcctccgtt agcggctcgg gccg aggctc cggaatgttt gccgggcgtc 
(- 129/-1408) atggcgacgg tggagccctg 
MLP-P1 (-91) pGL3 :J 
gctcaacaag cggccgcg g gttggctggc ggcacgaggc 
LP-P1(-44) pGL3 
(-69/-1348) cgaggaggag ggcggaggcg gaggg a g gg cagagggttg gtggagctgg aggaagctcc 
Putative TSS/ Exon 1A MLP-P1(+37) pG~ 
(-9/-1288) ggacgacg~ TGGAAGAAGG AGGCGGGCGG CCCGGGCCTC AGGCCC TCC CAGGCTCTGA 
(+52/-1228) GTCTCCCGGC TGCAGGCGGA TGGATGGGGC TTCTTCAGGC GGTGGCGGCA GCAGCGAAGG 
(+ 112/-1168) TGGCGGCGGC AGCAGCGGCA GCGGCT ....... .. ... 1046bp Intron ... . ...... . . .. . 
Exon 2A 
(+1181/-95) . . . §1GGTGT GGTCGCTCGA TTCTCCCAGT GCCTGGCTGA GTTTCGGACG TGGTTAAGAA 
);> Nucleotide counts include the number of base pairs from the putative TSS (first 
number) and the A TG translation start site (second number). The 1 046bp intron is 
also included in the count. The 5' starting position of each MLP-PI luciferase reporter 
gene deletion construct is indicated. The capital letters indicate UTR sequences 
orig inating from either exon 1 A or 2A as marked. The TSS is also denoted. 
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Appendix 2- mierl MLP-Pl Region Intron Sequence 
(+138/-1178) . . . . . . . . . . . . .. . .... . . .. . . . . . . . . . . . ..... . gta agtgcagcct ccacaagcca 
(+198/ - 1118) tctctcccct tctattccag tttgggatga ggggctcctg aggtgtcctc agtccccttt 
(+258/-1058) ctctccttcc cctcccccac ggcagtgtac cgcccggaag acccttaact tccggggagg 
(+318/-998) ggctgccgca gaacgcgcct ggcttgctct ccgccggctg ccaaaggcgc atgcgcagct 
(+378/-938) tcctccctct ggccatcgac tgcctcccag cgccgccttt ttgccttcgc ggtggtggcg 
(+438/-878) ccgcgctggg aatccgctgc ggagtgagtt cgcctcgccc cgttcgcttc ggtccctgat 
(+498/-818) cccagtcggg gtggggctaa gctgaccacc ctgctgtggc tccgcctctt tctcctgtat 
(+558/-758) ttccctcact tgtgtcccat ccccgggagg ctctcgcttg cactgcagcc tttatggtga 
(+618/-698) gcagcgccct gggccaactt gcccttttcg gatggagtca gggagggagg agagactcga 
(+678/-638) atagggtatt actgtaagga aacgaggtcc tcctagcgcg tgggaggatc ccttgggaca 
(+738/-578) gatgcccgcc gctctttact cttgttcttt cagcttgtag tggctaggtc cctggcctgg 
(+798/-518) agcctatctg tggtccctgc atgctgtgta accttgagcg agtcactatc cctctctggg 
(+858/-458) cttcagtttt ccctatttaa agcttcctcc aacgctagaa ttctgcattt ctgcagaaga 
(+918/-398) acttatgtaa ttacaagatt gacttggcta ttgaggccgc ttcaccaaga tgacccggag 
(+978/-338) ttgactgaac cttcttcact tatgggtgga atgaggcgac ctatttattg ggtcgctttt 
(+1038/-278) attcctttat cattagttac aaattgcatg acttaaggct cattaaatgt ttttctaaaa 
(+1098/-218) ttgtcatggg atccttgtcc tgattcccga ccatcttttt aaaaatgcga aacagggtgg 
(+1158/-158) atggtgagct tgtatcatcg tttctgtctc cttgctactg aggctctctt tcctttgatc 
(+1218/-98) cagATGGTGT GGTCGCTCGA TTCTCCCAGT GCCTGGCTGA GTTTCGGACG TGGTTAAGAA 
(+1279/-38) CCAACTGGTT GAGGTTCAAT GCAGACAAGA 
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~ Capital letters denote Exon 2A. The A TG translation start site of MLP-P I is indicated 
by the red box. Nucleotide counts include the number of base pairs from the putative 
TSS (first number) and the A TG translation start site (second number). 
229 
Appendix 3- mier 1 MAEP-P2 Promoter Region & Location of Primers used to 
Engineer Luciferase Reporter Gene Constructs 
~MAEP-P2 (-1316) pGL3 
(-1316/-1465)ca tgtct gtggactctt ttcctgtcaa attaccaggt aatgtccttt cacttagcag 
(-1256/-1405)ctacttcata tatctgtaaa tgcag ttat tcatgcacag attattattg gacataacag 
(-1196/-1345)tttcaaatta acattgaatc tttggaaata ggaaaatgct tgatagagtc tagaatttta 
(-1136/-1285)agggaatata aataatttaa tagcctcccc tatattgcat tataagttaa gtattaactt 
(-1076/-1225)taagaaaaat tgtatatgta cacatttatg caatgtagta ttggttcaca ttatttggaa 
(-1016/-1165)ggaatgaata attctcgtat ttaaatggtt gattttggta gccacttttg aaactgcatt 
(-956/-1105) aagaggaacc cttgaagatt aggaaaaaaa tcccagtctt ttgaaataaa gactttcaaa 
(-896/-1045) ctggtttagt aaaatatgtt ag gactgtt ttaatgtcac ctttgtgtta ttcagtatgt 
(-836/-985) gccttagtat aatggaagtg aaacatgtta gttactttga aatcattggt tctggccatc 
(- 776/-925) atcagcattg gcatcacggc caattggcag ctgtaggcca atacattaaa ataaacttca 
(-716/-865) agttacaggc atttcaggca ttgcaaataa gtaggttctc cctccatgct actaaataga 
(- 656/-805) tgatatccat aaaacagtca attttcagta ttttaaattt tgtctagttg tgcaaaattc 
(-596/-7 45 ) agtacataac tgt gttgcta ccggcatgac agaagtgtgt gagaaaacgc aaatgacatg 
(-536/-685) aggatggcgg actgcctatc ataacccctt ccattaattt ttgctctgac ctctctagag 
( - 476/- 625) atttggggat atagaatttt acatttcctg tcgggaatct actgatggag aaatatttgt 
(-416/-565) caaggcataa ccgctttcaa agcacagttc ttgccgccgt tgcatcacag caacatccgt 
MAEP-P2 (-312) pGL3 
( - 356/- 505) ttttcagcaa atgcatttca aaaacgacct acatgtaaaa ~ttacgtat ttttcctctg 
(-296/-445) ctgtgtcaat gctggatgtg actcctttgg cactgttcct tgacc ctct gatccgtaga 
(-236/-385) caaccccctc cgcctggagt ggcggatcag ctggagccag cgaagcgccc cgcgcggttg 
(- 176/- 325) cccacctcct cccacaccca ccttgactcc gccccctccg ctcttcccgg ggagggctgg 
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(-116/-265) 
(-56/-205) 
(+5/-145) 
(+65/-85) 
(+125/-25) 
ccgcggggcc gcgcgcgcgc ccctgctccg 
MAEP-P2 (-68) pGL3l 
gcgcgtgctc gctggtct~t tccctccagt 
TSS 
ccagcccagc cggggcgccg cgagggggcg gagtggggtg tggtgggcgc gctcg~GG 
CTCCTGCGCG TTCCCGCCGA 
I MAEP-P2 (+28) pGL3 
GGCt GTGGCG GCGGGAGCGG CAGAGACGGC AGCGGCCGGA 
GTCCCGTTGC TGAGTCTCAC ATCCGGGTTC TGGCCGTGAC CCAGCTGCGG CCGCCGCGGA 
GATGTGACCC GGCAGTACGG CAAAT~C G 
:l> Capital letters denote Exon I Band the ATG translation start site of MAEP-P2 is 
indicated by the red box. Nucleotide counts include number of base pairs from the 
TSS (first number) and the ATG translation start site (second number). The TSS is 
also denoted. 
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Appendix 4: Preliminary Results of the Characterization of the MLP-Pl 
Promoter Proximal Region 
In order to identify the candidate area ofMLP-PI promoter that would be used 
to construct further deletion constructs in order to investigate the location of the 
minimal and maximal MLP-PI promoter activity, luciferase assays were preformed on 
harvested cell lysates following transient transfection of HEK 293 cells with the 
following MLP-Pl luciferase reporter gene deletion constructs: pGL3 empty vector, 
MLP-Pl (-742) pGL3, MLP-PI( -185) pGL3, and MLP-Pl (+37) pGL3. Similarly to 
the procedural description in section 3.1, the pGL3 empty vector was used as a 
negative control for background luciferase activity. All procedures including transient 
transfection, cell lysis, luciferase assays, ~ gal assays, and were preformed as 
previously described in sections 2.5-2.7. These experiments were not normalized to 
protein levels, but were instead normalized to only transfection efficiency. Figure A I 
shows the results obtained following two repeats of these experiments. 
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MLP-Pl (-741} pGL3 
MLP-Pl (-185) pGL3 
MLP-Pl ( 137) pGL3 
pGL3 em p~y vector 
O.E 100 l.E 10S 4.E 105 6.E 10S 8.E10S l.E I 06 
Normalized RLUs 
Figure Al: Preliminary results of the characterization of mier 1 MLP-Pl 
promoter proximal region in HEK 293 cells 
l.E 106 
HEK 293 Cells were seeded at a density of 5 x 105 cells/well in a 6-well plate and grown in 
supplemented DMEM for approximately 18 hours. Cells were then transfected wi th 0.5 f.lg of MLP-P I 
promoter sequence luc i ferase reporter gene deletion construct and 0.25f.lg of pRSYI3-gal. Cell lysates 
were collected 48 hours following transfection and relative luciferase units were measured. !3-gal 
assays were preformed so as to normalize the luciferase data to the transfection efficiency of each 
well . Each luciferase reporter gene construct was performed in tripl icate and n=2. 
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The promoter sequence encompassed in the MLP-P I ( -185) pGL3 construct 
displayed maximum promoter activity (Fig A I), which was significantly higher than 
the upstream sequence containing construct MLP-P 1 ( -742) pGL3 (p<O.OO 1 ). As 
there was a also significant increase between MLP-P I ( -185) pGL3 and the MLP-P I 
(+37) pGL3 negative promoter activity control construct, the nucleotide sequences 
present between the 5' starting point ofthe MLP-P1 (-185) pGL3 and the MLP-P1 
(+37) pGL3 constructs were chosen for further analysis and construction of additional 
de letion constructs of the MLP-P1 promoter (section 2.4). 
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Appendix 5- MAEP-P2 Activity in HEK 293 Cells Recapitulates Previously 
Established Results Characterizing MAEP-P2 Promoter Activity in Alternate 
Cell Lines 
MAEP-Pl (-.312) pGL.3 
MAEP-Pl (-68) pGL.3 
MAEP-Pl ( 128) pGL.3 
pGL3 empty vector 
0.[100 4 .E105 8 .[ 105 1.[106 2.E 106 
Normalized RLUs 
Figure A2: Characterization of the MAEP-P2 proximal promoter region of mierl 
in HEK 293 cells 
HEK 293 e lls were seeded at a density of5 x 105 cells/well of a 6-well plate and grown in DMEM for 
approximate ly 18 h. Cells were then transfectcd with 0.5 1-1g of MAEP-P2 promoter sequence luciferase 
reporter gene de letion construct, 0.25!-lg of pRSV~-gal , and 0.5!-lg ERa pCDNA3. Cclllysatcs were 
collected 52 hours following transtection and relati ve light units were measured. BioRad and ~-gal 
assays were pre formed so as to collect necessary data in order to normalize the RLUs to transfection 
efficiency and protein levels as described in section 2.7. Each luciferase reporter gene construct was 
performed in triplicate and N=7. Refer to Ding et a!., 2004 or section 1.5.2. 1 to compare to already 
established MA EP-P2 promoter activity patterns in I lELA cells. 
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Appendix 6: Comparison of the MAEP-P2 Promoter Activity Across Multiple 
Breast Cancer Cell Lines Varying in ER Status and the HEK 293 Non-Cancerous 
Cell Line including the MAEP-P2 (+28) pGL3 Construct Results 
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Appendix 7: Human MLP-Pl Promoter Sequence Aligned to Various Species 
~ Note that the location on chromosome l whereby the maximal promoter activity 
region ofMLP-PI (between -185 to -91 bp from the MLP-PI putative TSS) in humans 
is chrl: 67, 163,045-67, 163, 139. The location on chromosome I for the minimal 
promoter activity region of MLP-P I (between -91 to -44bp rrom the MLP-Pl putative 
TSS) in humans is chr I: 67, 163, 139- 67, 163, 186. 
~ For the purposes ofthis appendix, the location ofthe MLP-PI maximal promoter 
activity region will be highlighted in yellow, whereby the minimal promoter activity 
region ofMLP-PI will be highlighted in turquoise. Furthermore, human MLP-PI 
promoter sequence is the top alignment in each case and the other species is the 
bottom alignment 
Appendix 7a: Human vs. Rhesus 
~ This alignment encompasses positions 67, 162,985-67, 163,404 on human chromosome 
I and 69,702,644-69,703,062 on rhesus chromosome I. 
067162985 CGACCAGCTGGGGAGTGGTGCACCACCCCTTTTTTTGGCCGCCTCTGAAGTCCCTGTACC 067163044 
11111111111 11 1 1 1111 1 1 11111 11 1111 111 11111 11 11111 11 111 111 11 
069702644 CGACCAGCTGGGGAGTGGTCCACCACCCC-TTTTCTGGCCGCCTCTGAAGTCCCTGTACC 069702702 
067163045 CCCAAGCTCCTCCGTTAGCGGCTCGGGCCGAGGCTCCGGAATGTTTGCCGGGCGTCATGG 067163104 
111111 I ll 1111 1 11 1 11111 1 1111 1 11 11111111111111111111 1111 
069702703 TCCAAGCCCCTGCGTTGGCGGTTCGGGCCGAGGATCCGGAATGTTTGCCGGGCGTCATGG 069702762 
067163105 t GACGGTGGAGCCCTGGCTCAACAAGCGGCCGCG 067163164 
111111111111 11111111111111111111111111111111111111111111111 
069702763 CGACGGTGGAGCTCTGGCTCAACAAGCGGCCGCGCGGTTGGCTGGCGGCACGAGGCCGAG 069702822 
067163165 067163224 
069702823 GAGGAGGGCGGAGGCGGAGGGGAGGGCAGAGGGTTGGTGGAGCAGGAGGAAGCTCCGGAC 069702882 
067163225 GACGACTGGAAGAAGGAGGCGGGCGGCCCGGGCCTCAGGCCCCTCCCAGGCTCTGAGTCT 067163284 
1111111 111 11111111111 11 11111 11111 11 1111111111111 111 11 11 11 1 1 
069702883 GACGACTAGAAGAAGGAGGCGGGCGGCCCGGGCCTCAGGCCCCTCCCAGGCTCTGAGTCT 069702942 
067163285 CCCGGCTGCAGGCGGATGGATGGGGCTTCTTCAGGCGGTGGCGGCAGCAGCGAAGGTGGC 067163344 
11111111111 11 1 1111111111111111111 1 1111 111111111 11 111111 111 1 1 
069702943 CCCGGCTGCAGGCGGATGGATGGGGCTTCTTCAGGCGGTGGCGGCAGCAGCGAAGGTGGC 069703002 
067163345 GGCGGCAGCAGCGGCAGCGGCTGTAAGTGCAGCCTCCACAAGCCATCTCTCCCCTTCTAT 067163404 
111111111111111111111111111111111111111111111111 1111 11111 I 
069703003 GGCGGCAGCAGCGGCAGCGGCTGTAAGTGCAGCCTCCACAAGCCATCTTTCCCCTTCTGT 069703062 
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Appendix 7b: Human vs. Mouse 
J> This alignment encompasses positions 67, 162,985-67, 163,343 on human chromosome 
I and 102,786,767- !02,787, 107 on mouse chromosome 4. 
067162985 CGAC-CAGCTGGGGAGTGGTGCACCACCCCTTTTTTTGGCCGCCTCTGAAGTCCCTGTAC 067163043 
Ill I II I I I 1111 II II I II I I II I II 
102786767 TGACTTTTTAGACCAGGGCTCGGCGCCCCC-TTCCCCAGCAGGTTCGGCGATGCCCGGAC 102786825 
067163044 CCCCAAGCTCCTCCGTTAGCGGCTCGGGCCGAGGCTCCGGAATGTTTGCCGGGCGTCATG 067163103 
1111 I II II I I 1111 11111111111111111 1111 
102786826 TCCCA-------------ACTGCCCGCTCAGCAGCTCAGGAATGTTTGCCGGGCGCCATG 102786872 
067163104 GCGACGGTGGAGCCCTGGCTCAACAAGCGGCCGCG TTGGCTGGCGGCAC A 067163163 
IIIII I IIIII 111111111 11111111111111111111111 II IIIII 
102786873 GCGACCGCGGAGC-CTGGCTCAAGAAGCGGCCGCGCGGTTGGCTGGCCGCTCGAGGTGGA 102786931 
067163164 A AGGGCAGAGGGTTGGTGGAGCTGGAGGAAGCTCCGGA 067163223 
I I I I I II I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I II I I 
102786932 GGAGGAGGGCGGAGGCGGAGGGGAGGGTAGAGGGTTGGTGGAGCTGGAGGAAGCTCGGG- 102786990 
067163224 CGACGACTGGAAGAAGGAGGCGGGCGGCCCGGGCCTCAGGCCCCTCCCAGGCTCTGAGTC 067163283 
1 11 1 I 111 1111111111111 1111 1111111111111 1 11 IIIII 
102786991 ---CGACGATTCGGAGGAGGCGGGCGGCCCAGGCCCTAGGCCCCTCCCAGGCTGCGAGTC 102787047 
067163284 TCCCGGCTGCAGGCGGATGGATGGGGCTTCTTCAGGCGGTGGCGGCAGCAGCGAAGGTGG 067163343 
1111111111111 1 1111111111111 Ill 1111111 1111111111111 Ill II 
102787048 TCCCGGCTGCAGGCGGATGGATGGGGCGTCTCCAGGCGGCGGCGGCAGCAGCGGAGGCGG 102787107 
Appendix 7c: Human vs. Rat 
);> This alignment encompasses positions 67, 162,985-67, 163,343 on human 
chromosome I and 124,048, 195-124,048,525 on rat chromosome 5. 
067162985 CGACCAGCTGGGGAGTGGTGCACCACCCCTTTTTTTGGCCGCCTCTGAAGTCCCTGTACC 067163044 
1111 I II I I 1111 II II I 1111 II II I II 
1 24048195 CGACTCTTAGATTAGGGCTTGGGAGCCCC-TTCCCCAGC-GGTTCTGCGGTGCCCGGACT 1240 48 252 
067163045 CCCAAGCTCCTCCGTTAGCGGCTCGGGCCGAGGCTCCGGAATGTTTGCCGGGCGTCATGG 067163104 
Ill I II I I I 1111 11111111111111111111111 
124048253 -CCA-------------ACTGCCCCCTCAGCAGCTCAGGAATGTTTGCCGGGCGTCATGG 124048298 
067163105 CGACGGTGGAGCCCTGGCTCAACAAGCGGCCGCG TT~ A 067163164 
1111 I 1111 111111111 11111111111111111111111 II IIIII Ill 
124048299 CGACCGCAGAGC-CTGGCTCAAGAAGCGGCCGCGCGGTTGGCTGGCCGCTCGAGGTTGAG 124048357 
067163165 AGGAGGGCGGAGGCGGAGG AGGGCAGAGGGTTGGTGGAGCTGGAGGAAGCTCCGGAC 067163224 
111111111111111 11111111111 1111111111111111111111111111 II 
124048358 GAGGAGGGCGGAGGCGGAGGGGAGGGTAGAGGGTTGGTGGAGCTGGAGGAAGCTCGGG-- 124048415 
067163225 GACGACTGGAAGAAGGAGGCGGGCGGCCCGGGCCTCAGGCCCCTCCCAGGCTCTGAGTCT 067163284 
1111 I 1111111111111111 1111111111111111 111111 
1240 48416 --CGACGATTCGGAGGAGGCGGGCGGCCC-------AGGCCCCTCCCAGGCTGCGAGTCT 124048466 
067163285 CCCGGCTGCAGGCGGATGGATGGGGCTTCTTCAGGCGGTGGCGGCAGCAGCGAAGGTGG 067163343 
11 111111111111111111111111 Ill 1111111 1111111111111 Ill II 
124048467 CCCGGCTGCAGGCGGATGGATGGGGCGTCTCCAGGCGGCGGCGGCAGCAGCGGAGGCGG 124048525 
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Appendix 7d: Human vs. Dog 
)> This alignment encompasses positions 67, 162,985-67,163,343 on human chromosome 
I and 46,592,462-46,592, I 06 on dog chromosome 5. 
067162985 CGACCAGCTGGGGAGTGGTGCACCACCCCTTTTTTTGGCCGCCTCTGAAGTCCCTGTACC 067163044 
1111 II I 111111 I II 1111 II I II II II I llllllll Ill 
046592462 CGACAGGCGGCGGAGTGCTCGGCCGCCCC-TTCCCTAGCTGCTTCCGGAGTCCCTGGACC 046592404 
067163045 CCCAAGCTCCTCCGTTAGCGGCTCGGGCCGAGGCTCCGGAATGTTTGCCGGGCGTCATGG 067163104 
II I I II I l l llllllll lllllllllll lllllllllllllllllllllll 
046592403 CCAACGGCCC-GCGTCAGCGGCTCCGGCCGAGGCTCGGGAATGTTTGCCGGGCGTCATGG 046592345 
067163105 CGACGGTGGAGCCCTGGCTCAACAAGCGGCCGCG~~~~~~~~~~~~ 
IIIII 1111111 llllllllllllllllllllllllllllllllll Ill 1111 
067163164 
046592344 AGACGGAGGAGCCCCGGCTCAACAAGCGGCCGCGCGGTTGGCTGGCGGCTGGAGACCGA- 046592286 
067163165 AGGAGGGCGGAGGCGGAGG AGGGCAGAGGGTTGGTGGAGCTGGAGGAAGCTCCGGAC 067163224 
llllllllllllllll llllllllllllllllllllllllll lllllllllllllll 
046592285 GAGGAGGGCGGAGGCGAAGGGGAGGGCAGAGGGTTGGTGGAGCAAGAGGAAGCTCCGGAC 046592226 
067163225 GACGACTGGAAGAAGGAGGCGGGCGGCCCGGGCCTCAGGCCCCTCCCAGGCTCTGAGTCT 067163284 
1111111 Ill lllllllll lllll llllllll llllllllllll l ll lllllllll 
046592225 GACGACTAGAAAAAGGAGGCGGGCGGCCCGGGCCCCAGGCCCCTCCCAGGTTCTGAGTCT 046592166 
067163285 CCC-GGCTGCAGGCGGATGGATGGGGCTTCTTCAGGCGGTGGCGGCAGCAGCGAAGGTGG 067163343 
Ill lll llllllllllllllllllllllllllllllllllllllllllll 11111111 
046592165 CCCCGGCTGCAGGCGGATGGATGGGGCTTCTTCAGGCGGTGGCGGCAGCAGTGAAGGTGG 046592106 
Appendix 7e: Human vs. Horse 
)> This alignment encompasses positions 67, 162,985-67, 163,344 on human chromosome 
I and 67, 186,71 0- 67, 186,354 on horse chromosome 5. 
067162985 CGACCAGCTGGGGAGTGGTGCACCACCCCTTTTTTTGGCCGCCTCTGAAGTCCCTGTACC 067163044 
067186710 NNNNNNNNNNNNNNNNNNNNNNNNNNNNN-NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 067186652 
067163045 CCCAAGCTCCTCCGTTAGCGGCTCGGGCCGAGGCTCCGGAATGTTTGCCGGGCGTCATGG 067163104 
067186651 NNNNNNNNNN-NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 067186593 
067163105 CGACGGTGGAGCCCTGGCTCAACAAGCGGCC 067163164 
067186592 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN- 067186534 
067186533 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 067186474 
067163225 GACGACTGGAAGAAGGAGGCGGGCGGCCCGGGCCTCAGGCCCCTCCCAGGCTCTGAGTCT 067163284 
111111111 111111 
067186473 NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCCCAGGCTCCGAGTCT 067186414 
067163285 CCCGGCTGCAGGCGGATGGATGGGGCTTCTTCAGGCGGTGGCGGCAGCAGCGAAGGTGGC 067163344 
llllllllllllllllllllllllllllll IIIII I lllllllllllll Ill Ill 
067186413 CCCGGCTGCAGGCGGATGGATGGGGCTTCTCCAGGCAGCGGCGGCAGCAGCGGAGGCGGC 067186354 
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Appendix 7f: Human vs. Chicken 
~ This alignment encompasses positions 67,163,045-67, 163,344 on human chromosome 
1 and 29,378,250-29,378,370 on chicken chromosome 8. 
067163045 CCCAAGCTCCTCCGTTAGCGGCTCGGGCCGAGGCTCCGGAATGTTTGCCGGGCGTCATGG 067163104 
I II II I I 
029378250 -------------------------------------------------AGGCGTTAT-- 029378258 
067163105 CGACGGTGGAGCCCTGGCTCAACAAGCGGCCGCGCGGTTG T GC 067163164 
II I II Ill 
029378259 ---------------------------------GCTGCTGTCTG---------------- 029378269 
067163165 CGGAGGCGGAGG AGGGCAGAGGGTTGGTGGAGCTGGAGGAAGCTCCGGAC 067163224 
Ill II I I II I I 
029378270 ------------------------------GGGCTGTAATACCAAACGGGAACC------ 029378293 
067163225 GACGACTGGAAGAAGGAGGCGGGCGGCCCGGGCCTCAGGCCCCTCCCAGGCTCTGAGTCT 067163284 
IIIII I I II I Ill II I I I 11 111 1 
029378294 ------------GAGGAGCAGCTGAGACCCGTCCTGAGATTTCCCGAA-----CGAGTCT 029378336 
067163285 CCCGGCTGCAGGCGGATGGATGGGGCTTCTTCAGGCGGTGGCGGCAGCAGCGAAGGTGGC 067163344 
II II I I I II II II II II II II Il l I 
029378337 CC--GCTGC---- --------------TCCTCCGGGGGGGGTCGCGGCCGCGCA------ 029378370 
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